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  i 
Abstract 
 
Background 
Accurate diagnosis of dementia with Lewy bodies (DLB) has important implications for 
treatment and prognosis, but it is not currently clear how frequently DLB is diagnosed in 
routine clinical practice, nor how frequently they are assigned an alternative dementia 
diagnosis. 
 
123I-metaiodobenzylguanidine (MIBG) may be capable of improving DLB diagnostic accuracy 
but it has not been investigated in clinically representative populations that include patients 
with comorbidities or interfering medications. 
 
Methods 
We conducted a cross-sectional survey of 5 569 patients attending three Psychiatry of Old 
Age services. From this cohort, 51 DLB and 51 matched non-DLB cases consented to 
extraction of data relating to the diagnostic process from their clinical case notes. 
 
We enrolled a clinically representative cohort of 17 patients with DLB and 16 with 
Alzheimer’s disease (AD) to a MIBG utility study. Each patient underwent detailed clinical 
examination, cardiac MIBG and FP-CIT SPECT imaging.  
  
Results 
DLB represented 5.6% of dementia cases but prevalence varied across services (3.5-5.9%). 
DLB cases were often given a different dementia subtype diagnosis (39%) and experienced a 
longer time from referral to diagnosis (265 days) than non-DLB patients (154 days).  
 
MIBG had a sensitivity and specificity of 71% and 75% for differentiating DLB from AD, but a 
lower HMR threshold enhanced specificity (100%) without compromising sensitivity. No 
significant relationships between HMR and either myocardial infarction, or medication 
prescription, were identified. 
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Conclusions 
Variation in DLB prevalence across services may suggest differences in detection rather than 
in the true prevalence of the disease. The higher frequency of clinical contacts seen in DLB 
may provide opportunities to improve both diagnostic accuracy and time to diagnosis. 
 
Our findings support the use of representative cohorts in further MIBG research, particularly 
in determining appropriate HMR cut-offs. Our finding that three DLB patients had normal 
MIBG, but abnormal FP-CIT results challenges the Braak hypothesis of DLB pathogenesis. 
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Chapter 1 
Introduction 
 
Dementia is the leading cause of disability and dependence in older people (Sousa et al., 2009, 
2010), and it represents arguably the most significant challenge facing the global health and social 
care community. An estimated 47 million people worldwide are living with dementia, and this is 
expected to increase to 75 million by 2030 and 132 million by 2050 (Prince et al., 2015). In the 
United Kingdom (UK) alone, 6.5% of the population over 65 have dementia (Matthews et al., 
2013), and 183 000 new cases develop annually; this is projected to increase as the population 
ages (Matthews et al., 2016). 
 
Dementia is composed of several subtypes. Alzheimer’s disease (AD), vascular dementia (VaD), 
frontotemporal dementia (FTD), and Lewy body dementia (comprising both dementia with Lewy 
bodies (DLB) and Parkinson’s disease dementia (PDD)) make up the majority of cases (Stevens et 
al., 2002).  
 
An important role of clinicians is to determine which dementia subtype applies to the patient 
presenting to their services. Each subtype has a characteristic combination of signs and symptoms, 
but these can overlap with each other, and can be complicated both by mixed pathologies and 
comorbid conditions (Schneider et al., 2009). Even when biomarkers are integrated into the 
assessment process, every subtype diagnosis is made with at least a degree of uncertainty, as only 
post-mortem examination can definitively confirm the pathology present. In spite of this 
uncertainty, good clinical practice recommends that a subtype diagnosis is made wherever 
possible (NICE, 2018), and accuracy of this diagnosis is of great importance as a patient’s dementia 
subtype has implications for management and prognosis.  
 
DLB is one such common dementia subtype with characteristic clinical features (McKeith et al., 
2017) and validated biomarkers (McKeith et al., 2007) but with difficulties in detection in routine 
secondary care (Nelson et al., 2012; Huang and Halliday, 2013) as many cases are missed, often 
mistaken for AD (Galvin, 2015). Accurate diagnosis of DLB is crucial, however, as DLB is associated 
with higher rates of neuropsychiatric symptoms, hospitalisation (Mueller et al., 2018), and shorter 
survival (Price et al., 2017). Accurate recognition reduces likelihood of prescription of 
 2 
antipsychotic medications, to which patients with DLB can experience severe sensitivity (Aarsland 
et al., 2005). 
 
This thesis will therefore examine DLB diagnostic practice in routine clinical services and the 
factors behind DLB detection. It will describe a large epidemiological study investigating DLB 
diagnostic rates in the UK National Health Service (NHS) secondary care services and how patients’ 
contact with these services differs from that of patients with other dementia subtypes. The thesis 
will then explore the role of several biomarkers in optimising the clinical detection in DLB, before 
investigating the utility of one such biomarker, 123I-metaiodobenzylguanidine (MIBG) cardiac 
scintigraphy, in differentiating DLB from AD. This first chapter will provide an overview of both DLB 
and AD, the subtype for which DLB is likely most commonly mistaken.  
 
1.1 Dementia with Lewy bodies 
1.1.1 Clinical features 
Dementia is defined as decline in cognitive function that interferes with a person’s ability to 
undertake their usual activities, which is not explained by delirium or another psychiatric disorder 
(McKhann et al., 2011). DLB diagnosis is made on the basis of recognition of characteristic signs 
and symptoms of disease in someone with dementia. 
The neuropsychological profile of this cognitive decline differs in DLB from that seen in AD. 
Patients in the early stages of DLB experience greater impairment in visuospatial, attentional and 
frontal-executive function, with greater preservation of memory than those with early AD 
(Metzler-Baddeley, 2007). 
Pronounced fluctuations in cognition, arousal and functioning, superimposed upon this 
progressive cognitive decline, are often seen in DLB and represent a characteristic diagnostic 
feature of the disease (McKeith et al., 2005, 2017). They are thought to arise as a consequence not 
of specific structural changes, but rather disruptions in functional networks (Peraza et al., 2014). 
The presence of these fluctuations can have a significant impact upon patients and their carers 
(Lee et al., 2013). Although variations in alertness and concentration in DLB have been 
demonstrated in computerised tests of reaction times (Ballard, et al., 2001), accurate detection of 
fluctuations in the clinic have proved challenging; clinicians assessing the symptom show low 
inter-rater reliability (Lee et al., 2012). 
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Another important symptom of DLB is the presence of recurrent complex visual hallucinations. 
The aetiology of this symptom is poorly understood (Boeve et al., 2003) but affect up to 80% of 
patients with DLB (Aarsland et al., 2001) and are associated with significant impairment in quality 
of life (Boström and Jönsson, 2007). The hallucinations themselves are often recurrent, detailed 
representations of small children or animals and although the reaction of the patient can vary 
from mirth and indifference to considerable anguish (McKeith et al., 2005), caregivers can 
experience significant distress as a consequence of this symptom (Ricci et al., 2009). Patients with 
DLB can also experience other neuropsychiatric features, such as depression, anxiety, apathy, 
delusions and hallucinations in other modalities, but none of these carry the same diagnostic 
specificity as visual hallucinations (McKeith et al., 2017). 
Spontaneous motor features of parkinsonism (bradykinesia, rigidity, rest tremor and gait and 
postural reflex abnormalities) are observed in up to 85% of patients with DLB (Ferman et al., 
2006). The phenotype of postural instability and gait disturbance is more commonly seen in DLB 
than tremor-dominant disease when compared with PD patients (Burn et al., 2006), but rest 
tremor, action tremor, bradykinesia, decreased facial expression and rigidity were observed as the 
features capable of best discriminating DLB from AD in a pathologically confirmed sample (Ballard 
et al., 1997). 
In recent years rapid eye movement (REM) sleep behaviour disorder (RBD) has emerged as a 
strong predictor of DLB at post-mortem (Ferman et al., 2011), preceding dementia or parkinsonism 
by up to 30 years (Boeve et al., 2003). It is also closely associated with other synucleinopathies, 
such as Parkinson’s disease (PD), PD dementia (PDD) and multisystem atrophy (MSA) (Iranzo et al., 
2013). RBD is characterised by a loss of physiological muscle atonia during REM sleep, manifesting 
as enactment of the patient’s dreams; punching, kicking or vocalising. This may result in injury to 
the patient or bed partner (Boeve, 2010). RBD is ideally confirmed using polysomnography (PSG) 
(McKeith et al., 2017) but a validated questionnaire for use in the clinical setting is associated with 
a high diagnostic sensitivity and acceptable specify for RBD (Boeve et al., 2011). 
Approximately half of DLB patients administered antipsychotic agents suffer from sensitivity 
reactions (Aarsland et al., 2005), which can range in severity from sedation, increased confusion, 
rigidity and immobility to markedly reduced survival (McKeith, Ballard and Harrison, 1995). The 
last decade has seen the antipsychotic prescription in patients with dementia half, but 11% still 
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receive these agents (Donegan et al., 2017) and as a pronounced and iatrogenic clinical feature, 
the risk of neuroleptic sensitivity remains an important rationale for the detection of DLB in the 
clinical setting (McKeith et al., 2017). 
Several clinical signs and symptoms, other than those already discussed, are associated with DLB, 
but their high prevalence in dementia populations mean that these features lack the specificity to 
carry significant weight towards DLB diagnosis (McKeith et al., 2017). These include frequent falls, 
transient loss of consciousness, delusions, depression, anxiety and autonomic dysfunction, which 
can manifest as constipation, urinary incontinence or orthostatic hypotension (Horimoto et al., 
2003). These symptoms direct clinicians towards useful management strategies and therefore 
require vigilance.  
 
Patients with DLB can therefore exhibit a range of symptoms in addition to the cognitive and 
functional decline associated with dementia itself. Several of these, notably cognitive fluctuations, 
visual hallucinations, spontaneous features of parkinsonism and RBD, are of particular use in the 
clinical setting by virtue of their prevalence and specificity in differentiating DLB from other 
dementia subtypes. 
 
1.1.2 Diagnostic criteria 
Diagnostic criteria for DLB have provided a framework for detection of the disease in both 
research and clinical settings by operationalising these characteristic clinical features and 
integrating validated biomarkers, an approach consistent with that employed in other dementia 
subtype criteria (McKhann et al., 2011). Successive revisions of criteria have aimed to enhance 
sensitivity and reflect important developments in the evidence base surrounding DLB. 
 
Criteria published as part the third report of the International DLB Consortium (“the third 
consensus criteria”) were observed to demonstrate superior sensitivity to their preceding criteria 
(McKeith et al., 1996) in a post-mortem validation study (McKeith et al., 2000b); however, meta-
analysis has since shown that this improvement in sensitivity has been at the expense of specificity 
(Rizzo et al., 2017). The third consensus criteria, displayed in Figure 1.1, allow diagnosis of 
“probable” or “possible” DLB based on different combinations of “core” and “suggestive” clinical 
symptoms. 
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Although since revised as part of the fourth report of the International DLB Consortium (“the 
fourth consensus criteria”) (McKeith et al., 2017), the third consensus criteria were the prevailing 
criteria at the time of the development and analysis of the studies comprising this thesis, and 
therefore incorporated in their design.  
 
Figure 1.1 Revised (“third consensus”) criteria for the clinical diagnosis of DLB   
(McKeith et al., 2005) 
 
Central feature (essential for diagnosis of probable or possible DLB) 
Dementia 
 
Core features* 
Fluctuating cognition with pronounced variations in attention and alertness 
Recurrent visual hallucinations that are typically well formed and detailed 
Spontaneous features of parkinsonism 
Suggestive features* 
REM sleep behaviour disorder 
Severe neuroleptic sensitivity 
Low dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET imaging 
Supportive features (commonly present but not proven to have diagnostic specificity) 
Repeated falls and syncope  
Transient, unexplained loss of consciousness  
Severe autonomic dysfunction e.g., orthostatic hypotension, urinary incontinence Hallucinations 
in other modalities 
Systematized delusions  
Depression  
Relative preservation of medial temporal lobe structures on CT/MRI scan  
Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity  
Abnormal (low uptake) MIBG myocardial scintigraphy 
Prominent slow wave activity on EEG with temporal lobe transient sharp waves 
 
*A diagnosis of probable DLB can be made in the presence of at least two core features, or one 
core feature and one suggestive feature. A diagnosis of possible DLB can be made in the 
presence of one core feature, or in the presence of one or more suggestive features. 
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Figure 1.2 Revised (“fourth consensus”) criteria for the clinical diagnosis of probable and 
possible DLB (McKeith et al., 2017) 
 
Essential 
Dementia 
Core clinical features * 
Fluctuating cognition with pronounced variations in attention and alertness 
Recurrent visual hallucinations that are typically well formed and detailed 
REM sleep behaviour disorder, which may precede cognitive decline 
One or more spontaneous cardinal features of parkinsonism 
Supportive clinical features 
Severe sensitivity to antipsychotic agents; postural instability; repeated falls; syncope or other 
transient episodes of unresponsiveness; severe autonomic dysfunction, e.g., constipation, 
orthostatic hypotension, urinary incontinence; hypersomnia; hyposmia; hallucinations in other 
modalities; systematized delusions; apathy, anxiety, and depression 
Indicative biomarkers* 
Reduced dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET 
Abnormal (low uptake) 123 iodine-MIBG myocardial scintigraphy. 
Polysomnographic confirmation of REM sleep without atonia 
Supportive biomarkers 
Relative preservation of medial temporal lobe structures on CT/MRI scan 
Generalized low uptake on SPECT/PET perfusion/metabolism scan with reduced occipital 
activity ± the cingulate island sign on FDG-PET imaging 
Prominent posterior slow-wave activity on EEG with periodic fluctuations in the pre-alpha/ theta 
range. 
 
*A diagnosis of probable DLB can be diagnosed on the basis of two or more core clinical 
features, or one core clinical feature and one indicative biomarker. Possible DLB can be 
diagnosed on the basis of one core clinical feature, or if one or more indicative biomarkers are 
present in the absence of any core clinical features. 
 
 
The fourth consensus criteria (Figure 1.2) have maintained the fundamental structure of the third 
consensus criteria. They aimed to enhance sensitivity of diagnosis but have not yet been 
compared with neuropathological data. These criteria increased the diagnostic weighting of RBD, 
including it as a core clinical feature, and replaced the suggestive symptom category of the third 
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criteria with a group of “indicative” biomarkers; reduced dopamine transporter uptake in basal 
ganglia demonstrated by single photon emission computed tomography (SPECT) or positron 
emission tomography (PET) imaging, reduced uptake on MIBG myocardial scintigraphy, and PSG 
confirmation of REM sleep without atonia. 
 
Both criteria detail the distinction between DLB and PDD, based on the temporality of dementia 
relative to parkinsonian symptoms. Where dementia occurs concurrently, or shortly before the 
onset of parkinsonism, a DLB diagnosis is appropriate, whereas, PDD refers to the onset of 
dementia in the context of established PD. This distinction is operationalised for research by the 
“one year rule”, in which DLB, rather than PDD, is diagnosed when cognitive symptoms precede, or 
occur within a year of the emergence of parkinsonian symptoms (McKeith et al., 2017). 
 
1.1.3 Biomarkers 
A biomarker is a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pharmacologic responses to a therapeutic intervention, or, indicators 
of pathogenic processes (Biomarkers Definitions Working Group, 2001). Biomarkers are of 
increasing importance as research frameworks begin to move away from a syndromic definition of 
dementia subtypes (that is, on the basis of signs and symptoms), to a more biological construct 
that allows more precise characterisation of disease processes. In of DLB, biomarkers also play an 
important clinical role in case detection (Jack et al., 2018). 
 
Both the third and fourth consensus criteria incorporate several biomarkers, of which three may 
be combined with clinical symptoms to arrive at a possible or probable DLB diagnosis. Of these, 
two are nuclear medicine techniques; low dopamine transporter uptake in the basal ganglia, 
typically determined by ¹²³I-2β- carbometoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane 
SPECT (FP-CIT), and reduced myocardial denervation measured by MIBG uptake scintigraphy. Both 
are discussed in detail in Chapter 3. The third technique is PSG, used to confirm the presence of 
RBD. PSG incorporates data from several physiological parameters, most notably 
electroencephalography (EEG) used to determine the high frequency, low amplitude activity 
suggestive of REM sleep, and electromyography (EMG), used to measure skeletal muscle activity. 
REM sleep without the presence of atonia is diagnostic of RBD, and even in the absence of other 
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core features is highly predictive of a synucleinopathy in a patient with dementia (Boeve et al., 
2013).  
 
1.1.4  Neuropathology 
Although diagnostic criteria maintain a focus on clinical symptoms, a definitive diagnosis of DLB 
can only be made upon post-mortem examination, when the pathological hallmarks of the 
disease, Lewy bodies (LBs) and Lewy neurites (LNs), can be observed.  Both LBs and LNs contain 
the aggregates of a-synuclein, a synaptic protein, and can therefore be detected using techniques 
such as staining with anti-a-synuclein antibodies (Gómez-Tortosa et al., 2000). In addition to LB 
and LN pathology, the characteristic substrates of AD, neurofibrillary tangles (NFTs) and amyloid-
beta (Ab), are seen in a high proportion of DLB cases (McKeith et al., 2005). The extent of this 
pathology can greatly influence the clinical phenotype (Thomas et al., 2018b). 
 
LBs and LNs are distributed throughout the central and peripheral nervous system in patients with 
DLB (Beach et al., 2010), as well as in other dementia subtypes such as AD and in a proportion of 
healthy individuals (Zaccai et al., 2015). Clinicopathological diagnosis therefore depends on the 
distribution of AD pathology (Montine et al., 2012) as well as that of both LBs and LNs. 
 
Figure 1.3 Assessment of the likelihood that the pathologic findings are associated with a 
typical, dementia with Lewy bodies, clinical syndrome (McKeith et al., 2017) 
 
 
 
Lewy related pathology 
Alzheimer disease neuropathological change (NIA-AA) 
Low 
(Braak 0-II) 
Intermediate 
(Braak III – IV) 
High 
(Braak IV -VI) 
Diffuse (neocortical) High High Intermediate 
Limbic (transitional) High Intermediate Low 
Brainstem-predominant Low Low Low 
Amygdala-predominant Low Low Low 
Olfactory bulb only Low Low Low 
 
Five main patterns of distribution of LBs and LNs are recognised, each carrying varying likelihoods 
that pathological findings correspond to clinically apparent DLB (McKeith et al., 2017) (Figure 1.3). 
Of these five patterns, diffuse distribution of LBs and LN throughout the neocortex is the most 
common in DLB (Zaccai et al., 2015); where observed in this manner there is a high likelihood of 
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expression of clinical DLB symptoms in all but cases with advanced AD disease. The probability of a 
DLB phenotype in a patient with limbic LB/LN pathology is associated with lower burdens of AD 
pathology. 
 
Our understanding of the pathogenesis of DLB is largely derived from neuropathological PD 
research. Braak et al. (2003) observed the distribution of α-synuclein in PD patients with varying 
disease severity, as well as in asymptomatic subjects in whom LB/LN pathology had been 
identified post-mortem. A uniform, predictable spread of pathology conforming to six stages was 
devised, hypothesised to start in vulnerable “sentinel” structures (such as the olfactory bulb and 
the dorsal motor nucleus of the vagal nerve) before ascending through the pons, midbrain, 
subcortical structures and neocortex. These stages were sequential; neocortical disease, 
representing the final symptomatic stages (stages 5 and 6) was only observed in patients in whom 
there was also evidence of pathology in lower structures, representing stages 1 to 4 and 
consistent with asymptomatic or mild disease. However, patterns of α-synuclein spread consistent 
with this “Braak hypothesis” have been observed in around only half of patients with clinical LB 
pathology in a community-based sample (Zaccai et al., 2015). This is further supported by the 
proportion of DLB patients with neocortical LB pathology that fail to demonstrate findings 
associated with striatal pathology, as would be expected from the Braak hypothesis; 15-20% never 
develop parkinsonian symptoms (Ferman et al., 2006; Walker et al., 2016) and 10% have negative 
FP-CIT scans antemortem (Thomas et al., 2017a). This has led to suggestions that the mechanisms 
underpinning pathogenesis are more complex than previously suggested by the Braak hypothesis, 
and that both α-synuclein spread and neuronal death may be subject to cell-mediated factors 
capable of varying between different anatomical regions (Surmeier, Obeso and Halliday, 2017). 
 
1.1.5 Disease progression 
There is increasing evidence that the progression of DLB is both heterogeneous and distinct from 
that seen in other dementia subtypes (Cercy and Bylsma, 1997; Mueller et al., 2017). One possible 
reason for this heterogeneity may be the effect of varying burdens of pathology, as mixed DLB/AD 
cases appear to deteriorate more rapidly than those with pure LB pathology (Olichney et al., 1998; 
Kraybill et al., 2005; Nedelska et al., 2015). 
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A five-year prospective cohort study found that patients with DLB demonstrated a greater annual 
decline in MMSE (4.4 points) than those with AD (3.2 points) (Rongve et al., 2016). This was 
supported by a larger retrospective analysis of DLB patients across 18 countries which found than 
MMSE score declined more rapidly in DLB than both AD and PDD (Kramberger et al., 2017). 
 
This cognitive decline is mirrored by a more rapid deterioration in functional ability; DLB patients 
experience higher levels of disability (Boström et al., 2007), shorter time from presentation to 
nursing home admission (Rongve et al., 2014) and lower overall quality of life (Boström and 
Jönsson, 2007).  
 
DLB also appears to be associated with a more complex, extensive course of contact with 
healthcare services than other dementia subtypes. A retrospective analysis of healthcare records 
found that DLB patients were admitted to hospital more frequently, and for longer periods of 
time, than both AD patients and the general elderly population (Mueller et al., 2018). Higher rates 
of comorbidities, such as stroke, migraine and depression have also been observed in DLB groups 
(Fereshtehnejad et al., 2014). These factors may contribute to the higher rates of mortality in DLB 
patients; one retrospective naturalistic cohort study observed that the time between initial 
presentation and death was a median 3.72 years in DLB patients, but 6.95 years in AD patients, 
independent of age, sex and antipsychotic prescription (Price et al., 2017). 
 
1.1.6 Epidemiology 
DLB is frequently cited as the second most common neurodegenerative dementia but there is little 
consensus regarding the prevalence and incidence of the disease. Neuropathological evidence of 
DLB is observed in 15 – 30% of patients with dementia (Oinas et al., 2009; Jellinger and Attems, 
2011) but clinical signs and symptoms are seen in a smaller proportion of patients antemortem. A 
meta-analysis of 31 epidemiological studies observed DLB in 4.2% of dementia cases in the 
community and 7.5% of those in secondary services and reported an incidence of the disease of 
0.87 per 1 000 patient-years (Vann Jones and O’Brien, 2014).  
 
Among the reasons that DLB prevalence in clinical studies may vary from those in 
neuropathological studies may be difficulty in diagnosing the disorder in routine practice. Delays in 
diagnosis often occur and patients may be assigned a different dementia subtype before later 
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revision to DLB (Galvin, 2015). The clinical epidemiology of DLB, and the detection of the disease in 
routine clinical practice, is discussed in detail in Chapters 2, 4, 5, and 6. 
 
1.1.7 Management 
It is not currently possible to stop or slow down the accumulation of DLB pathology, but several 
pharmacological agents are in routine use for the symptomatic treatment of DLB. Non-
pharmacological treatments, such as interventions to improve gait and swallowing in DLB patients 
have been investigated with encouraging results (Logemann et al., 2008; Rochester et al., 2009), 
but a recent systematic review failed to identify any studies of sufficient quality to be included in 
meta-analysis (Connors et al., 2017). 
 
1.1.7.1 Cognitive symptoms 
Cholinergic deficits are seen earlier, and at a greater severity, in DLB than AD, and in the former 
are associated with both cognitive impairment and visual hallucinations (Tiraboschi et al., 2002). 
The acetylcholinesterase inhibitors donepezil and rivastigmine therefore form the cornerstones of 
DLB management. Three randomised controlled trials (RCTs) have demonstrated the efficacy of 
donepezil and rivastigmine in the treatment of DLB (McKeith et al., 2000a; Mori et al., 2012; Ikeda 
et al., 2015). Meta-analysis of these studies (Stinton et al., 2015) indicated that both donepezil and 
rivastigmine were associated with improvements in global outcome measures. Those 
administered donepezil in these RCTs demonstrated a mean increase of 1.26 points on MMSE 
compared to those receiving placebo, and improvements in attention following rivastigmine 
prescription have also been observed (McKeith et al., 2000a). Both agents have shown efficacy in 
treating neuropsychiatric symptoms (Stinton et al., 2015), particularly apathy, anxiety, 
hallucinations and delusions (McKeith et al., 2000a). Improvements in cognitive fluctuations, sleep 
disturbances, and psychiatric symptoms have been reported with a third acetylcholinesterase 
inhibitor, galantamine (Edwards et al., 2007), but the agent has thus far only been investigated 
using an open-label design. 
 
Side effects to acetylcholinesterase inhibitors occur up to three quarters of patients with DLB 
(Bhasin et al., 2007) but these are usually of mild severity; trial dropout rates were no greater in 
patients with DLB treated with donepezil than those with placebo (Stinton et al., 2015). 
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Two RCTs have investigated the use of the N-methyl-D-aspartate (NMDA) receptor antagonist 
memantine in mixed DLB and PDD samples (Aarsland et al., 2009; Emre et al., 2010). Meta-analysis 
suggests that memantine offered no superiority over placebo in cognition, neuropsychiatric 
symptoms, or functioning, but did demonstrate improvements in continuous measurement of 
global assessment (Stinton et al., 2015). Secondary analysis of these studies has, however, 
suggested that memantine is associated with improvements in sleep behaviour (Larsson et al., 
2010) and aspects of quality of life (Larsson et al., 2011). 
 
1.1.7.2 Parkinsonism 
Much as in PD, the treatment of parkinsonian symptoms in DLB is primarily with levodopa. 
Improvements in motor function are seen in around a third of DLB patients treated with levodopa 
(Bonelli et al., 2004; Molloy et al., 2005; Goldman et al., 2008), a response rate lower than that 
seen in both PD (80-90%) (Hughes et al., 1993; Lucetti et al., 2010) and PDD (65-70%) (Stinton et 
al., 2015). Although well tolerated by the majority of patients (Molloy et al., 2005), one third 
experience an escalation in psychotic symptoms (Goldman et al., 2008). Agents such as 
amantadine, rotigotine and selegiline are routinely prescribed to patients with PD, but there is 
little evidence to support their use in DLB (Stinton et al., 2015). 
 
1.1.7.3 RBD, psychosis and depression 
In both patients with and without cognitive impairment, treatment of RBD focuses on minimising 
the risk of injury rather that stopping dream enactment itself (Boeve, 2010) and clonazepam and 
melatonin are the mainstays of management. Neither have been investigated substantially in DLB 
(Stinton et al., 2015), but the more favourable side effect profile of melatonin favours its use over 
clonazepam in older patients. 
 
Psychotic symptoms such as hallucinations and delusions are common in DLB, but management is 
complicated by both the limited efficacy of antipsychotics, and the risk of pronounced adverse 
reactions to such agents (McKeith, Ballard and Harrison, 1995; Ballard et al., 1997; Aarsland et al., 
2005). Cholinesterase inhibitors therefore represent the first-line management of psychosis in 
DLB. Quetiapine is favoured over neuroleptics with strong dopamine 2 receptor antagonism, such 
as typical antipsychotics and the atypical agents olanzapine and risperidone (Boot et al., 2013), but 
was not associated with an improvement in neuropsychiatric, cognitive, functional or motor 
symptoms, nor clinician’s impression of change in a placebo-controlled trial. Clozapine has 
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demonstrated the ability to diminish psychotic symptoms in PD in two open-label trials (Factor et 
al., 2001; Morgante et al., 2004) and one RCT (Pollak et al., 2004), but has not been investigated in 
DLB populations. Although pimavanserin, a selective serotonin 5-hydroxytryptamine receptor 2A 
(5-HT2A) inverse agonist, has demonstrated efficacy in reducing neuropsychiatric symptoms at six 
weeks in both PD psychosis (Cummings et al. 2014) and AD psychosis (Ballard et al. 2018), there 
have been no published studies investigating its use in DLB patients, and concerns regarding the 
safety of pimavanserin have recently arisen (Webster, 2018). 
 
DLB diagnosis therefore guides clinicians towards suitable management strategies and 
necessitates consideration of important adverse effects. A paucity of robust evidence surrounds 
the treatment of symptoms such as depression, and the role of non-pharmacological treatments. 
Systematic reviews have noted the importance in optimising DLB diagnosis in recruiting suitable 
cohorts for further research into DLB therapies (Stinton et al., 2015; Connors et al., 2017). 
 
1.1.8 Summary 
DLB is a common dementia subtype characterised by a tetrad of symptoms that include cognitive 
fluctuations, visual hallucinations, spontaneous parkinsonism and RBD. The presence of 
combinations of these symptoms, together with biomarkers, guide clinicians towards a probable 
or possible diagnosis of DLB. Definitive diagnosis, however, can only occur post-mortem, when the 
LNs and LBs characteristic of the disease can be identified. These findings are often seen in 
combination with AD pathology, which may make detection of some symptoms more difficult and 
contribute towards the lack of consensus between pathological and clinical epidemiological 
studies. Accurate antemortem diagnosis is nonetheless crucial, both in guiding clinicians to 
appropriate management strategies, and in providing disease-specific information to patient and 
carer; this may include the more rapid rates of cognitive and functional decline and higher 
mortality rates seen in DLB than in other subtypes. 
 
1.2 Alzheimer’s disease 
AD is the most common dementia subtype, comprising 50-70% of patients with dementia (Lobo et 
al., 2000; Reitz, Brayne and Mayeux, 2011). As already discussed, DLB cases often exhibit AD 
neuropathology (Chapter 1.1.4), potentially influencing the clinical presentation (Tiraboschi et al., 
2006), and patients with DLB are often diagnosed with AD prior to subsequent revision (Galvin et 
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al., 2010). This section therefore aims to provide a brief overview of AD to further contextualise 
discussion surrounding the clinical detection of DLB. 
 
1.2.1 Clinical features 
AD is characterised by an insidious onset of progressive cognitive impairment, with initial and 
most prominent deficits seen most commonly in episodic memory (McKhann et al., 2011). Non-
amnestic presentations occur less frequently, with disturbances in language, visuospatial ability or 
executive function. Neuropsychiatric symptoms occur less frequently than in DLB (Hanyu et al., 
2009), but depression and apathy are common in the early stages of AD, and other symptoms such 
as agitation, delusions and hallucinations may occur in the later stages of the disease (Lyketsos et 
al., 2011). 
 
1.2.2 Diagnostic criteria 
Like DLB, a definite diagnosis of AD can only be made post-mortem. Diagnostic criteria for AD 
(McKhann et al., 2011) were developed by the United States of America (USA) National Institute 
on Aging and Alzheimer’s Association (NIA-AA). The criteria share many characteristics of those 
demonstrated by the third and fourth consensus criteria for DLB (McKeith et al., 2005, 2017), 
classifying combinations of clinical observations to arrive at a probable or possible diagnosis, 
reflecting the likelihood of the presence of AD neuropathology. Probable criteria for AD are shown 
in Figure 1.4. A possible diagnosis is made on the basis of either an atypical, rather than insidious, 
clinical course, or the presence of signs or symptoms associated with other dementia subtypes; 
this includes the core symptoms characteristic of DLB (McKhann et al., 2011).  
 
1.2.3 Biomarkers 
NIA-AA criteria included a separate diagnostic category of probable AD with evidence of the AD 
pathophysiological process in which biomarkers are combined with the criteria for probable AD to 
reflect a higher certainty that the dementia syndrome is related to neuropathological AD 
(McKhann et al., 2011). These include cerebrospinal fluid (CSF) biomarkers and imaging 
biomarkers. 
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1.2.3.1 CSF biomarkers 
Three main CSF biomarkers have been identified and tested; the 42-aminoacid form of Aβ (Aβ42), 
total tau (T-tau) and phosphorylated tau (P-tau). Aβ42 reflects the cortical deposition of amyloid 
plaques, while T-tau and P-tau are measures of neuronal and axonal damage and degeneration. T-
tau is recognised as a non-specific marker of neuronal injury, when compared with P-tau, which is 
more specific to AD (Jack et al., 2018). All three markers individually demonstrate the ability to 
distinguish AD from healthy controls (Olsson et al., 2016), but achieve higher levels of sensitivity 
(87%) and specificity (84%) when used in combination (Ferreira et al., 2014). Their utility is lower 
in distinguishing AD from other dementia subtypes (Olsson et al., 2016), and Aβ42, T-tau and P-tau 
demonstrate value in early disease, discriminating between mild cognitive impairment (MCI) due 
to AD and stable MCI (Olsson et al., 2016). 
 
Figure 1.4 NIA-AA diagnostic guidelines for probable Alzheimer’s disease   
(McKhann et al., 2011) 
 
Meets criteria for dementia 
Evidence of cognitive decline in two or more cognitive domains 
Significant interference in ability to function at work or in usual daily activities 
AND demonstrates all of the following characteristics; 
Insidious onset 
Clear-cut history of worsening of cognition by report or observation 
AND demonstrates initial and most prominent cognitive deficits in;  
Episodic memory (amnestic presentation) 
Language, visuospatial ability or executive function (non-amnestic presentation) 
AND the absence of evidence for; 
Substantial concomitant cerebrovascular disease 
Core features of Dementia with Lewy bodies 
Prominent features of behavioural variant frontotemporal dementia 
Prominent features of semantic variant primary progressive aphasia or non- fluent/agrammatic 
variant primary progressive aphasia; 
Evidence for another concurrent, active neurological disease, or a non-neurological medical 
comorbidity or use of medication that could have a substantial effect on cognition. 
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Routine use of CSF biomarkers is, however, complicated by variation in how individual studies 
establish cut-offs between AD patients and controls, partly due to variation in collection, 
processing and analysis of samples (Mattsson et al., 2013). This has led to the creation of a global 
quality control programme to standardise practice across sites (Blennow, Zetterberg and Fagan, 
2015). 
 
1.2.3.2 Imaging biomarkers 
Like CSF biomarkers, imaging biomarkers for AD reflect both the amyloid deposition (detected 
with PET amyloid imaging) and downstream degeneration (through atrophy on structural imaging 
and reduced regional metabolism with 18fluorodeoxyglucose (FDG) uptake on PET) characteristic 
of AD pathology. 
The development of the 11C-labelled PET ligand Pittsburgh Compound-B (PiB), and subsequently 
18F-labelled ligands such as florbetapir, flutametamol and florbetaben, have allowed detection of 
amyloid pathology in vivo (Klunk et al., 2004). The diffuse, asymmetric pattern of high tracer 
uptake seen in the prefrontal cortex, precuneus and posterior cingulate, followed by the lateral 
parietal, lateral temporal cortex, and striatum reflects the distribution of amyloid plaques 
observed post-mortem (Braak et al., 1999). Several studies have observed an excellent sensitivity 
(>90%) and good specificity (>80%) for distinguishing patients with AD from both healthy controls 
and patients with other dementia subtypes (Rowe et al., 2010; Rabinovici et al., 2011; Morris et 
al., 2016). However, the relationship between amyloid deposition and dementia weakens with 
age, and around 23% of cognitively healthy individuals have amyloid pathology post-mortem 
(Savva et al., 2009). The lower positive predictive value of an amyloid scan in older individuals may 
mean that such scans are more helpful in ruling out AD (given its excellent sensitivity) rather than 
in confirming the presence of an AD pathophysiological process. 
The structural imaging methods, computed tomography (CT) and magnetic resonance imaging 
(MRI) can detect the early degenerative changes of AD seen in medial temporal lobe (MTL) 
structures. MTL atrophy distinguishes AD from healthy controls in with greater than 85% accuracy 
(Scheltens et al., 2002), and is correlates with both the severity cognitive decline and of AD 
neuropathology. 
FDG PET is used to detect areas of hypometabolism consistent with dysfunction and 
neurodegeneration. In AD, this is observed in temporo-parietal areas, particularly the angular 
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gyrus, the cuneus and the posterior cingulate cortex with relative preservation of metabolism in 
the basal ganglia, motor cortex and visual cortex (Herholz, 2011). This method has demonstrated 
good sensitivity (85%) and excellent specificity (90%) in distinguishing AD from healthy controls 
(O’Brien et al., 2014a). 99mTc-hexamethyl propyleneamine oxime (HMPAO) SPECT, which detects 
areas of regional neurodegeneration by measurement of cerebral blood flow, is listed in best 
practice guidelines as a second line investigation in dementia subtype diagnosis (NICE, 2018), but 
is not specified as an AD biomarker in NIA-AA criteria (McKhann et al., 2011). Both FDG PET and 
HMPAO are discussed further in Chapter 2.  
1.2.4 Neuropathology 
The main pathological substrates in AD are neurofibrillary tangles (NFTs) and amyloid-beta (Ab) 
plaques, which are seen in association with neuronal degeneration and death. 
 
NFTs are intracellular aggregations of the protein tau, which in its physiological function has a role 
in maintaining structural cellular integrity through stabilisation of microtubules. 
Hyperphosphorylation of tau prevents its binding to microtubules and leads to aggregation into 
insoluble NFTs, which impair neuronal and synaptic function. Beginning in the transentorhinal 
cortex, NFT pathology appears to develop in a largely uniform manner, spreading to the 
hippocampus, limbic system and cortex (Braak et al., 2006). The degree of tau pathology burden 
correlates closely with AD disease severity (Nelson et al., 2012; Ossenkoppele et al., 2016). 
 
Ab plaques are formed when the physiological processing of amyloid precursor protein (APP) is 
disrupted by the pathological cleavage catalysed by one or more enzymes, in what has become 
known as the “amyloid cascade” hypothesis; accumulation of insoluble Ab then triggers plaque 
and NFT formation, leading to cell dysfunction and death (Reitz, 2012). In contrast to the pattern 
of NFT development, plaques are first observed in the neocortex before proceeding in a caudal 
direction to allocortical and brainstem structures (Brettschneider et al., 2015).  
 
1.2.5 Management  
No disease-modifying therapies for AD are currently available, and recommended treatment is 
primarily with the acetylcholinesterase inhibitors, donepezil, rivastigmine and galantamine, and 
the NMDA receptor antagonist memantine (O’Brien et al., 2017; NICE, 2018). Meta-analysis of ten 
randomised, double blind placebo-controlled trials found that prescription of one of these 
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medications in patients with mild and moderate AD was associated with improvements, albeit 
with small effect sizes, in global clinical state, activities of daily living (ADLs) and behaviour (Birks, 
2006). Symptomatic benefits in cognition were also seen, equivalent to 1.4 points on MMSE and 
2.7 points on the Alzheimer’s disease assessment scale cognitive subscale (ADAS-Cog). 
 
1.2.6  Summary 
AD is the most common dementia subtype, characterised by an insidious onset of cognitive 
impairment. This is typically most pronounced in the domain of episodic memory, but a smaller 
proportion of patients my present with deficits in language, visuospatial ability, or executive 
function. Like in DLB, diagnostic criteria for AD attempt to combine clinical observations with the 
neuropathological changes seen in AD, but definitive diagnosis cannot be made antemortem, even 
in the presence of imaging and CSF biomarkers closely associated with amyloid deposition and 
neuronal degeneration.  
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Chapter 2 
Understanding DLB detection in clinical services 
 
2.1 Introduction 
Understanding and optimising the clinical diagnosis of DLB is important. Identification of DLB 
directs clinicians' attention towards the detection and treatment of symptoms associated with the 
disease; for example, dopamine replacement therapy for parkinsonian symptoms (Bonelli et al., 
2004; Onofrj et al., 2013), or clonazepam for RBD (Massironi, Galluzzi and Frisoni, 2003). Similarly, 
a DLB diagnosis should direct clinicians away from harmful management strategies like 
antipsychotic prescription, capable of producing fatal reactions to in patients with DLB (McKeith, 
Ballard and Harrison, 1995). Detection is also crucial to providing the patient and carer with 
accurate and evidence-based information on the disease itself, its symptoms, treatments and 
prognosis. Outcomes associated with DLB, such as increased rates of hospitalisation (Hanyu et al., 
2009), nursing home admission (Rongve et al., 2014) and carer stress (Leggett et al., 2011; Lee et 
al., 2013) are important points of discussion between clinicians, patients and carers. Despite this 
importance of recognition, and the existence of validated diagnostic criteria (McKeith et al., 2005, 
2017), initial misdiagnosis of DLB is a common experience (Galvin et al., 2010). 
 
Although frequently cited as the second most common neurodegenerative dementia (McKeith et 
al., 2017), there is little consensus regarding the prevalence of DLB. In this chapter we will discuss 
the different methodologies used to investigate DLB case frequency, exploring the strengths and 
limitations in each and discussing why comparison of the findings of different studies can be 
challenging. 
 
2.2 DLB prevalence and incidence 
The majority of studies investigating DLB prevalence and incidence are cross-sectional surveys of 
dementia populations and often adopt one of two main types of methodology in defining a DLB 
case. The first type of study defines DLB cases on the basis of Lewy body pathology detected in 
post-mortem samples (neuropathological studies); the second type on the basis of the 
antemortem clinical signs and symptoms characteristic of DLB (clinical studies). As well as 
comparing the findings from these two groups, this chapter will discuss the strengths and 
limitations of each. 
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Prior to discussing DLB prevalence and incidence, it is important to clearly define what we mean 
by these terms. Prevalence is the proportion of cases in population at a given point in time 
(Coggon, Rose and Barker, 2003), and in the case of DLB prevalence is discussed throughout 
previous studies as the percentage of cases with DLB within a dementia cohort (Vann Jones and 
O’Brien, 2014). Similarly, incidence is expressed as a percentage of new DLB cases among newly 
diagnosed dementia cases (Vann Jones and O’Brien, 2014). This chapter will therefore refer to 
prevalence and incidence in these terms.  
 
Both prevalence and incidence are useful ways of discussing DLB frequency. All-cause dementia 
cases provide us with a conceptually and numerically stable denominator (Matthews et al., 2016) 
with which clinicians are familiar and comfortable; as a numerator, DLB may be less well 
understood in clinical practice, having undergone conceptual evolution over the past two decades 
(McKeith et al., 1996, 2005, 2017). Since DLB cases, when not recognised, are likely to be 
misdiagnosed as AD rather than a non-dementia diagnosis (Gaugler et al., 2013; Galvin, 2015), 
referring to variation in detection or recognition as a percentage of all dementia cases is practical 
and can be easily contextualised to clinical services. 
 
Incidence has been investigated in considerably fewer studies than DLB prevalence (Miech et al., 
2002; Matsui et al., 2008; Perez et al., 2010; Savica et al., 2013) and for both this reason, and to 
enable comparison between neuropathological and clinical study designs, the discussion will focus 
on DLB prevalence.  
 
2.2.1 DLB prevalence in neuropathological cohorts 
Of the two methodologies described above, neuropathological studies typically report the higher 
rates of DLB prevalence, with most studies identifying pathology in 15-30% of subjects with 
dementia. In a hospital-based consecutive autopsy group comprising 1 100 subjects over the age 
of 70 with dementia, DLB was noted as the predominant pathology in 8.5%, with a further 8.9% 
demonstrating mixed AD and DLB pathology (Jellinger and Attems, 2011). One sample researching 
a community sample of 601 people aged 75 or over described DLB in 22% of 137 dementia cases 
(Rahkonen et al., 2003) and the Vantaa 85+ study found that 36% of 304 subjects had pathological 
evidence of LB disease (Oinas et al., 2009).  
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Interpretation of this data in a clinical context is challenging, as α-synuclein pathology has been 
found in up to 11% of patients without dementia at death (Wakisaka et al., 2003) and in patients 
with other dementia subtypes (Ince, 2001; Jellinger, 2003). There is no consensus regarding a 
threshold of α-synuclein pathology that accurately differentiates patients with dementia from 
healthy older controls (Ince, 2001; Sonnen et al., 2007; Zaccai et al., 2015).  
 
Most neuropathological studies therefore reflect the extent of pathology observed, rather than 
whether or not this was related to clinical expression of DLB symptoms. This is further complicated 
by the high proportion of DLB cases that have comorbid AD findings, and that in such cases the 
clinical phenotype may more closely resemble AD than DLB (Tiraboschi et al., 2006; Weisman et 
al., 2007; Thomas et al., 2018b). There is therefore a strong possibility that a proportion of DLB 
cases, both pure and with comorbid AD pathology, will not and indeed could not be detected in 
routine clinical practice using current diagnostic methods. 
 
Other factors further challenge clinical contextualisation of neuropathological data. Sample sizes 
in autopsy studies are generally smaller than in clinical studies and have been demonstrated to be 
subject to selection bias; subjects volunteering for autopsy studies are more likely to be white, 
married, more highly educated and have a longer duration of symptoms than those in a clinical 
population (Fillenbaum et al., 1996; Tsuang et al., 2006). Some studies, such as the Cognitive 
Functioning and Ageing Study (CFAS) (Ince, 2001) have attempted to recruit from community 
samples in an effort to minimise referral bias, but are still subject to consent bias, considerable 
attrition bias and a relative lack of ethnic variation (Zaccai, Ince and Brayne, 2006). 
 
It is also difficult for autopsy studies to correlate clinical findings with neuropathological data. 
When classifying participants as dementia cases or healthy controls, retrospective studies rely on 
incomplete or unreliable data (Zaccai, Ince and Brayne, 2006). Some studies regularly collect 
antemortem data with standardised clinical tools (Ince, 2001; Polvikoski, Sulkava and Myllykangas, 
2001), but a duration of up to two years between assessments mean that the cognitive status at 
last interview may not be representative of that immediately prior to death (Zaccai, Ince and 
Brayne, 2006).  
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In summary, neuropathological studies reflect the extent of pathology, but not the clinical 
expression of DLB symptoms, which may not be present in a proportion of cases. Factors such as 
selection bias and small sample sizes may contribute to the higher rates of DLB prevalence 
described in post-mortem studies. Neuropathological studies provide a useful upper margin for 
DLB prevalence but generalising their findings to clinical populations is difficult. 
 
2.2.2 DLB prevalence in clinical cohorts 
Clinical studies of DLB prevalence screen the entirety of an at-risk population (e.g. residents over 
60 years old), or a random sample of a population in a particular community or region. 
Participants typically complete standardised screening tools before undergoing further 
assessment if dementia is suspected. DLB prevalence in these studies can often therefore 
expressed both as a proportion of all residents in the cohort studied and of dementia cases in the 
cohort studied (Stevens et al., 2002; Rahkonen et al., 2003; Yue et al., 2016).  
 
A 2014 meta-analysis of 18 such DLB prevalence studies, comprising a collective 26 137 patients 
aged 65 and over, reported that DLB represented 4.24% (95% CI 3.44–5.17%) of all dementia cases 
(Vann Jones and O’Brien, 2014). There was, however, considerable variation demonstrated among 
contributing studies; three studies, collectively comprising 3 579 cases, 290 patients of whom had 
dementia, failed to identify a single DLB case between them (Yamada et al., 2002; Arslantaş et al., 
2009; Yusuf et al., 2011). Although a Finnish study of 601 individuals over the age of 75 reported a 
DLB prevalence of 21.9% (Rahkonen et al., 2003), diagnosis was made on the basis of post-mortem 
examination, and its presence as an outlier underlines that it more closely represents a 
neuropathological study than others contributing to meta-analysis; no other study included 
reported a DLB prevalence higher than 10% (Vann Jones and O’Brien, 2014). 
 
Since publication of meta-analysis, the largest single clinical DLB prevalence study to date has 
been published, totalling 5 542 people in a rural Chinese population aged 60 and over and 
reporting that DLB cases represented 10.1% of 574 dementia cases (Yue et al., 2016). Although 
this figure included patients likely to have PDD rather than DLB, previous studies adopting the 
same practice have reported similar prevalence rates (9.1-9.7%) (Stevens et al., 2002; Gascón-
Bayarri et al., 2007; Fernández Martínez et al., 2008). Among these three is the sole population-
based prevalence study conducted in a UK population (Stevens et al., 2002). 
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Clinical studies offer an advantage over neuropathological studies in helping to understand how 
commonly the clinical DLB phenotype can arise in communities. The systematic approach that 
they adopt in identifying symptoms and diagnoses can circumvent the referral bias that clinical 
studies may be subject to, potentially identifying dementia in the 43% of patients that do not 
present to services (Lang et al., 2017). Although the diagnostic processes used in these studies are 
not as accurate as the gold standard of neuropathological diagnosis, some studies combine the 
two study designs, following up cases with post-mortem examination (Rahkonen et al., 2003; 
Savica et al., 2013). 
 
Clinical epidemiological studies also have their limitations. The multi-tiered approach to case 
identification can, in some instances, mean that any screening process with sub-optimal sensitivity 
can lead to exclusion of large numbers of cases. This is demonstrated by a large DLB prevalence 
study which used recorded parkinsonism as a means of identifying the population at risk of DLB 
(Savica et al., 2013). Not only did recruitment depend of on the sensitivity of the clinician 
identifying parkinsonism, but it excluded the 15-20% of patients with DLB that never demonstrate 
parkinsonism during the course of their illness (Harvey, Skelton-Robinson and Rossor, 2003; 
Ferman et al., 2006; Walker et al., 2016). The same study also illustrated a comparative weakness 
of population-based studies in comparison to neuropathological studies; although agreement 
between antemortem and post-mortem diagnosis was very high (94.1%), one of the 17 patients 
that underwent neuropathological examination demonstrated AD features with no evidence of LB 
disease (Savica et al., 2013).  
 
Another problem in interpreting DLB prevalence-based data is the small sample sizes included in 
such studies. Of 18 papers contributing to meta-analysis (Vann Jones and O’Brien, 2014) only 
three (Rahkonen et al., 2003; Gascón-Bayarri et al., 2007; Fernández Martínez et al., 2008) 
identified more than ten DLB cases, and in all three of these studies, patients with PDD were 
included among DLB cases. The single largest all-cause dementia sample size included in meta-
analysis is 351, lower than that used in many clinical prevalence studies (Vann Jones and O’Brien, 
2014). 
 
The clinical studies described thus far all define their at-risk populations on the basis of 
characteristics like age, and the majority of these participants would not have been in contact with 
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clinical services. However, a large proportion of clinical studies have investigated DLB prevalence 
in dementia populations seen within health services. For the purposes of this thesis, these studies 
of DLB prevalence are the most important to consider in greater detail.  
 
When considering the real-life detection of DLB, and how it can be optimised, clinical prevalence 
in the context of cases presenting to secondary services therefore provides the most helpful 
reference point for discussion. It is a practically useful measure for several parties; for the 
researcher, in helping determine how many potential participants could be recruited from a 
particular service; for the manager, in determining the extent to which indicative biomarkers like 
FP-CIT SPECT and MIBG scintigraphy could be funded; and for the clinician, in helping benchmark 
his/her diagnostic sensitivity by comparing their own case detection rate with that reported 
elsewhere. It is around the characteristics of patients presenting to memory and cognitive 
services, rather than around cases in the wider community, that management pathways have 
been constructed (NICE, 2006). Were new methods of optimising DLB detection to emerge, such 
as new biomarkers, or validated assessment tools (Galvin, 2015; Thomas et al., 2017b), clinical 
prevalence before and after the introduction of such methods can help quantify their clinical 
usefulness. 
 
Numerous studies have investigated the prevalence of DLB in secondary care clinical populations. 
A 2014 meta-analysis (Vann Jones and O’Brien, 2014) included ten studies reporting the 
prevalence of DLB (Londos et al., 2000; Chan et al., 2002; Harvey, Skelton-Robinson and Rossor, 
2003; Takada et al., 2003; Sambrook et al., 2004; Yokota et al., 2005; Shinagawa et al., 2007; 
Aarsland et al., 2008; Alladi et al., 2011; Yoshida et al., 2011). These studies collectively totalled 3 
144 participants with dementia and reported that DLB comprised 7.47% (95% CI 6.58–8.45) of this 
cohort. However, there was considerable variation in the frequency rates reported in individual 
studies; DLB comprised 2.18% (95% CI 0.80–4.69) of one cohort (Takada et al., 2003) and 
15.82% (95% CI 11.01–21.69) of another (Aarsland et al., 2008). 
 
Direct comparison of individual studies is challenged by a considerable variation in methodology. 
Only two of ten studies in secondary care populations (Aarsland et al., 2008; Alladi et al., 2011) 
contributing to this meta-analysis used the third consensus criteria (McKeith et al., 2005), which 
has demonstrated higher sensitivity (85% (McKeith et al., 2000b)) than the 1996 criteria (McKeith 
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et al., 1996) used in the remaining eight studies (75% (Mega et al., 1996)). Both reported DLB 
frequency rates higher than the 7.47% mean generated by the meta-analysis.  
 
Other characteristics also contributed to the heterogeneity of included studies. Small sample sizes 
(ranging from 102 to 766) resulted in wide confidence intervals in each cohort. Several were 
conducted predominantly in specialist or tertiary care services (Takada et al., 2003; Sambrook et 
al., 2004; Shinagawa et al., 2007; Alladi et al., 2011), inpatient populations (Chan et al., 2002), or 
among younger patients with dementia (Harvey, Skelton-Robinson and Rossor, 2003; Shinagawa 
et al., 2007) while others took place in more clinically representative settings. Differences 
between studies also go beyond recruitment; four of ten papers published did not include a 
neurological examination as part of their methodology (Londos et al., 2000; Chan et al., 2002; 
Sambrook et al., 2004; Yoshida et al., 2011), and each applied varying inclusion and exclusion 
criteria.  Importantly, only two studies included a longitudinal component to their study design 
(Harvey, Skelton-Robinson and Rossor, 2003; Takada et al., 2003; Sambrook et al., 2004), thus 
failing to account for the emergence of core symptoms after initial diagnosis, and therefore the 
possibility of diagnostic revision.  
 
Studies of clinical DLB prevalence published since this meta-analysis have reported case frequency 
rates lower than the 7.47% reported by Vann Jones and O’Brien (2014) (Avila-Castells et al., 2012; 
Ikejima et al., 2012; El Tallawy et al., 2013; Garcia-Ptacek et al., 2014; Sadak et al., 2014; Goodman 
et al., 2017) (Table 2.1).  
 
Among these was a study that included the single largest cohort of DLB patients in the literature to 
date. Goodman et al. (2017) reported the prevalence of dementia subtype diagnoses from 21.6 
million patients over the age of 68 and enrolled in USA federal health insurance schemes 
(Medicaid and Medicare) between 2011 and 2013. The authors reported that DLB and PDD 
together comprised 5.4% (n= 168,629) of 3.1 million patients with dementia. However, the same 
study reports that 46.1% never received a subtype diagnosis other than “Dementia (not otherwise 
specified)” and Medicaid and Medicare data has been demonstrated to have poor sensitivity for 
subtype diagnosis when compared with structured assessment methods (Taylor, Jr. et al., 2009). 
The study also investigated patients enrolled in the most basic of Medicare packages and 
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therefore likely to over-represent individuals from lower socio-economic groups. (Goodman et al., 
2017) 
 
Table 2.1 DLB prevalence studies in secondary and tertiary care populations 
 
Study Year DLB (n) Dementia (n) DLB Prevalence % (95% CI) 
Londos et al.* 2000 48 200   24.0 (18.3 – 30.5) 
Chan et al. 2002 3 102 2.9 (0.6 – 8.4) 
Harvey et al. 2003 12 185   6.5  (3.4 – 11.1) 
Takada et al. 2003 6 275 2.2  (0.8 – 4.7) 
Sambrook et al.* 2004 23 766 3.0  (1.9 – 4.5) 
Yokota et al. 2005 17 464 4.0  (2.3 – 6.3) 
Shinagawa et al. 2007 53 483 11.0  (8.3 – 14.1) 
Aarsland et al. 2008 39 196   15.8  (11.0 – 21.7) 
Yoshida et al. 2011 11 126  8.7  (4.4 - 15.1) 
Alladi et al. 2011 31 347   8.9  (6.2 – 12.4) 
Avila-Castells et al.* 2012 100 1 894 5.3  (4.4 - 6.4) 
Ikejima et al. 2012 35 768 4.6 (3.3 – 6.3) 
Bonanni et al.  2013 2 042 541   26.5 (24.6 – 28.5) 
El Tallawy et al.* 2013 7 87   8.1 (4.0 – 15.7) 
Garcia-Ptacek et al. 2014 461 15 209 3.0 (2.8 – 3.3) 
Sadak et al. 2014 241 3 768 6.4 (5.7 – 7.2) 
Goodman et al. 2017 168 629 3 110 654 5.4  (5.4 – 5.5) 
 
*Reported prevalence of DLB and PDD combined 
 
Another large DLB prevalence study, (Bonanni et al., 2013), conducted among a dementia 
population of 2 042 Italian participants, reports that DLB comprises 25-28% of new dementia cases 
in a range of secondary and tertiary services. When considered alongside neuropathological 
prevalence studies, this figure would appear unfeasibly high, particularly in a clinically 
representative population. This study is discussed further in Chapter 6.2.2. 
 
One of the difficulties presented by the heterogeneity of both clinical and neuropathological 
studies to date is the failure to consider possible variation in the true prevalence of DLB between 
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different countries, and thus the possibility that environmental factors may precipitate or 
predispose certain populations to DLB. Among countries represented in populations discussed 
above, only Japan contributed more than one study, and variation in DLB case frequency (3.95 - 
10.97%) and differences in study methodology, even between these three studies, precludes 
comparison between these populations (Shinagawa et al., 2007; Yokota et al., 2007; Yoshida et al., 
2011).  
 
Similarly, studies comparing several services in the same region might help determine whether the 
practice or expertise of clinicians in each service, rather than environmental factors within the 
region, might contribute to variation in DLB prevalence. However, only one study (Bonanni et al., 
2013) has compared DLB prevalence between different services and identified no significant 
differences in the proportion of DLB observed in secondary and tertiary care dementia services. 
 
The same factors that contribute to variation between studies also factors limit generalisability of 
individual studies, and meta-analysis, to a UK population. A single study contributing to meta-
analysis was conducted in the UK (Harvey, Skelton-Robinson and Rossor, 2003), and itself 
investigated dementia subtypes in younger onset dementia patients. Furthermore, neither this 
study, nor any of those included in meta-analysis, reflect populations representative of those seen 
in UK populations, recruiting from neurology, geriatric medicine or neuropsychiatry services; in 
contrast the majority of dementia cases in UK clinical practice are diagnosed by an Old Age 
Psychiatrist. 
 
The difficulties in comparing individual DLB prevalence studies, and in generalising this body of 
evidence to a UK clinical population, also present challenges in understanding the relationships 
between age, gender and DLB prevalence, particularly as several studies have failed to report such 
characteristics of their samples. Vann Jones and O’Brien (2014) reported that of 28 prevalence 
samples contributing to their meta-analysis, eight DLB samples reported gender composition. Of 
these eight studies, five observed a preponderance of female patients in their sample population. 
PDD is recognised as being more common in men (Mayeux et al., 1995) and recent large-scale DLB 
studies have reported significant higher rates of male patients in their samples (Savica et al., 2013; 
Goodman et al., 2017), although others have failed to identify any preponderance (Yue et al., 
2016).  
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The ages of DLB samples are more consistently reported than gender, but considerable variation is 
observed in prevalence and incidence studies; of those contributing to meta-analysis (Vann Jones 
and O’Brien, 2014) mean ages ranged from 58.7 years (Harvey, Skelton-Robinson and Rossor, 
2003) to 79.0 years (Chan et al., 2002). The only study of subtype prevalence in dementia 
populations under the age of 65 reported a comparatively high case frequency (6.5%) that might 
suggest a preponderance in younger populations (Harvey, Skelton-Robinson and Rossor, 2003) but 
larger samples have demonstrated consistent rates of DLB prevalence across the age groups of 
clinical samples (Yue et al., 2016; Goodman et al., 2017). 
 
In summary, studies investigating DLB case frequency in clinical populations provide a useful 
means of understanding and discussing prevalence of the disease. Like population-based studies 
they identify cases on the basis of clinical phenotype, but generally do so using larger sample sizes 
by sampling directly from dementia populations. Although neuropathological studies offer gold 
standard accuracy, clinical prevalence is the most helpful measure in understanding DLB diagnosis 
in clinical services.  
 
Despite this, more research in required into clinical DLB epidemiology, as existing studies have 
included small sample sizes, failed to include representative populations and failed to offer an 
insight into whether true disease prevalence may vary between different services and different 
regions. These studies have also failed to establish consistent relationships between DLB and both 
patient gender and age. These factors challenge the generalisation of current epidemiological 
research to UK practice, and underline the importance of a large-scale study of DLB prevalence in 
representative NHS services.  
 
2.3 Understanding DLB recognition in clinical services 
Understanding the detection of DLB in clinical services must go beyond examining the frequency 
of DLB among all-case dementia cases. Most epidemiological prevalence and incidence studies fail 
to capture the longitudinal nature of patients’ contact with services; clinical diagnoses in these are 
largely based on single assessments (Chan et al., 2002; Yokota et al., 2005; Shinagawa et al., 2007; 
Aarsland et al., 2008; Alladi et al., 2011; Yoshida et al., 2011). Even when routinely followed up 
(Rahkonen et al., 2003), assessment takes the form of structured interview and does not reflect 
the shorter, less focused nature of clinical follow-up. 
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One of the reasons why this is significant is that a proportion of patients with DLB are initially 
assigned an alternative dementia subtype diagnosis. Several clinicopathological studies described 
diagnostic revision at post-mortem examination, but as previously discussed (Chapter 2.2.1), 
extrapolating neuropathological findings to a clinical population can be challenging, as some cases 
autopsy-confirmed DLB pathology will not demonstrate detectable clinical features antemortem, 
particularly if comorbid AD pathology is present. A more suitable group of studies with which to 
compare naturalistic diagnostic revision are those that incorporate longitudinal assessment or 
review of clinical notes.  
 
Three of twenty-five cases (12%) recruited to one such autopsy study were diagnosed with AD at 
baseline, but developed core features later in their presentation; all three demonstrated DLB 
pathology at post-mortem examination (Thomas et al., 2017a). The same group also reported on 
22 neuropathologically mixed DLB/AD cases, of whom 14 were given an initial diagnosis of AD 
(Thomas et al., 2018b). Seven of these clinical AD cases later developed features of DLB and either 
given a subsequent diagnosis of DLB (n=2) or mixed DLB/AD (n=5). These findings are supported by 
data from a cross-sectional survey conducted by the USA Lewy Body Dementia Association among 
962 carers of patients with either DLB or PDD, reporting that of patients presenting to clinicians 
with cognitive symptoms, 19% were initially diagnosed with AD, 5% with FTD, 4% VaD and 4% 
unspecified dementia (Galvin, 2015).  
 
One of the reasons that revision of diagnosis may have occurred in these three studies was that 
opportunities were identified to reappraise diagnosis on the basis of emergence of new clinical 
features, either through study design (Thomas et al., 2017a; Thomas et al., 2018b), or by routine 
clinical care (Galvin et al., 2010). The latter provides data on the extent of contact with services, 
reporting that patients attended a mean of 3.7 ± 1.9 appointments before DLB or PDD diagnosis 
was made, and more than six visits were required in 33% of cases. This observation was 
accompanied by variation in time to diagnosis; 19% percent of respondents were diagnosed within 
a month of first contact with services and 51% were diagnosed within one year (Galvin et al., 
2010).  
 
The differences in USA and UK dementia healthcare (Knapp et al., 2007) prevent generalisation of 
this caregiver survey to NHS practice, and as a retrospective survey, findings may be subject to 
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recall bias. Although delays in diagnosis have been studied in NHS populations, these have focused 
primarily on delay in referral to specialist services on the part of general practitioners (GPs), and 
have examined the dementia syndrome rather than subtype diagnosis (O’Connor et al., 1988; 
Bamford et al., 2007; Koch, Iliffe and project, 2010). 
 
Any helpful discussion of how DLB is recognised and diagnosed in clinical services should therefore 
include consideration of diagnostic revision and investigate the opportunities that arise during 
routine clinical care to reappraise clinical symptoms and subtype diagnosis. 
 
2.4 Summary 
Despite the importance of DLB recognition in guiding clinical management and providing accurate 
information to patients and their carers, there is a lack of consensus regarding the frequency of 
DLB in dementia services. Although two broad groups of study design have been employed in 
attempting to rectify this, each has their respective strengths and limitations and report DLB as 
representing varying proportions of dementia cases. 
 
Clinical prevalence studies offer findings most relevant to understanding the prevalence of DLB in 
routine clinical care, but studies of this type have reported wide variation in methodology and 
primary findings, limiting our ability to compare studies and impairing their generalisability to the 
NHS services. An investigation into the clinical prevalence of DLB in a UK population, preferably 
involving several discrete services, is therefore important. 
 
Further understanding DLB detection requires an investigation into how frequently cases are 
initially assigned a subtype diagnosis other than DLB, as this has been reported in some studies 
with longitudinal data collection. Examining the characteristics of DLB patients’ contact with 
services, including the frequency of opportunities to reappraise diagnosis, and the duration of 
time over which symptoms evolve in order to prompt diagnostic reappraisal, would further 
improve our understanding of detection in the clinical environment. Chapter 4 describes such a 
study undertaken within UK clinical services. 
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Chapter 3 
Imaging in DLB diagnosis                        
    
3.1 Introduction 
Chapter 2 described the difficulties in interpreting the varied and limited evidence base 
surrounding DLB epidemiology but concluded that DLB nevertheless appears to comprise a 
substantial proportion of cases of neurodegenerative dementia. The chapter also discussed the 
importance of accurate DLB diagnosis (Hanyu et al., 2009; Lee et al., 2013; Stinton et al., 2015), 
but noted that many cases are not recognised in the clinical setting, and are often misdiagnosed as 
AD. 
 
The development of suitable biomarkers may provide a mechanism by which DLB case detection 
could be enhanced. Successive DLB diagnostic criteria have incorporated biomarkers capable of 
distinguishing DLB from AD. The third consensus report included striatal impairment detected by 
FP-CIT SPECT as a suggestive feature for DLB, and the fourth consensus criteria listed FP-CIT and 
MIBG cardiac scintigraphy as indicative biomarkers (McKeith et al., 2017).  
 
This chapter will provide a brief overview of imaging methods used in DLB research and clinical 
diagnosis, focusing on these two indicative biomarkers. 
 
3.2 Structural imaging 
CT and MRI are methods of assessing structural changes to the brain related to pathology and are 
capable of identifying the presence of cerebrovascular disease and reversible aetiologies 
manifesting as dementia, such as normal pressure hydrocephalus and neoplasms. Brain CT or MRI 
is therefore recommended by UK national guidelines for every patient presenting to memory 
services (NICE, 2006). MRI provides superior contrast and specific tissue characterisation to CT, 
which is cheaper, more widely available and can now be done very rapidly (Watson and Colloby, 
2016).  
 
Structural imaging methods, particularly MRI, have demonstrated some capability in 
differentiating DLB from AD. In particular, preservation of the MTL is sensitive (91%) and specific 
(94%) in distinguishing DLB from AD (Burton et al., 2009) and has been included as a supportive 
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biomarker in the fourth consensus criteria (McKeith et al., 2017). Interpretation of MTL atrophy is 
complicated, however, by the high prevalence of concurrent AD pathology in DLB cases (Jellinger 
and Attems, 2008); the rates of atrophy seen in patients with mixed DLB/AD are similar to those 
observed in subjects with AD pathology alone (Nedelska et al., 2015). While the absence of MTL 
atrophy in the presence of a degenerative dementia is therefore suggestive of DLB, the presence 
of MTL atrophy is consistent with mixed AD and LB pathology as well as an absence of LB 
pathology.  
 
3.3 Nuclear Medicine 
In spite of their higher cost, the functional imaging methods, FP-CIT and MIBG cardiac 
scintigraphy, carry greater diagnostic weight in consensus criteria than MTL preservation on CT or 
MRI (McKeith et al., 2017). The fourth consensus criteria also include two other supportive 
functional imaging biomarkers; low perfusion on HMPAO SPECT and reduced metabolism on FDG 
PET.  
 
The nuclear medicine techniques of PET and SPECT allow observation and measurement of some 
aspects more closely associated with synaptic dysfunction, rather than frank neuronal loss alone. 
Both techniques involve visualisation of functional analogues via measurement of emissions from 
attached radioisotopes. These are labelled with a radioactive moiety, most usually iodine or 
technetium (for SPECT) or carbon or fluorine (for PET) to tracers, after which they are 
administered to the patient via intravenous injection. Both PET and SPECT measure the emission 
of γ-rays produced from the decay of the radioisotope; the difference between the two modalities 
is the mechanism by which these γ-rays are generated. 
 
In PET imaging, the positron emitted following the decay of the isotope is mutually 
annihilated with an electron from the surrounding area, producing two 511keV γ-rays travelling in 
opposite directions. Opposing pairs of scintillation detectors within PET scanners simultaneously 
register these pair of photons (the "coincidence event") and enable tracing of their lines of 
response (LOR). Data derived from both the coincidence event and LOR are used to determine the 
source of positron annihilation, and thus tracer location, and are subsequently converted into a 
tomographic image.  
 
SPECT imaging differs from PET in that γ-rays are emitted in the form of single photons, rather 
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than produced through annihilation. Both modalities offer high detection sensitivity and good 
spatial resolution, and are capable of producing tomographic images, but PET provides higher 
localisation and image resolution than SPECT (Lu and Yuan, 2015). PET radiopharmaceuticals 
generally have a shorter half-life than those used in SPECT imaging, in some cases requiring the 
proximity of a cyclotron for manufacture and can therefore be more expensive (Lu and Yuan, 
2015).  
 
Nuclear medicine investigations come with important considerations that may limit their routine 
clinical use. Acute side effects of nuclear medicine techniques are rare, with 0.9 events per 100 
000 investigations reported (Matsuda et al., 2016). Although radiation exposure from 
radiopharmaceuticals are associated with an increased risk of malignancy (Soucy et al., 2013), the 
dose of radiation from FP-CIT SPECT, for example, is equivalent to exposure from background 
radiation in the UK over two years (Public Health England, 2018). Prophylactic potassium iodide 
can decrease thyroid dose from iodine-labelled radiopharmaceuticals (Nauman and Wolff, 1993), 
but this it brings its own risks of allergic reactions and gastrointestinal disturbance; however, these 
instances are believed to be very rare (Sicherer, 2004).  
 
Nuclear Medicine methods can be more expensive than structural imaging investigations such as 
CT and MRI (Rayment et al., 2016), by virtue not only of the cost of equipment, materials, and 
expertise, but in many cases by the additional human resource requirements associated with the 
presence of the patient and carer at facilities for several hours prior to image acquisition. This 
longer duration may be compounded by travel time to and from the specialist facilities, and 
complicated by clinical characteristics associated with an elderly population, such as cognitive 
impairment, mobility symptoms, or frailty. 
 
3.3.1 FDG PET 
The uptake of FDG, a glucose analogue, is used as a measure of glucose metabolism in PET 
imaging, highlighting areas of hypometabolism consistent with areas of dysfunction and 
neurodegeneration suggestive of dementia. Patients with DLB and AD demonstrate overlapping 
but distinct patterns of regional hypometabolism (Watson and Colloby, 2016). In AD, 
hypometabolism is reported as commonly affecting temporoparietal areas, with the posterior 
cingulate and medial temporal areas particularly affected, and sensory motor cortices largely 
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spared. In DLB, reductions in occipital activity are frequently observed, with significant reduction 
in the primary visual cortex demonstrating 90% sensitivity and 80% specificity for differentiating 
DLB from AD in one autopsy-confirmed sample (Minoshima et al., 2001). However, larger studies, 
with scans conducted earlier in the course of disease, have observed a lower sensitivity (67-70%) 
and specificity (74-92%) for occipital hypometabolism in differentiating DLB from AD (Ishii et al., 
1998; O’Brien et al., 2014a).  
 
The “cingulate island sign” - the relative preservation of the posterior cingulate relative to 
precuneus and cuneus, has also been suggested as a characteristic FDG PET finding in DLB, 
demonstrating superior sensitivity (83%) and specificity (93%) than occipital hypometabolism for 
discriminating DLB and AD (Lim et al., 2009), although these findings have yet to be supported by a 
multicentre study. 
 
In summary, FDG PET shows promise as a biomarker in differentiating DLB from AD but 
comparatively small sample sizes and the inconsistency in reported utility are reflected in its 
suggestive, rather than indicative, biomarker status (Watson and Colloby, 2016; McKeith et al., 
2017; Surendranathan and O’Brien, 2018). 
 
3.3.2 HMPAO SPECT 
99mTc-hexamethyl propyleneamine oxime (HMPAO) SPECT uses regional cerebral blood flow, 
rather than regional metabolism, as a means of measuring neuronal activity. As a consequence, 
HMPAO SPECT demonstrates uptake patterns similar to those observed in FDG PET studies; 
occipital and temporal lobe hypoperfusion are used as markers for DLB and AD respectively 
(Watson and Colloby, 2016). 
 
Studies assessing the clinical utility of HMPAO SPECT showed variable DLB sensitivity (64%-85%) 
and AD specificity (64%-87%) but were characterised by small sample sizes (Yeo et al., 2013). 
Although HMPAO had initially been favoured over FDG PET due to its wider availability, lower cost 
and perceived better patient tolerability, the superiority of the former in both discriminating DLB 
from AD, and degenerative dementia from healthy controls, has been demonstrated, and a 
marked decrease in the cost of FDG PET in recent years clearly supports its use over HMPAO 
(O’Brien et al., 2014a).   
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3.3.3 Amyloid PET 
The development of amyloid radiopharmaceuticals, such as 11C Pittsburgh compound B, which is 
taken up by both diffuse and neuritic plaques, has allowed in vivo measurement of amyloid 
pathology, previously confined to post-mortem examination alone. Amyloid PET has been studied 
extensively in AD populations and incorporated into revised AD criteria (McKhann et al., 2011), but 
it is less well established in DLB populations. Amyloid binding is higher in DLB than PDD and 
healthy controls, compared to in AD (Donaghy, Thomas and O’Brien, 2015) but the amyloid PET 
negativity in up to half of DLB patients, and the prevalence of amyloid positivity in healthy controls 
(Ossenkoppele et al., 2015), limit its use as a diagnostic tool. Use has generally been limited to 
research studies and amyloid PET is not included in the fourth DLB consensus report as an 
indicative or suggestive biomarker for DLB (McKeith et al., 2017).  
 
3.3.4 FP-CIT SPECT  
123I-FP-CIT SPECT (FP-CIT) assesses the presence of nigrostriatal degeneration, by visualising 
radiopharmaceutical uptake at the dopamine transporter reuptake sites in the striatum. As a 
reduction in dopamine terminals is observed in the striata of patients with DLB, subjects 
demonstrate significantly reduced striatal FP-CIT uptake compared with both their AD 
counterparts and healthy older controls (Walker et al., 2002; O’Brien et al., 2004). 
 
Studies using both ante-mortem clinical diagnosis and post-mortem neuropathological findings as 
gold standard measurements have supported the utility of FP-CIT as a biomarker, consistently 
reporting high specificity, if variable sensitivity, for DLB against other dementia subtypes. An early 
study investigating an autopsy-confirmed cohort reported a DLB sensitivity of 88% and a non-DLB 
specificity of 100% (Walker et al., 2007). A larger study comparing FP-CIT with clinical diagnosis 
observed a DLB sensitivity of 78% and AD specificity of 88% (O’Brien et al., 2004). The largest 
single FP-CIT study to date, a multicentre trial comprising 147 patients with probable or possible 
DLB, reported a mean sensitivity and non-DLB specificity of 78% and 90% respectively (McKeith et 
al., 2007), again comparing FP-CIT against the clinical diagnosis.  
 
A recent study compared ante-mortem clinical diagnosis with FP-CIT in a cohort of 30 pure DLB or 
mixed DLB/AD cases (Thomas et al., 2017a). FP-CIT demonstrated an 80% DLB sensitivity and 92% 
AD specificity, compared with the 87% sensitivity and 72% specificity of clinical assessment. The 
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superior overall accuracy of FP-CIT in this study (86%) compared to clinical diagnosis (79%) 
supports a previous meta-analysis reporting similar observations (Brigo, Turri and Tinazzi, 2015). 
 
A number of other factors beyond the clinical utility of FP-CIT positively influence its validity as a 
biomarker. Procedural guidelines for the method have been established and it is reproducible 
both within and between different research centres (Darcourt et al., 2010; Seibyl et al., 2014). 
Factors like age and gender on FP-CIT positivity have been investigated (Varrone et al., 2013), and 
procedures for interpretation are well established (Benamer et al., 2000). Low dopamine 
transporter uptake was therefore included as a suggestive DLB feature in the third (McKeith et al., 
2005) and an indicative biomarker in the fourth DLB consensus criteria (McKeith et al., 2017). 
 
A further practical consideration in FP-CIT is the absence of evidence to suggest significant 
interactions between the radiopharmaceutical and prescribed medications. Although medications 
that bind to the dopamine transporter with high affinity have been hypothesised to interfere with 
FP-CIT uptake and interpretation (Darcourt et al., 2010), only modafinil has been implicated as 
doing so in a published human study (Borghammer et al., 2014), and only amphetamines have 
been recommended to clinicians as appropriate to stop prior to FP-CIT (Booij and Kemp, 2008). 
 
There are, however, important limitations to the use of FP-CIT. Despite its excellent reported 
specificity, values for sensitivity are consistently reported in the moderate range (78%-
80%)(O’Brien et al., 2004; McKeith et al., 2007; Thomas et al., 2017a). Thomas et al. (2017a) 
reported a higher specificity and overall accuracy of FP-CIT over clinical diagnosis, but a higher 
sensitivity was observed in the latter (87% vs 80%). The same study reported negative FP-CIT 
findings in three cases among their neuropathologically-confirmed cohort of 30 DLB patients. Each 
of these cases demonstrated predominantly neocortical or limbic pathology rather than striatal 
disease, and had presented with fluctuations and visual hallucinations, suggesting that FP-CIT may 
have limited sensitivity in such clinical groups.  
 
A further three cases from this study met clinical criteria for probable AD at the time of scanning, 
but subsequently developed DLB symptoms, indicating that striatal impairment in some cases may 
not be sufficient to produce an abnormal FP-CIT result in the early stages of disease (Thomas et 
al., 2017a). This has been supported by a study from the same group, reporting that FP-CIT 
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demonstrated limited sensitivity (54.2%) but good specificity (89.0%) in distinguishing MCI with LB 
disease from MCI in AD (Thomas et al., 2018a).   
 
This absence of substantial striatal pathology in a proportion of patients with neocortical Lewy 
body disease is supported by findings in community-based neuropathological cohorts (Zaccai et 
al., 2015) and raises the theoretical, though currently unsubstantiated, possibility that FP-CIT 
sensitivity may be lower in certain DLB disease phenotypes; in particular, patients without 
parkinsonian symptoms. Since the dopamine transporter loss measured by FP-CIT has been shown 
to be less pronounced in subjects without parkinsonism (Piggott et al., 1999), and since less than 
85% of DLB patients demonstrate such symptoms during the course of their illness (Harvey, 
Skelton-Robinson and Rossor, 2003; Ferman et al., 2006; Savica et al., 2013; Walker et al., 2016), it 
might be expected that FP-CIT produces a higher rate of false negative results in those without 
extrapyramidal features than in other DLB phenotypes. FP-CIT utility has not been researched 
specifically in patients without parkinsonism, but the absence of striatal pathology in 
neuropathologically confirmed DLB cases, albeit in small sample sizes, could encourage 
investigation of alternative biomarkers in such groups. 
 
As well as the potential for these false negative FP-CIT findings, clinically relevant false positive 
results can also occur. Frontotemporal dementia, basal ganglia infarcts, progressive supranuclear 
palsy (PSP) and MSA, all of which can share clinical characteristics with DLB and PDD, can all 
produce positive FP-CIT findings (Zijlmans et al., 2007; Vlaar et al., 2008; Morgan et al., 2012).  
 
In summary, FP-CIT is validated as a biomarker for differentiating DLB from AD and non-DLB 
dementias, demonstrating excellent specificity and overall accuracy as reported by a range of 
studies. It is not, however, without its weaknesses, including a suboptimal sensitivity that may be 
related to certain disease phenotypes, and alternative biomarkers may be helpful in such 
populations. 
 
3.4 MIBG cardiac scintigraphy 
3.4.1 MIBG studies in clinical populations 
123I-metaiodobenzylguanidine (MIBG) is a radiopharmaceutical which permits visualisation and 
semiquantification of sympathetic innervation with planar scintigraphy or SPECT imaging.  An 
 38 
analogue of guanethidine, MIBG is taken up by the postganglionic presynaptic nerve endings, and 
radioactive labelling of MIBG permits visualisation of innervation in vivo. Semi-quantification of 
cardiac MIBG uptake, and thus degree of sympathetic denervation, is achieved through calculation 
of the heart to mediastinum ratio (HMR) of MIBG uptake on planar imaging. These images are 
acquired at 20 minutes (“early” images) and 240 minutes (“late” images) following radioisotope 
injection. A region of interest (ROI) is drawn over the heart, and a ROI positioned on the upper 
mediastinum. HMRs are calculated as a fraction of the mean count per pixel in the heart ROI 
divided by that in the upper mediastinum ROI.  
 
First used to determine sympathetic dysfunction in congestive cardiac failure and myocardial 
infarction (MI) (Henderson et al., 1988; Schofer et al., 1988), MIBG was later employed to 
investigate systemic autonomic dysfunction in PD and came to be proposed as a means of 
distinguishing PD from MSA (Braune et al., 1998; Orimo et al., 1999). Watanabe et al. (2001). 
Yoshita et al. (2001) first reported significant differences in HMR uptake between DLB and AD 
patients. 
 
Early work investigating MIBG in DLB populations was conducted among Japanese patients; six of 
the eight studies contributing to a 2012 meta-analysis of MIBG utility investigated Japanese 
cohorts (Treglia and Cason, 2012). Between 2001 and 2009, several studies observed MIBG’s 100% 
sensitivity and specificity in differentiating DLB from AD (Watanabe et al., 2001; Yoshita, Taki and 
Yamada, 2001; Oide et al., 2003; Yoshita et al., 2006; Noguchi-Shinohara et al., 2009). Hanyu et al. 
(2006) described not only a 100% sensitivity and 92% specificity of MIBG for distinguishing DLB 
from AD, but also observed a lower MIBG uptake in patients with DLB than those with VaD, 
Parkinson’s Plus dementia syndromes and FTD. MIBG had a 95% DLB sensitivity and 87% non-DLB 
specificity. 
 
Yoshita et al. (2015) published the findings of their study of MIBG in the largest single DLB cohort 
to date (n=87; probable DLB n=61, probable AD n=46). Data was collected at ten Japanese sites, 
necessitating the development of a calibration method to standardise practice across participating 
centres (Nakajima et al., 2012). An overall MIBG sensitivity of 69% and specificity of 89% to 
differentiate probable DLB from probable AD was reported, with higher accuracy reported (77% 
sensitivity, and 94% specificity) in patients with mild dementia (MMSE ≥ 22). 
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The favourable utility of MIBG in DLB diagnosis in these samples has contributed to the 
widespread use of MIBG in Japanese clinical practice (Nakajima et al., 2008) and recognition of the 
modality as a supportive imaging tool by the nation’s social health insurance authorities (Orimo et 
al., 2016). 
 
Four prospective European studies have investigated MIBG in DLB populations; three in Italian 
groups, and one in a Spanish cohort (Estorch et al., 2008; Novellino et al., 2010; Treglia et al., 
2012; Tiraboschi et al., 2016). Estorch et al. (2008) reported on MIBG findings from a group 
comprising 19 Spanish DLB subjects (each with two or more clinical DLB features), as well as 12 AD 
patients and 13 recruits with other neurodegenerative diseases with cognitive impairment. A post 
hoc HMR cut-off of 1.36 corresponded to a sensitivity and specificity of MIBG of 94% and 96% 
respectively. Novellino et al. (2010) reported an abnormal HMR in all DLB patients (probable DLB n 
=8, possible DLB n=1) and normal HMR in FTD (n=6) and controls (n=16), with MIBG demonstrating 
a 100% accuracy in distinguishing the two groups. 
 
3.4.2 MIBG and potentially interfering medications 
Although the evidence base relating to MIBG has encouraging implications for clinical practice, the 
important limitations of the research conducted thus far make translation of research data into 
routine use difficult.  
 
The majority of MIBG studies to date have excluded patients prescribed any medications 
suspected to interfere with MIBG uptake (Oide et al., 2003; Hanyu et al., 2006; Yoshita et al., 
2006; Wada-Isoe et al., 2007; Estorch et al., 2008; Noguchi-Shinohara et al., 2009; Novellino et al., 
2010), citing guidelines by the European Association of Nuclear Medicine (Giammarile et al., 
2008), or a review relating to MIBG use in the treatment of neuroblastoma (Solanki et al., 1992). 
As an analogue of noradrenaline, MIBG is transported into presynaptic terminals through a 
number of mechanisms; chiefly, the energy-dependent “Uptake-one” process mediated by the 
norepinephrine transporter (NET), a transmembrane protein (Streby et al., 2015). Other processes 
also influence noradrenaline transport across the cell membrane, including active transport into 
vesicles, granular uptake, and calcium channel-mediated reuptake. Disruption of any of these 
mechanisms has the theoretical potential to diminish noradrenaline, and therefore MIBG, uptake 
(Giammarile et al., 2008). 
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This practice of excluding patients on such medications, while important in accounting for 
confounding variables in an emerging evidence base, presents considerable difficulty in 
establishing MIBG in routine clinical practice. Among the medications identified as potentially 
interfering with MIBG are a number of commonly prescribed, clinically important agents that 
include analgesics, antidepressants, antipsychotics, cardiovascular medications and inhaled 
sympathomimetics used in the treatment of asthma and chronic obstructive pulmonary disease.  
 
Marquié Sayagués et al. (2010) demonstrated the scale of exclusion of such patients in a 2010 
non-controlled study investigating MIBG use in the diagnosis of DLB and PDD. Thirty one of the 77 
patients (40%) recruited to the study were prescribed medications identified as potentially 
interfering with uptake; these included antipsychotics (n=26), levodopa (n=29; 38%), venlafaxine 
(n=4; 5%), and amitriptyline (n=2; 3%). Twenty-seven participants (35%) were also prescribed 
antihypertensive medication. The study failed to identify a significant difference in HMR between 
patients prescribed potentially interfering medications (HMR 1.47 ± 0.23) and those that were not 
(HMR 1.40 ± 0.33). That such a high proportion of participants were prescribed such medications 
in this clinically representative sample indicates the impracticability of restricting MIBG use in 
these patients, both in research and clinical settings. 
 
The argument against excluding patients prescribed medications identified as interfering was 
strengthened further by a comprehensive review, which assessed published data on drug 
interactions with MIBG uptake (Jacobson and Travin, 2015). The authors noted that the majority 
of studies involved in vitro or non-human methodologies and recommended that only labetalol or 
tricyclic antidepressants should be withdrawn prior to MIBG imaging. 
 
More recent MIBG utility studies have created inclusion and exclusion criteria with the intent of 
recruiting more clinically representative populations. Yoshita et al’s (2015) multicentre study 
excluded patients on the basis of reserpine or tricyclic antidepressants alone, while an Italian 
MIBG study withheld medications, rather than exclude their participants, prior to cardiac 
scintigraphy (Tiraboschi et al., 2016). Withholding medications poses its own practical difficulties; 
restricting use of medications such as inhalers, analgesics or dopaminergic agents for even short 
periods could lead to an escalation in symptoms and deterioration in wellbeing.  
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3.4.3 MIBG and comorbidities 
Similar concerns exist surrounding the exclusion of patients with medical comorbidities from MIBG 
utility studies. In determining the presence of impaired sympathetic uptake, MIBG studies in DLB 
diagnosis have presumed such findings to be attributable to neuronal denervation secondary to α-
synuclein deposition; however, several common conditions are capable of producing similar 
findings. Early MIBG studies restricted the recruitment of patients with comorbidities. In order to 
prevent the possibility of reduced MIBG uptake in diabetic neuropathy, studies excluded patients 
with any history of diabetes mellitus (Hanyu et al., 2006; Yoshita et al., 2006; Wada-Isoe et al., 
2007; Estorch et al., 2008; Noguchi-Shinohara et al., 2009). Patients with “heart disease” were 
excluded to account for the generalised reduction in noradrenergic uptake observed in left 
ventricular dysfunction and the more localised reduction secondary to both chronic and acute 
myocardial ischaemia (Hanyu et al., 2006; Yoshita et al., 2006; Estorch et al., 2008; Noguchi-
Shinohara et al., 2009; Novellino et al., 2010; Wada-Isoe et al., 2012). Subjects with thyroid 
disease, capable of producing autonomic dysfunction, and therefore impaired MIBG uptake, were 
excluded in two of these studies (Hanyu et al., 2006; Yoshita et al., 2006). 
 
Marquié Sayagués et al. (2010) demonstrated that medical comorbidities affected a substantial 
proportion of the population likely to benefit from MIBG and found no significant relationship 
between HMR and comorbidity status. Twenty-four of 77 subjects had a history of “diseases that 
may interfere with uptake”, including arrhythmias, MI and cardiac failure.  
 
Two more recent studies have attempted to address the difficulty in translating the findings of 
early MIBG studies into clinical practice. Yoshita et al’s (2015) multicentre study did recruit a 
population with some comorbidities, including subjects with a history of ischaemic heart disease 
or myocardial blood flow abnormalities, provided they occurred more than six or twelve months 
respectively before consent. The same study did, however, also exclude patients with thyroid 
disease and insulin-controlled diabetes.  
 
Tiraboschi et al. (2016) did not cite any medical illnesses in the exclusion criteria of their study, 
explicitly stating that they deliberately included subjects “with common illnesses in the elderly 
(including ischemic, hypertensive, dilated cardiomyopathy, and diabetes) that might reduce 123I-
MIBG uptake”, in an effort to investigate a cohort representative of clinical practice. While the 
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same paper failed to cite how many of its participants were affected by such illnesses, it did report 
that DLB and non-DLB subjects reported a mean of 0.8 and 0.5 conditions (as structured by the 
Cumulative Illness Rating scale) respectively. 
 
To summarise, although early MIBG studies excluded large proportions of patients on the basis of 
both medical comorbidities and prescribed medications, the high prevalence of these factors 
severely restricts the translation of such findings into clinical practice (Marquié Sayagués et al., 
2010). Although two more recent studies, conducted in Japan and Italy, have recruited more 
representative cohorts, the former reported the lowest overall accuracy of MIBG published to 
date, and the latter temporarily withdrew medications deemed capable of interacting with MIBG 
uptake (Yoshita et al., 2015; Tiraboschi et al., 2016). 
 
3.4.4 Comparing MIBG and FP-CIT 
As two of the indicative biomarkers listed by the fourth consensus criteria, direct comparison of 
FP-CIT and MIBG is important in guiding clinical decision making. Although as described above, 
some studies have shown sensitivity (98%) and specificity (94%) for MIBG superior to that of FP-
CIT (sensitivity 79%, specificity 90%) (McKeith et al., 2007; Treglia et al., 2012), research relating to 
the latter has been conducted on more clinically representative populations. 
 
Two Italian studies directly compare MIBG and FP-CIT in a concurrent group of patients (Treglia et 
al., 2012; Tiraboschi et al., 2016). Treglia et al. (2012) described four different combinations of FP-
CIT and MIBG results in a group of 31 patients with dementia; 17 of 20 DLB patients (85%) had 
abnormal findings in both imaging modalities. Identical results for DLB sensitivity (90%), AD 
specificity and overall accuracy (91%) were reported for both FP-CIT and MIBG in this group.  
 
Tiraboschi et al’s (2016) findings also described all four combinations of FP-CIT and MIBG result in 
a cohort comprising 30 DLB patients (probable DLB n=27, possible DLB n=3) and 29 recruits with a 
non-DLB dementia diagnosis. MIBG was reported to have a superior sensitivity (93%) and 
specificity (100%) to FP-CIT in this group (sensitivity 90%, specificity 76%); the two modalities 
agreed on 68% of cases enrolled in the study. It should be noted, however, that the study included 
thirteen patients with FTD and PSP among their non-DLB group, and such conditions capable of 
producing false positive FP-CIT results (Vlaar et al., 2008; Morgan et al., 2012). The two Italian 
groups employed different methods of determining whether a HMR finding was abnormal. The 
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Tiraboschi et al. (2016) study used the 1.6 cut-off used by Yoshita et al. (2006), while Treglia et al. 
(2012) considered myocardial uptake abnormal if it was more than two standard deviations below 
the population mean; this corresponded to a threshold of 1.55. 
 
3.4.5 HMR cut-off 
A weakness of the evidence surrounding MIBG is that there does not appear to be a clear 
consensus regarding what represents a normal and an abnormal scan. This is in contrast to the 
established visual rating system used in FP-CIT interpretation (Benamer et al., 2000). 
 
As previously discussed, semi-quantification of cardiac MIBG uptake is achieved through 
calculation of the HMR; the MIBG uptake in a heart ROI is divided by uptake in the reference 
mediastinal ROI. An MIBG scan is deemed abnormal when HMR falls below a certain value. If a 
cut-off were too low, DLB cases with lesser degrees of denervation (and thus higher HMR values) 
might not fall under the threshold, producing a false negative result; too high a threshold, and 
non-DLB cases with uptake at the lower end of normal range could produce false positive results.  
 
MIBG studies to date have varied in their approach to the threshold between abnormal and 
normal scans. Only a handful of studies report a priori HMR cut-offs, citing values of 1.56-1.60 
derived from the mean values of older patients in local databases (Estorch et al., 2008; Marquié 
Sayagués et al., 2010; Tiraboschi et al., 2016). Several Japanese studies calculated post hoc cut-offs 
between 1.68 and 2.10 (Yoshita et al., 2006; Wada-Isoe et al., 2007), or sought only to identify a 
significant difference between DLB and non-DLB group mean values (Watanabe et al., 2001; Oide 
et al., 2003; Noguchi-Shinohara et al., 2009). Others characterised abnormal scans as those with 
HMR values falling two or three standard deviations below the control population mean (Hanyu et 
al., 2006; Novellino et al., 2010). Although two studies did employ a visual rating system in parallel 
with HMR analysis, semiquantification was the preferred method of analysis in discussion (Yoshita 
et al., 2015; Tiraboschi et al., 2016). 
 
The observed variation in HMR cut-off practices presents difficulty in translating MIBG into clinical 
practice, where nuclear medicine departments may not have access to a control population 
against which to compare HMR values in people with dementia. The range of reported post hoc 
values might also suggest that different control populations may possess factors influencing HMR, 
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and therefore MIBG utility. This is particularly significant when one considers that the vast 
majority of MIBG research to date has taken place in Japanese populations. Nakajima et al. (2012) 
attempted to account for such variation across centres using a calibration method for ten 
participating departments, a practice extended to European centres in a recent study (Verschure 
et al., 2017), but MIBG otherwise currently lacks the standardised approach to reporting 
possessed by FP-CIT. 
 
3.4.6 MIBG Conclusions 
MIBG shows promise as an accurate biomarker in distinguishing DLB from AD. Studies in both 
Japan and Europe have suggested encouraging, but variable rates of sensitivity and specificity (87-
100%); several of these are reported rates superior to those seen in FP-CIT (Estorch et al., 2008; 
Noguchi-Shinohara et al., 2009; Novellino et al., 2010). However, the largest sample size in the 
field to date reported relatively inferior sensitivity (69%) and comparable specificity (89%) to FP-
CIT (Yoshita et al., 2006). 
 
The evidence surrounding MIBG has important limitations that challenge integration into routine 
clinical practice, which future research should seek to address. Study samples to date have largely 
failed to accurately represent clinical populations, particularly with respect to inclusion of subjects 
with comorbidities and those with medications suspected to interfere with MIBG uptake. No 
studies to date have researched MIBG in a UK population. MIBG and FP-CIT have not been 
extensively compared in concurrent populations, despite the potential value of doing so to clinical 
decision making. This is further complicated by the absence of a consensus regarding a clear HMR 
threshold to distinguish an abnormal MIBG scan from a normal scan. 
 
3.5 Summary 
Several biomarkers exist to assist clinical decision making in DLB diagnosis, each with their 
respective strengths and weaknesses, but FP-CIT and MIBG in particular are capable of 
distinguishing DLB from AD and from other non-DLB pathologies. FP-CIT is supported by a 
developed evidence base, comprised by studies comparing its utility with both clinical and 
neuropathological DLB diagnosis. Although reliable and widely available, it does have weaknesses 
that include a suboptimal sensitivity. Other concerns surround its accuracy in patients without 
parkinsonian features and in subjects in the early stages of their illness. 
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Some MIBG studies have reported sensitivity and specificity superior that of FP-CIT, but despite its 
equivalent status as an indicative biomarker in the fourth consensus criteria (McKeith et al., 2017), 
the evidence base surrounding MIBG is less well developed than that of FP-CIT. The role of 
interfering medications and comorbidities, as well as the practical considerations such as the HMR 
threshold in differentiating normal and abnormal scans, must be further explored before MIBG is 
established alongside FP-CIT as a routine biomarker for differentiating DLB from AD. 
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Chapter 4 
A study of the frequency of DLB cases in NHS clinical services - aims, hypotheses 
and methods 
 
4.1 Aims 
The aim of this study was to determine the prevalence of DLB in a number of different NHS clinical 
services. Through subsequent detailed extraction of data from clinical case notes, it also aimed to 
compare the clinical pathway to diagnosis in DLB cases, to those with non-DLB dementia 
diagnoses; in particular, factors including the time to make a diagnosis, and the degree of clinical 
contact, both before and after diagnosis. As a measure of frequency, we examined the number of 
DLB cases seen as a proportion of all dementia cases seen during an 18-month period 
(prevalence). We also measured the proportion of new DLB diagnoses, made during the same 18-
month period, as a proportion of all new dementia diagnoses made during this time (incidence). 
 
Our intention was to better understand DLB prevalence using a large, representative clinical 
population using a systematic methodology. Time to diagnosis and degree of clinical 
contact among a large DLB cohort were explored in order to understand the implications of DLB 
diagnosis to routine clinical care. Rates of diagnostic revision, and clinical characteristics of 
patients undergoing diagnostic revision, were investigated with the intent of exploring 
opportunities to improve DLB recognition and diagnosis in routine NHS care.  
 
4.2 Objectives and hypotheses 
4.2.1 Objective 1 
Our first objective was to determine the prevalence and incidence of DLB in NHS services through 
clinical note screening. Based on previous literature, discussed in Chapter 2, suggesting that many 
DLB cases were not recognised during life, we hypothesised that:  
- DLB would represent less than 5% of all dementia cases seen in Psychiatry of Old Age (POA) 
services; 
- that DLB prevalence would vary across services examined; 
- DLB would be equally prevalent in men and women; 
- DLB would be equally prevalent in patients of different ages. 
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4.2.2 Objective 2 
Our second objective was to determine clinical factors related to DLB diagnosis and matched non-
DLB dementia controls through detailed case note analysis. Because of previously suggested 
difficulties in making an accurate DLB diagnosis we hypothesised that: 
- The diagnostic process would be significantly longer for DLB diagnoses than for non-DLB 
diagnoses. 
- A higher proportion of patients with DLB than non-DLB patients would receive one or more 
alternative dementia diagnoses prior to their final diagnosis.  
- Patients with DLB would undergo more clinical contacts before and after diagnosis than 
their non-DLB counterparts. 
 
Although an early objective of the study was to determine the mortality rate in our screening 
population, it became immediately apparent early in the process that the recording practices 
for death were extremely inconsistent and incomplete in all three services. Data collected on 
mortality was not therefore included in analysis. 
 
4.3 Methods 
This study was conducted in two phases. Phase 1 was a retrospective cohort study, in which the 
clinical records of all patients seen in three POA services were examined and limited demographic 
information retrieved for each patient.  
 
Phase 2 was a matched retrospective cohort study. DLB patients identified during Phase 1 were 
approached for consent to a detailed case note review and analysis of all clinical interactions 
during their contact with services. Non-DLB controls, matched for gender, age (± 3 years) and 
MMSE (± 5 points) at the point of diagnosis, were also approached for consent. Ethical approval 
for both phases was granted by Newcastle and North Tyneside NHS Research Ethics Committee 
(REC). Permission was granted by the Confidentiality Advisory Group (CAG) to access clinical data 
without individual patients’ consent for Phase 1 of the study. This was important in ascertaining 
prevalence accurately, as approaching every individual seen in services would have been 
impractical and subjected our findings to selection bias and survivor bias. 
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4.3.1 Phase 1 - Case screening 
4.3.1.1 Study design 
Phase 1 was a retrospective cohort study of POA services in North East England. The study 
team retrospectively reviewed notes from all patients seen in three services in North East England 
over an 18-month period between 1st January 2013 and June 30th, 2014. This period of time was 
chosen as it would allow sufficient time for additional investigations (e.g. FP-CIT) or revision of 
diagnosis where necessary. A longer timeframe would have been both unfeasible and may have 
also been susceptible to changes in the structure and personnel in participating services. 
 
Services were selected by the research team on the basis of a number of factors; 
- Clinicians’ consent to participate in the exercise. Although CAG afforded access to patient 
notes, the research team felt it good practice to approach the clinicians leading the 
services and gain their permission to access and analyse their caseloads. None of the 
services approached declined permission to take part in the study. 
- The volume of patients attending each participating service. The research team hoped to 
identify at least 30 patients to participate in Phase 2 of the study, estimating that 
approximately 50% of patients would consent to detailed case note review. We 
hypothesised that DLB would comprise less than 5% of all dementia diagnoses, so 
estimated that 60 DLB cases would be identified amongst a minimum of 1200 dementia 
cases. A DLB sample size of 60 in an overall dementia population of 1200 would, using 
Wilson’s method (Brown, DasGupta and Cai, 2001), provide a 95% confidence interval of 
3.8 to 6.4% for the actual DLB prevalence.  
- The generalisability of the services to those existing in other NHS trusts and regions. The 
research team felt it important that the wide range of service structures, clinical skills and 
patient populations in the NHS nationally were represented in the study cohort.  
 
The case notes of patients from three services, operating within two healthcare trusts each and 
comprising several components, were therefore screened;  
- Newcastle upon Tyne memory services (Northumberland Tyne and Wear Foundation 
Trust); this comprises a large group of integrated memory clinics and associated 
Community Mental Health Teams (CMHTs). It also includes a tertiary Lewy body disease 
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clinic and a mental health day hospital. It services a predominantly urban population and is 
closely associated with Newcastle University. 
- St George’s Hospital, Morpeth (Northumberland Tyne and Wear Foundation Trust); this 
service comprises a group of memory clinics and paired CMHTs affiliated with a rural 
psychiatric hospital. It serves a predominantly rural population. 
- North Tyneside Memory Clinic and associated CMHTs (Northumbria Healthcare 
NHS Foundation Trust); this service comprises a group of memory clinics and CMHTs 
affiliated with a District General Hospital. This service also includes a specialist team 
addressing behavioural and psychological symptoms of dementia in local nursing homes. It 
serves a mixed rural and urban population. 
 
For the purposes of analysis and discussion, these three services were anonymised; we have 
referred to “Services A, B and C” throughout the remainder of this thesis. 
 
Informatics services at participating trusts provided the research team with lists of patients seen 
during the 18-month screening window. These included all forms of contact, including scheduled 
clinical appointments, hospital liaison reviews, day hospital and inpatient reviews, home visits, 
information groups and emergency assessments. Contact was led by a range of multidisciplinary 
professionals that included psychiatrists, nurses, social workers, psychologists, support workers, 
physiotherapists, and occupational therapists, amongst others. Although patients may not have 
been reviewed by a psychiatrist during the 18-month screening window, all patients under review 
by participating services had a named psychiatric consultant coordinating their care. Consultant 
caseloads therefore provided the most accurate and extensive record of patients seen by 
multidisciplinary services. Although only patients with dementia seen within the screening window 
were included, the entirety of each patient’s clinical notes were reviewed, as in some cases it was 
expected that diagnostic revision would occur after the end of the screening period. Follow-up 
occurred for a minimum of one year. 
 
The research team conducting the collection of data for both Phases 1 and 2 comprised; 
- Joseph Kane (JK), Clinical Research Associate and PhD candidate, Newcastle University. 
- Sally Barker (SB), Clinical Research Nurse, Newcastle University. 
- Neil Fullerton (NF), Clinical Trials Officer, National Institute for Health Research Clinical 
Research Network: Dementias and neurodegeneration (DeNDRoN) 
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Both JK and SB had prior clinical experience in working with patients with dementia, in their 
respective roles as a training psychiatrist and district nurse. NF, through his role as Clinical Trials 
Officer, had experience in research studies recruiting patients with dementia. This role also 
included note screening and data collection. None of the research team conducting data collection 
for Phases 1 and 2 had been previously been employed by any of the participating services.  
 
The research team accessed the clinical notes of each patient identified by each informatics list. 
Patients with a clearly documented diagnosis of dementia were recorded. Patients who had 
previously documented that they did not wish their notes to be accessed by research teams and 
those without a history of dementia recorded during the screening window were excluded from 
this process, such as patients with mild cognitive impairment or delirium and those with psychotic, 
affective and addiction disorders. Cases initially given these non-dementia diagnoses, but later 
diagnosed with dementia within the screening dates were included.  
 
From the records of patients with a diagnosis of dementia, gender, date of birth and subtype 
diagnosis were recorded. During the screening each patient was categorised as either prevalent 
(initial dementia diagnosis prior to 1st January 2013 but still being seen in the service) or incident 
(dementia newly diagnosed between 1st January 2013 and 30th June 2014). A patient’s 
prevalent/incident status was not affected by subtype diagnosis revision; if the diagnosis of a 
prevalent case with AD was revised to DLB during the 18-month screening period, the case would 
be categorised as a prevalent DLB case. Mini-mental state score (MMSE) at the point of dementia 
diagnosis was recorded for matching purposes. 
 
Figure 4.1  Examples (simulated data) of patient information recorded during Phase 1 
 
 
 
Some patients attended more than one participating service during the 18-month screening 
window. Each patients’ name was therefore recorded in order to identify duplicate records, so 
that the same subject was not inadvertently included as two separate subjects. In such cases, 
patients were included amongst the cohort corresponding to the service in which they were first 
seen during the screening window. The duplicate records were then removed from analysis. 
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Patients selected for approach for Phase 2 also had their address and trust identification number 
temporarily recorded for administrative purposes and communication with clinical teams. 
Dementia subtype diagnosis was determined by the primary working diagnosis. Mixed DLB/AD 
cases were documented as DLB. Where primary dementia subtype diagnosis was unclear from the 
documentation available, the diagnosis was recorded as “Dementia not otherwise specified”. 
 
Patients with a recorded diagnosis of one subtype during the screening window, but in whom the 
diagnosis was later revised after the screening window (June 2014) had their most recent primary 
diagnosis recorded. Date of death, where available, was recorded in patients who had deceased.  
 
Prior to analysis, dementia subtypes were recoded to two groups; DLB and non-DLB.  
 
4.3.1.2 Statistical analysis 
Data were entered into a Microsoft Excel spreadsheet. This data, once anonymised and cleaned, 
was imported to Statistical Package for Social Sciences (SPSS, version 24) for statistical analysis. 
 
Prevalence was calculated as the percentage of DLB cases amongst of all dementia cases seen by 
services within the 18-month window. Incidence was calculated as the number of incident DLB 
cases as a proportion of all incident dementia cases.   Confidence intervals for both prevalence and 
incidence were calculated using the Wilson method (Brown, DasGupta and Cai, 2001).  
 
For a large number of cases, the exact date of dementia diagnosis was not available, and it was 
not possible therefore to determine patient age at the time of dementia diagnosis. In lieu of 
patient age at dementia diagnosis, the age of each patient on 1st October 2013 (the midpoint of 
our screening window) was calculated. The mean ages of the DLB and non-DLB cases were 
compared using Student’s independent t-test.  
 
Thereafter, patients were stratified into age groups of five years and the Mantel-Haenszel χ2 test 
used to test for a relationship between age and prevalence. The χ2 test was used to compare 
gender prevalence between DLB and non-DLB groups. For each test statistic, a probability value of 
p<0.05 was regarded as significant. 
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4.3.2 Phase 2 - Detailed case note review 
4.3.2.1 Study design 
Phase 2 was an observational retrospective matched cohort study. It used data retrieved from the 
clinical notes of patients identified during Phase 1. All patients with a diagnosis of DLB, first 
recorded during the 18-month screening period were considered for Phase 2. Patients in whom a 
non-DLB dementia subtype was recorded during the screening period, but whose diagnosis was 
revised to DLB after the screening period, were also included in this group. A member of the 
multidisciplinary team currently treating the patient was consulted regarding suitability to 
approach for consent. In cases where the patient had been discharged from secondary services, 
the clinician whom the patient had most recently seen was consulted regarding suitability. 
 
Eligible DLB cases were then approached by the patients’ clinical team, contacting patients via 
a letter that included a form to “opt out” of the study and any further contact with the research 
team. Patients who neither returned the “opt out” form, nor contacted the research team to 
express further interest, were contacted by telephone (SB and JK). Patients expressing interest in 
taking part were visited by the research team (SB and JK) and, where applicable, obtained 
informed consent. In cases where patients did not have capacity to consent to participation, but 
the patient demonstrated a willingness to participate, a consultee provided consent on their 
behalf. 
 
We adopted an individual matching methodology; recruited DLB cases were matched to the next 
non-DLB patient seen consecutively within the respective service, matched for gender, age (± 3 
years) and MMSE (± 5 points). Where the first matched non-DLB patient declined participation, 
the next consecutive patient satisfying matching criteria was approached, and so on. 
 
The research team obtained the clinical records for each recruited participant. Only the medical 
notes from participating organisations were accessed; where a patient underwent clinical contact 
in another organisation (such as an Accident & Emergency department (A&E) attendance in an 
acute trust), this was only recorded if it was documentation of the event was made in the 
participating services’ notes. We collected data from the first point of contact in the clinical notes 
(often GP consultation and referral to secondary services) to the day of Clinical Record Form 
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(CRF) completion. The duration of time over which this data was collected was calculated in both 
DLB and non-DLB groups. 
 
The team (JK, SB) extracted detailed data to a CRF. This included several sections;  
1. Personal details; age, gender, ethnicity; status as prevalent/ incident case. 
2. Diagnostic details; date of referral, date first seen, date of first diagnosis; date of 
subsequent diagnoses; the specialty of the first clinician to make each of these diagnoses 
was also noted. 
3. Clinical symptoms; the presence of each central, core, suggestive and supportive DLB 
symptom (as defined by the third consensus criteria (McKeith et al., 2005)) were recorded.  
The date of onset was each symptom was estimated and recorded (e.g. where a "two-
month history of depression” was noted in clinical documentation, the date two months 
prior to the clinic date was entered). Where no duration was noted for such symptoms, the 
date of the clinical documentation referring to the symptom was noted. Further qualitative 
information on each symptom was noted for the purposes of the validation process.  
The third consensus criteria refers to two symptom groups rather than individual 
symptoms; “spontaneous features of parkinsonism” and “severe autonomic dysfunction”. 
For each of these groups, the CRF recorded the presence and date of onset of individual 
symptoms in addition to the presence and onset of symptom groups. Bradykinesia, rest 
tremor, rigidity, shuffling gait and postural instability comprised features of parkinsonism; 
constipation, orthostatic hypotension, urinary incontinence and comprised severe 
autonomic dysfunction. The presence of one or more symptom was noted to have 
indicated the presence of the symptom group, and the earliest date of onset was noted to 
have indicated the date of onset of the symptom group. 
4. Past medical history; significant health conditions, hospitalisations (for both psychiatric 
and physical health presentations), A&E presentations and operations were documented 
with date of onset and qualitative information. 
5. Drug history; drug names, doses and frequency at the point of dementia diagnosis were 
documented. Start dates, end dates, side effects and efficacy for each drug were also 
noted. 
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6. Drug changes; changes made since contact with secondary services, including changes in 
preparation or dose, were recorded, together with side effects, start dates, end dates and 
efficacy. Where titration of a drug occurred, the highest daily dose of each agent was 
noted. 
7. Family history of significant chronic health conditions were recorded. 
8. Basic physical information, including height, weight, pulse, standing and lying blood 
pressure were recorded. Physical examinations, and the findings of such examinations 
were also documented. 
9. Investigations and tests were recorded and dated, including neuropsychology tests, blood 
tests, neuroimaging and other imaging investigations, electrocardiograph, EEG, lumbar 
puncture and any other documented investigation.  
10. Clinical contact prior to dementia diagnosis was recorded, along with information on the 
date, clinic type (including home visits), clinicians involved and whom, if anyone, 
accompanied the patient during the appointment. Referrals made to other services, 
including voluntary sector services, during these appointments were noted, as were 
documented instances of carer stress. 
11. Post-diagnostic management strategies were noted in detail. Pharmacological 
management, referral to other services, voluntary sector referral, recommendation for 
driving assessment, medicolegal advice amongst other treatment strategies were 
documented. 
12. Post-diagnostic clinical contact, with information on date, clinic type, clinicians involved 
and persons accompanying the patient to each appointment documented. 
Each CRF also included a brief (approximately 200 word) clinical vignette outlining the clinical 
course and symptom profile. These were written by JK and SB and were prepared primarily for the 
purposes of assisting with the case validation by independent experts. JK completed 64 CRFs, SB 
completed 35 CRFs. JK and SB completed 5 CRFs together to ensure that data was collected and 
recorded in a consistent manner. 
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4.3.2.2 Case validation 
Each DLB case and non-DLB control was validated by two independent clinical experts, neither of 
whom had had prior clinical contact with the patient (JK, Professor John O’Brien (JOB), Dr John-
Paul Taylor (JPT), Professor Ian McKeith (IMcK)). The experts, using all the information contained 
in each CRF, systematically applied diagnostic criteria for major subtypes for each case. They 
then documented the rationale for a final diagnosis. Where the final diagnosis returned by raters 1 
and 2 differed (in 25 cases), a third expert (IMcK, JPT) was asked to review and validate diagnosis. 
Where, even after a third expert was consulted, no two clinical experts agreed on diagnosis (which 
occurred in 3 cases), raters 1, 2 and 3 reviewed the case in question and together came to a 
consensus on diagnosis. In cases where the consensus diagnosis returned was not one of 
dementia (e.g. MCI), the case in question was excluded from analysis (n=1). In cases in which a 
non-DLB case fulfilled criteria for DLB, or vice versa, the case in question was excluded from 
analysis (n=1).  
 
This method has been shown to be an acceptable, practical and suitably accurate alternate to the 
post-mortem gold standard for DLB diagnosis (McKeith et al., 2000b). 
 
4.3.2.3 Data entry 
CRF data was transposed to a bespoke Microsoft Access database by members of the research 
team (JK, SB). Ten CRFs were selected at random and compared with transposed entries. An error 
rate of below 5% was deemed satisfactory at the start of the process. A total of 28 errors, each in 
different data fields, were identified and rectified during this process, representing less than 
0.01% of all data entered. 
 
4.3.2.4 Data analysis 
Access database data were imported into SPSS for data analysis. Continuous variables were 
compared using independent t-test and categorical variables compared with χ2 test. Wilcoxon 
signed-rank test was used to compare non-parametric matched samples and Mann-Whitney U test 
used for non-parametric independent samples. For each test statistic, a probability value of p<0.05 
was regarded as significant. Bonferroni correction for multiple comparisons was not used; 
Armstrong (2014) advises against the use of such tests in post hoc testing, particularly in 
exploratory studies such as this one. Results are described in the next chapter. 
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Chapter 5 
A study of the frequency of DLB cases in NHS clinical services - results 
 
5.1 Recruitment and matching 
5.1.1 Phase 1 
A total of 5 569 cases, each of whom had attended the three participating services between 1st 
January 2013 and June 2014, were screened during Phase 1. Of these cases, 2 575 (46.2%) had a 
recorded diagnosis of dementia, of which 144 cases had a DLB diagnosis and 2 431 a non-DLB 
diagnosis.  
 
5.1.2 Phase 2 
Every individual identified during Phase 1 as having a diagnosis of DLB was approached for 
participation in Phase 2. Of this group, 52 patients gave consent for the research team to review 
and collect data from their clinical records. Fifty-four matched participants were also recruited for 
Phase 2. 
 
Figure 5.1 provides a complete account of case identification, recruitment and matching for both 
Phase 1 and Phase 2. 
 
5.2 Phase 1 results 
The results presented in Table 5.1 are divided into prevalent and incident cases, as previously 
described, whereby prevalent cases are all dementia cases seen, and incident cases are those with 
a new diagnosis made during the 18-month screening window.  
 
Table 5.1 DLB prevalence and incidence 
 
Service Dementia (all subtypes) DLB 
 
Prevalent Incident Prevalent 
% of prevalent 
dementia cases 
(95% CI) 
Incident  
% of incident 
dementia cases 
(95% CI) 
A 1 115 548 66 5.9% (4.6-7.5%) 35 6.4 (4.6-8.8%) 
B 1 178 637 68 5.8% (4.6-7.3%) 36 5.7 (4.1-7.7%) 
C 282 106 10 3.5% (1.9-6.4%)   4 3.8 (1.5-9.3%) 
Total 2 575 1 291 144 5.6% (4.7-6.5%) 75 5.8 (4.6-7.2%) 
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Figure 5.1  Flow diagram of patient identification, recruitment and matching for Phases 1 and 2 
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The clinical prevalence of DLB (n= 144) in our screened (n= 2 575) population was 5.6% (95% CI 
4.7-6.5%) (Table 5.1).  Prevalence ranged from 3.5% (95% CI 1.9-6.4%) to 5.9% (95% CI 4.6-7.5%).  
When incident cases alone were analysed, DLB cases (n=75) comprised 5.8% (95% CI 4.6 - 7.2%) of 
dementia cases (n=1 291) (Figure 5.2). No significant difference in prevalence (χ2 =2.54, p = 0.28) 
nor in incidence (χ2 =1.17, p = 0.56) was observed between the three services.  
 
Figure 5.2 DLB prevalence across participating services 
 
 
 
In prevalent cases, DLB was significantly more common in men than in women (χ2 = 24.0, p<0.01).  
Males comprised 55.6% (95% CI 47.1 - 63.8%) of DLB cases, but only 36.5% (95% CI 34.6 - 38.4%) 
of non-DLB cases. There was also a significant difference when incident cases alone were 
compared (χ2 = 6.2, p=0.01) (Table 5.2). 
 
There was no significant difference in age between DLB and non-DLB dementia when considering 
either prevalent (80.7 ± 7.4 vs 81.9 ± 7.6; (t (2573)= -1.849, p =0.65) or incident (81.2 (± 7.1) v 81.7 
± 7.8; t. (1289)= -0.55, p =0.58) cases (Table 5.2).  
 
The proportion of DLB cases represented among dementia cases in various age groups was also 
assessed (Figure 5.3). DLB cases were observed at higher rates in younger age groups presenting 
to clinical services (χ2= 5.03, p=0.03); prevalence comprised 7.9% (95% CI 4.9-12.4%) of cases in 
patients 70 and under, but only 3.0% (95% CI 1.4-6.3%) of cases in patients between the ages of 91 
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and 95. No significant correlation was identified between age and DLB incidence (χ2=0.75, p 
=0.39). 
 
Table 5.2 Age and gender of DLB and non-DLB patients 
 
 DLB non-DLB p 
 
Age at screening (years)(SD)    
      Prevalent  80.7 (± 7.4) 81.9 (± 7.6) 0.65 
      Incident 81.2 (± 7.1) 81.7 (± 7.8) 0.58 
 
Gender M/F (% M)    
      Prevalent 80/64 (55.6%) 859/1572 (36.5%) <0.01 
      Incident 38/37 (50.7%) 442/774 (36.3%) 0.01 
 
 
 
Figure 5.3 DLB prevalence and age 
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5.3 Phase 2 results 
5.3.1 Case matching 
Every patient identified as having a DLB diagnosis during Phase 1 was considered for approach for 
Phase 2. Seventy-five DLB cases were not approached; 42 having deceased between Phases 1 and 
2, and 21 cases considered by either the treating clinician or research team as unsuitable for 
approach (Figure 5.1). In 12 cases, the research team was unable to contact the patient or a 
suitable consultee. Once an individual declined participation in the second phase of the study we 
disposed of their matching data. This, together with our failure to adequately cross-reference 
databases from Phase 1 and Phase 2, meant that we were unable to compare patients enrolled in 
Phase 2 and those that were not. 
 
DLB and non-DLB groups were well matched on an individual basis by gender, age at dementia 
diagnosis, MMSE at dementia diagnosis and duration of follow up (Table 5.3).  
 
Table 5.3 Demographic details of cases 
 
 Gender M/F 
(%M) 
Age at recruitment 
(years)(SD) 
MMSE score at 
recruitment (SD) 
Duration of follow 
up (days)(SD) 
 
DLB (n=51) 
 
31/20 (60.8%) 77.6 (± 7.3) 21.6 (± 5.1) 1365 (± 811) 
non-DLB (n=51) 31/22 (58.5%) 77.7 (± 7.3) 20.7 (± 4.7) 1215 (± 928) 
 
 
5.3.2 Revision of diagnosis 
Throughout Phase 2 of data analysis, a number of time points at which to compare different 
groups were employed; 
- “Initial dementia diagnosis” refers to the date of dementia diagnosis for DLB and non-DLB 
patients; 
- “Final dementia diagnosis” the date after which there was no recorded revision of dementia 
subtype, and; 
- “Final data collection” the date after which the research team no longer recorded clinical data 
from the patient’s notes for use in the study. 
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Table 5.4 Revision of initial diagnosis 
 
 DLB (n=51) non-DLB (n=51) p 
Patients whose dementia diagnosis was 
revised/ changed 
n (% of cases) 
 
20 (39%) 1 (2%) <0.01 
 
Twenty patients with DLB (39%) were initially diagnosed with an alternative dementia subtype (AD 
n=14, VaD n=2, mixed AD/VaD n=3, PDD n=1). This proportion was significantly higher than that 
observed amongst patients with non-DLB subtypes (2%; χ2 = 21.6, p<0.01). 
 
5.3.3 Time to diagnosis 
The case notes of participants were reviewed in detail, and relevant time points, including date of 
referral, date of first assessment, date of initial diagnosis, and date of final diagnosis, extracted. In 
some instances, one of more of these data were not detailed in the clinical documentation. Thus, 
such cases could not contribute to the comparison of respective timescales, such as those 
represented by Table 5.5. The sample sizes (n), representing the number of patients for whom 
valid data was available for each measurement, are therefore provided in each table. 
 
All data comprising time to diagnosis calculations had skewed distributions; Wilcoxon signed-ranks 
test and Mann Whitney U test were therefore used to compare data between groups. 
 
Table 5.5 Time from referral to diagnosis 
 
 DLB non-DLB p 
n 
Mean 
(days)(SD) 
Median 
(days) 
n 
Mean 
(days)(SD) 
Median 
(days) 
 
 
Referral to 
first assessment 
 
44 71 (± 90) 35 49 62 (± 53) 47 0.64 
 
Referral to 
initial dementia 
diagnosis 
 
42 324 (± 504) 170 47 47 (± 503) 146 0.94 
 
Referral to 
final diagnosis 
 
45 567 (± 656) 265 48 48 (± 542) 154 0.04 
 
CORE 
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Table 5.6 Time from first assessment to diagnosis 
 
 
DLB non-DLB p  
n 
Mean 
(days)(SD) 
Median 
(days) 
n 
Mean 
(days)(SD) 
Median 
(days) 
 
 
First assessment to 
initial dementia 
diagnosis 
 
45 251 (± 487) 98 48 256 (± 499) 90 0.98 
 
First assessment to 
final diagnosis 
 
48 481 (± 623) 207 49 291 (± 532) 90 0.02 
 
 
Table 5.7 Time from initial dementia diagnosis to final dementia diagnosis 
 
 DLB non-DLB p  
n 
Mean 
(days)(SD) 
Median 
(days) 
n 
Mean 
(days)(SD) 
Median 
(days) 
 
 
Initial dementia 
diagnosis to final 
dementia diagnosis 
 
51 287 (± 464) 0 50 46 (± 193) 0 <0.01 
 
The time from referral to final diagnosis (z= -2.01, p=0.04) (Table 5.5), first assessment to final 
diagnosis (z=-2.38, p=0.02) (Table 5.6) and initial dementia diagnosis to final dementia diagnosis 
(z=-3.32, p<0.01) (Table 5.7) were all significantly higher in the DLB group compared to the non-
DLB group. These relationships are unsurprising as 98% of non-DLB patients underwent no revision 
of subtype diagnosis and thus the value for this parameter was zero (Table 5.4).  
 
Our significant findings regarding longer time to diagnosis in DLB patients led us to consider 
factors that might contribute to these findings, one of which might be the need for additional 
investigations, especially scans, that might cause delays for logistical reasons. We therefore 
compared the same data points for DLB patients who had FP-CIT imaging as part of their 
diagnostic work-up with DLB patients that did not.  
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Table 5.8  FP-CIT and time from referral to diagnosis 
 
 
DLB patients  
who had FP-CIT imaging 
DLB patients  
who did not have FP-CIT imaging 
p 
n 
 
Mean 
(days)(SD) 
Median 
(days) 
Mean 
rank 
n 
 
Mean 
(days)(SD) 
Median 
(days) 
Mean 
rank 
 
Referral to first 
assessment 
 
27 90 (± 101) 47 26 17 40 (± 58) 22 17 0.02 
 
Referral to initial 
dementia diagnosis 
 
25 451 (± 617) 211 26 17 137 (± 133) 100 15 <0.01 
 
Referral to final 
diagnosis 
 
27 611 (± 735) 245 23 18 501 (± 528) 358 23 0.90 
 
57% (n= 29/51) of recruited patients with DLB had FP-CIT scans during their contact with 
secondary care. Again, data regarding date of referral, assessment and diagnosis were not 
available for every patient, so sample sizes varied between different measurements of time (e.g. 
referral to first assessment). 
 
There was a significantly longer period of time between referral and initial dementia diagnosis 
between DLB subjects who had FP-CIT scans (median 211 days) and those who did not (median 
100 days; U= 110, z=-2.63 p<0.01). We also observed a significantly longer period of time between 
referral and first assessment in those who attended a FP-CIT scan (median 47 days) compared to 
those who didn’t (22 days; U = 130, z=-2.40, p=0.02) (Table 5.8). 
 
Despite this, we observed a non-significant trend for those who had FP-CIT to experience a shorter 
time from referral to final DLB diagnosis.  
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Table 5.9 FP-CIT and time from initial diagnosis to final diagnosis 
 
 
 
No significant relationship was observed between FP-CIT status and time from initial dementia 
diagnosis to final dementia diagnosis (Table 5.9). 
 
Table 5.10 Revision of initial diagnosis in patients who had FP-CIT imaging 
 
 DLB patients  
who had FP-CIT imaging 
(n=29) 
DLB patients  
who did not have FP-CIT 
imaging (n=22) 
p 
 
Patients whose dementia diagnosis  
was revised/ changed 
n (% of cases) 
 
11 (38%) 9 (38%) 0.98 
 
Of DLB patients who had FP-CIT imaging, eleven (38%) had their dementia subtype diagnosis 
revised during their contact with secondary services. This was not significantly different to the 
proportion of DLB patients who did not have FP-CIT imaging and whose initial subtype diagnosis 
was later revised (χ2 = 0.001, p=0.98) (Table 5.10). 
 
In summary, patients with DLB who had FP-CIT scans experienced a significantly longer period of 
time from referral to initial assessment, and from referral to initial dementia diagnosis, than those 
not referred for FP-CIT. However, FP-CIT was not associated with a longer period from referral to 
final diagnosis. Overall, no significant difference was observed in the rate of diagnostic revision in 
DLB patients who had FP-CIT scans than those who didn’t have such scans. 
 
 DLB patients  
who had FP-CIT imaging 
DLB patients  
who did not have FP-CIT imaging 
p  
n 
Mean 
(days)(SD) 
Median 
(days) 
Mean 
rank 
n 
Mean 
(days)(SD) 
Median 
(days) 
Mean 
rank 
 
Initial dementia 
diagnosis to final 
dementia diagnosis 
 
29 273 (± 436) 0 27 22 305 (± 509) 36 25 0.63 
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5.3.4 Clinical contact 
We will now compare aspects of the clinical care received by DLB and non-DLB groups, examining 
clinical contact firstly in the time prior to their dementia diagnosis, and secondly throughout the 
entirety of their time spent in secondary care. 
 
Overall, we found no significant relationship between the number of contacts with services prior 
to dementia diagnosis and DLB status (Table 5.11). However, when we investigated the total 
number of contacts between participants and clinical services throughout their time in secondary 
care, we found that the total number of appointments was significantly higher in DLB patients 
than non-DLB patients (z=-2.82, p=0.01) (Table 5.12).  
 
Table 5.11 Total clinical appointments prior to initial dementia diagnosis 
 
 DLB non-DLB p  
n Mean (SD) Median n Mean (SD) Median  
 
Appointments 
(All healthcare 
professionals) 
 
51 6.9 (± 12.5) 2 51 3.3 (± 4.2) 2 0.14 
 
 
Table 5.12 Total number of clinical appointments throughout contact with services 
 
 DLB non-DLB p  
n Mean (SD) Median n Mean (SD) Median  
 
Appointments  
(All healthcare 
professionals) 
 
51 24.1 (± 22.8) 17 51 14.5 (± 17.6) 10 0.01 
 
These findings led us to consider the type of contact that each subject had had during their time 
with secondary care services. Patients were seen by a range of practitioners. These included 
medical professionals (such as psychiatrists, neurologists and geriatricians), as well as other 
members of the multidisciplinary team (specialist nurses, occupational therapists, 
physiotherapists, social workers, support workers and psychologists).  
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We first investigated the number of contacts between participants and each subspecialty prior to 
diagnosis. DLB patients had a significantly higher number of appointments with specialist nurses 
than non-DLB patients (U=133.5, z= -2.21, p=0.03) (Table 5.13). No other significant differences 
were detected between DLB and non-DLB groups for the number of contacts with any other 
healthcare professional.  
 
Table 5.13 Appointments with clinicians (prior to initial dementia diagnosis) 
 
 DLB non-DLB 
p n Mean  
(SD) 
Median Mean 
rank 
n Mean  
(SD) 
Median Mean 
rank 
 
Psychiatrist/ 
neurologist/ 
Geriatrician 
 
51 2.6 (± 3.7) 2 57 51 1.5 (± 1.3) 1 48 0.14 
Specialist nurse 15 6.1 (± 10.0) 3 28 28 2.3 (± 3.1) 1 19 0.03 
Occupational 
therapist 
12 3.0 (± 4.9) 1 7 2 3.5 (± 3.5) 4 9 0.52 
Physiotherapist 3 2.3 (± 2.3) 1 2 0 n/a n/a 0 n/a 
Social worker 8 1.3 (± 0.5) 1 5 1 1.0 n/a 4 0.59 
Psychologist 7 7.9 (± 6.8) 8 7 4 3.0 (± 2.3) 3 5 0.32 
Support worker 0 n/a n/a n/a 2 2.0 (± 1.4) n/a 2 n/a 
Other clinician 0 n/a n/a n/a 0 n/a n/a n/a n/a 
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When frequency of contact with individual specialties throughout the entirety of patients’ time in 
secondary care was considered, DLB cases attended a higher number of appointments with 
medical practitioners (U=701, z=-3.68, p<0.01) and a higher number of appointments with 
specialist nurses (U= 424, z=-2.93, p<0.01) than non-DLB cases (Table 5.14). No other significant 
relationships were identified between subtype diagnosis and the number of contacts with each 
professional group. 
 
Table 5.14 Appointments with clinicians (overall) 
 
 DLB Non-DLB 
p 
n Mean (SD) Median Mean 
rank 
n Mean (SD) Median Mean 
rank 
Psychiatrist/ 
neurologist/ 
geriatrician 
51 9.8 (± 6.7) 7 60 48 5.4 (±3.7) 5 39 <0.01 
Specialist nurse 34 12.0 (± 12.0) 11 46 41 7.2 (±14.0) 3 31 <0.01 
Occupational 
therapist 20 4.6 (± 8.8) 3 17 14 4.3 (±6.0) 2 18 0.81 
Physiotherapist 12 3.2 (± 2.7) 3 9 6 3.3 (±2.9) 3 10 0.96 
Social worker 14 2.6 (± 3.3) 2 9 3 1.7 (±0.6) 2 9 0.95 
Psychologist 11 11.9 (± 8.2) 11 12 8 5.0 (± 5.5) 3 7 0.08 
Support worker 5 3.4 (± 3.6) 1 6 9 6.0 (± 5.2) 6 8 0.33 
Other clinician 3 1.3 (± 0.6) 1 2 1 4.0 n/a 4 0.16 
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After investigating the frequency of contacts between participants and clinician groups, we 
explored the proportion of patients in DLB and non-DLB groups receiving contact with each 
profession. 
 
In the period prior to dementia diagnosis, we identified no relationship between DLB status and 
proportion of patients seen by psychiatrist, neurologist or geriatrician (Table 5.15).  
 
Table 5.15 Proportion of DLB and non-DLB patients attending appointments with medical 
professionals prior to initial dementia diagnosis  
 
 
DLB (n=51) 
n (% of DLB cases) 
non-DLB (n=51) 
n (% of non-DLB cases) 
χ2 p 
Psychiatrist 44 (86%) 41 (78%) 0.30 
Neurologist 4 (8%) 3    (6%) 0.68 
Geriatrician 2 (4%) 2    (4%) 1.00 
Allied health professional only 1 (2%) 6  (12%) 0.05 
 
 
Of participants receiving contact from allied health professionals prior to diagnosis, a significantly 
higher proportion of DLB patients than non-DLB patients were seen by an occupational therapist 
(χ2= 8.28, p<0.01) or social worker (χ2 =5.97, p =0.02) (Table 5.16). Contact with a specialist nurse 
was more common for non-DLB patients (55%) than DLB patients (29%) in the period prior to 
initial dementia diagnosis (χ2 = 6.80, p = 0.01).  
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Table 5.16 Proportion of patients attending appointments with allied health professionals prior 
to initial dementia diagnosis  
 
 DLB (n=51) 
n (% of DLB cases) 
non-DLB (n=51) 
n (% of non-DLB cases) 
χ2 p 
Specialist nurse 15 (29%) 28 (55%) 0.01 
Occupational therapist 12 (24%) 2 (4%) <0.01 
Physiotherapist 3 (6%) 0 (0%) 0.08 
Social worker 8 (16%) 1 (2%) 0.02 
Psychologist 7 (14%) 4 (8%) 0.31 
Support worker 0 (0.0%) 2 (4%) 0.16 
 
When both contact with services before and after diagnosis were analysed, a significantly higher 
proportion of DLB patients (33%) than non-DLB patients (8%) were reviewed by a geriatrician at 
some point during their contact with services (χ2 = 9.25, p<0.01). Whilst a higher proportion of DLB 
patients than non-DLB patients had contact with a psychiatrist or neurologist during their time in 
services, the relationship between proportion of patients seen and subtype diagnosis was not 
statistically significant in either case (Table 5.17).  
 
Table 5.17 Proportion of patients receiving contact from medical clinicians (overall) 
 
 
DLB (n=51) 
n (% of DLB cases) 
non-DLB (n=51) 
n (% of non-DLB cases) 
χ2 p 
Psychiatrist 51 (100%) 48 (94%) 0.09 
Neurologist 8 (16%) 3 (6%) 0.14 
Geriatrician 17 (33%) 4 (8%) <0.01 
 
The significant trend for a higher proportion of DLB patients than non-DLB patients to see a social 
worker in the prediagnostic phase was also observed when all contacts were considered (28% vs 
6%; χ2 = 8.54, p<0.01). No other significant relationships were identified between DLB status and 
contact with any other member of the multidisciplinary team (Table 5.18). 
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Table 5.18 Proportion of patients receiving contact from allied health professionals (overall) 
 
 DLB (n=51) 
n (% of DLB cases) 
non-DLB (n=51) 
n (% of non-DLB cases 
χ2 p  
Specialist nurse 34 (67%) 41 (80%) 0.12 
Occupational therapist 20 (39%) 14 (28%) 0.21 
Physiotherapist 12 (24%) 6 (12%) 0.12 
Social worker 14 (28%) 3 (6%) <0.01 
Psychologist 11 (22%) 8 (16%) 0.46 
Support worker 5 (10%) 9 (18%) 0.25 
Other clinician 3 (6%) 1 (2%) 0.31 
 
In summary, DLB patients attended a higher number of appointments than non-DLB patients over 
the course of their contact with secondary care. DLB cases seen by a specialist nurse attended a 
higher number of appointments than non-DLB cases, both overall and in the time before dementia 
diagnosis. They also saw medical practitioners on a higher number of occasions than their non-DLB 
counterparts.  
 
A higher proportion of DLB patients than non-DLB patients saw a social worker throughout their 
contact with services. In the time prior to diagnosis, a higher proportion of the DLB group had 
contact with a social worker, a specialist nurse or an occupational therapist. 
 
5.3.5 DLB symptom prevalence 
We have discussed how 39% of DLB patients in this sample were initially assigned an alternative 
dementia subtype, and how the time from both referral and first review to final diagnosis is longer 
in our DLB group than our non-DLB group. As the presence or absence of clinical symptoms plays 
an important part in DLB diagnosis, we investigated the frequency of core, suggestive and 
supportive features at initial dementia diagnosis, final dementia diagnosis, and at the point of data 
collection. 
 
The frequency of most core, suggestive and supportive symptoms increased over the course of 
DLB patients’ contact with services, from first assessment to initial dementia diagnosis (mean 251 
 72 
days, SD ± 811), to final diagnosis (481 days ± 623), to the point of our final data collection (1365 
days ± 811) (Table 5.19. Figure 5.4).  
 
Twenty-four participants (24/51; 47%) had had an abnormal FP-CIT scans at the point of data 
collection. This includes three patients who had two FP-CIT scans during their contact with 
services; in each case the first of these scans were reported as normal, but the second scan 
reported abnormal findings. Six of the twenty patients in our DLB cohort initially diagnosed with 
another dementia subtype had abnormal FP-CIT scans between their initial diagnosis and final DLB 
diagnosis.  
 
Table 5.19 Prevalence of symptoms at initial dementia diagnosis, final diagnosis and data 
collection 
 
 At Initial dementia 
diagnosis 
n (% DLB patients) 
At final dementia 
diagnosis 
n (% DLB patients) 
At time of final data 
collection 
n (% DLB patients) 
Visual Hallucinations 24 (47%) 34 (67%) 39 (77%) 
Fluctuations 17 (33%) 22 (43%) 29 (57%) 
Parkinsonism 16 (31%) 23 (45%) 32 (63%) 
    
REM Sleep behaviour disorder 17 (33%) 24 (47%) 27 (53%) 
Reduced striatal uptake  
on FP-CIT imaging 17 (33%) 20 (39%) 24 (47%) 
Neuroleptic sensitivity 1 (2%) 1 (2%) 3 (6%) 
    
Falls  16 (31%) 21 (41%) 28 (55%) 
Transient loss of  
consciousness 1 (2%) 1 (2%) 1 (2%) 
Autonomic symptoms 21 (41%) 22 (43%) 36 (71%) 
Delusions 10 (20%) 15 (29%) 17 (33%) 
Hallucinations  
in other modalities 10 (20%) 12 (24%) 14 (28%) 
Depression 6 (12%) 9 (18%) 11 (22%) 
 
 
  
 
 
73 
Figure 5.4 Prevalence of symptoms at initial dementia diagnosis, final diagnosis and data 
collection (DLB patients)  
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5.4 Summary 
We conducted this study in two phases; the first, a retrospective observational study of DLB 
prevalence in clinical services; the second, a detailed observational analysis of patients’ 
interactions with secondary care services and their observed clinical symptoms over the course of 
these interactions. 
 
From the first phase, we found that DLB was diagnosed in 5.6% of cases of dementia in secondary 
care, with non-significant variation between participating services. DLB was significantly higher 
amongst men and younger patients. 
 
Fifty-one of 144 DLB cases identified during the first phase were recruited to the second phase, in 
which information on the time, frequency and nature of interactions with secondary services was 
retrieved and analysed. Participants with DLB were initially given an alternative subtype dementia 
diagnosis, prior to subsequent diagnostic revision, in 39% of cases. 
 
The duration of time from referral to final diagnosis was longer for patients with DLB than for 
those with non-DLB dementias. DLB was associated with longer periods of time from first 
assessment to final dementia diagnosis, and from initial dementia diagnosis to final dementia 
diagnosis. Cases with DLB who had FP-CIT imaging experienced longer periods between referral 
and initial assessment, and referral to initial dementia diagnosis, but not between referral and 
final dementia diagnosis. No relationship was observed between FP-CIT scan and proportion of 
DLB patients requiring diagnostic revision during the course of contact with services. 
 
All prediagnostic and post-diagnostic clinical contacts with secondary services were recorded.  
Patients with DLB attended a higher number of appointments than those with non-DLB diagnoses 
over the course of their contact with secondary care and recorded a higher number of contacts 
with specialist nurses and medical practitioners over this time. DLB subjects also had a higher 
frequency of contacts with specialist nurses than non-DLB subjects in the time prior to dementia 
diagnosis. 
 
A significantly higher proportion of patients with DLB saw a geriatrician or social worker during the 
entirety of their contact with services than those with non-DLB diagnoses. Although a higher 
proportion of patients with DLB than non-DLB dementias were seen by a social worker or 
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occupational therapist prior to dementia diagnosis, a greater proportion of non-DLB patients were 
seen by a specialist nurse in this period. 
 
Our review of clinical symptoms in DLB patients observed that the prevalence of core, suggestive 
and supportive symptoms increased over time. Visual hallucinations was the most frequently 
recorded core symptom at each of three recorded time points. 
 
 
. 
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Chapter 6 
A study of the frequency of DLB cases in NHS clinical services - discussion 
 
6.1 Introduction 
We conducted a longitudinal observational cohort survey of three Psychiatry of Old Age (POA) 
services in North East England, recording the age, gender, MMSE and clinical diagnosis of the 2575 
patients attending these services over an 18-month period. We performed a detailed 
retrospective notes review of 51 patients with DLB and 51 with non-DLB dementia, comparing 
diagnostic practices, symptom prevalence and contact with services from the point of referral. 
 
6.2  Prevalence and incidence of DLB 
We identified that DLB formed 5.6% (95% CI 4.7-6.5%) of dementia cases. DLB was more common 
in male patients, and there was no significant difference in the age of DLB and non-DLB cohorts. 
We did, however find that DLB was found at lower rates within older age groups presenting to 
services. Our reported prevalence is lower than the 15-20% reported by neuropathological studies 
(Perry et al., 1990), the 7.47% reported by meta-analysis of clinical samples (Vann Jones and 
O’Brien, 2014), and the 10.1% described by a recent epidemiological survey amongst a Chinese 
population (Yue et al., 2016). Of newly diagnosed (incident) cases during the study period, DLB 
comprised a remarkably similar proportion of dementia cases (5.8%) to that seen in the prevalent 
population, though this fell well below the 25-28% reported from a large-scale Italian cohort (25-
28%) (Bonanni et al., 2013).  
 
We will consider the factors that could contribute to the differences between our observations 
and those presented in previous studies; variation in true DLB prevalence, differences in study 
methodologies, and disparities in DLB detection. In doing so, we will compare our findings with 
some observations from our sister study, conducted at The University of Cambridge, that might 
suggest that differences in DLB case detection are more likely to be attributable to differences in 
DLB detection than variation in the true prevalence of the disease. 
 
6.2.1 Neuropathological prevalence studies 
It is possible that the difference between our observed DLB prevalence of 5.6% and the higher 
rates reported by other studies (Perry et al., 1990) reflects a true variation in the prevalence of 
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pathology in dementia patients. If so, this could result from geographical differences in genetic 
burden or exposure to any environmental factors which may increase risk of DLB (Greenamyre and 
Hastings, 2004).  
 
An important argument against the true DLB rates actually being lower in our cohort is the 
substantial body of evidence suggesting that cases demonstrating post-mortem DLB 
neuropathology frequently fail to meet clinical DLB diagnosis prior to death. High rates of revision 
of diagnosis, both over the course of illness and at post-mortem, have been demonstrated in 
several studies (Perry et al., 1990; Thomas et al., 2017b). This would suggest that diagnostic 
inaccuracy does frequently occur, and that it is a significant factor in variation between samples 
and services. Additionally, studies have demonstrated that the sensitivity of third consensus 
criteria is both variable and suboptimal (McKeith et al., 2000b; Aarsland et al., 2008; Skogseth et 
al., 2017). 
 
As discussed in Chapter 2, it is likely that neuropathological studies provide us with an upper 
margin for true DLB prevalence. Post-mortem examination remains the most robust method of 
DLB diagnosis and the practice follows a structure outlined by the third consensus criteria 
(McKeith et al., 2005). A high frequency of cases with mixed DLB/AD pathology are observed in 
autopsy samples (Ince, 2001; Jellinger and Attems, 2011) and the close relationship between tau 
progression and cognitive decline (Jellinger and Attems, 2008), have led to the suggestion that LB 
and LN pathology could reflect a non-specific end stage of AD (Skogseth et al., 2017). As 
neuropathological studies include an older group of patients than those seen in clinical studies 
(Zaccai et al., 2015), DLB would be expected to be observed at higher rates in the former than in 
the latter. 
 
Where cases with mixed DLB/AD do present to clinical services, a high proportion will not 
demonstrate characteristic DLB features (Tiraboschi et al., 2006; Thomas et al., 2018b). This leaves 
us uncertain as to the clinical characteristics of patients with mixed pathology, and thus the clinical 
prevalence of pure DLB which potentially could be clinically identified. Comparison of 
neuropathological findings with data from studies such as ours is therefore of limited value from 
the perspective of clinical practice. 
Interpretation of neuropathological data must also be made after consideration of the effect of 
selection bias. Subjects consenting to autopsy are more likely to be Caucasian, more highly 
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educated, and have a longer duration of symptoms than patients in clinical populations 
(Fillenbaum et al., 1996; Tsuang et al., 2006). Research centres conducting post-mortem studies 
overestimate pathologies like DLB due to their proximity to specialist clinics, and referral to such 
services are more closely related to severity of symptoms than the subtype diagnosis itself (Zaccai, 
Ince and Brayne, 2006). 
 
Post-mortem studies aid our understanding of the prevalence of DLB neuropathology, but the 
absence of core clinical features in a proportion of these patients dissuade comparison with 
clinical prevalence data and present a clear rationale for retaining a clinical perspective in 
examination of the factors influencing DLB diagnosis.  
 
6.2.2 The role of methodology in DLB prevalence studies 
The difference in DLB rates between our study and others might be due to differences in 
methodology used. Our cohort of 2 575 dementia patients is considerably larger than the ten 
clinic-based prevalence studies contributing to meta-analysis (sample sizes 102 to 766) and 
approaches the cumulative sample size of 3 144 (Vann Jones and O’Brien, 2014)(Figure 6.1). These 
smaller sample sizes have produced comparatively wide 95% confidence intervals, and of the six 
studies reporting higher DLB prevalence rates than those observed in our study, two have a lower 
confidence limit than both our reported prevalence (5.6%) and our lower confidence limit (4.7%) 
(Harvey, Skelton-Robinson and Rossor, 2003; Yoshida et al., 2011).  
 
Several studies contributing to meta-analysis have applied exclusion criteria that lower the 
denominator in any prevalence calculation and may contribute towards a selection bias. For 
example, some have excluded patients over 65 years old (Harvey, Skelton-Robinson and Rossor, 
2003), moderate and severe dementia cases (Aarsland et al., 2008), patients with a history of 
bipolar disorder or psychotic disorder, or those with a dementia subtype diagnoses other than AD, 
VaD, DLB or FTD (Yoshida et al., 2011). Two studies were conducted in tertiary or specialist 
services, and thus likely to comprise a higher proportion of non-AD cases than in the secondary 
services contributing to our study (Shinagawa et al., 2007; Alladi et al., 2011). The highest rate of 
DLB in studies contributing to meta-analysis (24.0%; 95% CI 18.26-30.53) was reported by a group 
who drew their clinical sample retrospectively from a neuropathological cohort, reviewing 
antemortem patient notes to arrive a clinical diagnosis (Londos et al., 2000).  
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Figure 6.1 Reported DLB prevalence rates among selected clinical studies 
 
 
Of studies published since the aforementioned meta-analysis, an Italian study is of note as an 
outlier, reporting DLB incidence rates of 25-28% in a range of secondary and tertiary services 
(Bonanni et al., 2013). Whilst such high figures are not unprecedented, they have not been 
reported by other studies of such scale and methodology. Neurology services contributing towards 
the data outnumber both geriatric medicine and POA services, although this is to be expected as 
neurologists diagnose the majority of dementia cases in Italy (Wilkinson, 2004; Azermai et al., 
2013). The study utilised a large cohort (2 042 patients) and adopted follow-up and diagnostic 
revision where necessary within the methodology. DLB prevalence was largely uniform across 
different specialities and between secondary and tertiary services, despite the lack of access to FP-
CIT imaging in the former. Neuropathological validation data is not available, but in a sample this 
size, such measures are impracticable, and as discussed previously, subject to their own biases. 
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It is unclear whether the results of this study represent a higher prevalence of DLB in central Italy, 
a higher sensitivity to DLB amongst enrolled services, or the presence of other factors. Walker et 
al.(2015b) noted the higher observed prevalence rates in studies that included neurological 
examination in their methodology, but this alone is insufficient to explain such high figures for DLB 
incidence. There is perhaps a suggestion that incidence of dementia observed in the 
studied region is much lower than would be expected in an equivalent UK population (Matthews 
et al., 2016) and the high rates of VaD also suggest that typical AD cases might be seen and 
diagnosed in other services (such as general practice) or are simply not presenting to services at 
all.  
 
All but one of the aforementioned studies (Harvey, Skelton-Robinson and Rossor, 2003) were 
conducted in countries other than the UK. It is, of course, possible that DLB rates vary from 
country to country, but the variation in methodology and reported prevalence makes it impossible 
to draw any such conclusions on the strength of the data from our study. Nevertheless, the fact 
that we observed a range in DLB prevalence between individual services in North East England 
suggests that differences in true disease variation are not interregional. Indeed, our 3 services 
were very geographically close (16-33 miles apart), minimising the likelihood that genetic or 
environmental variation is a likely cause of the differences in prevalence. 
 
The likely presence of such variation between services can be further supported by data from our 
sister study, conducted in East Anglia (Kane et al., 2018). Our colleagues from The University of 
Cambridge adopted the same methodology, allowing us to scrutinise differences in epidemiology 
independent of aspects of study design. The team screened a patient population of 1 929 over six 
services (comparative in size to our three services) and reported a prevalence of 3.3% (95% CI 2.6 -
4.2%) and incidence of 3.8% (95% CI 2.8 -4.9%). Interestingly, prevalence rates within services 
contributing to this cohort ranged from 2.4% to 5.8%. This supports the hypothesis that observed 
differences in prevalence go beyond those attributable to methodology and compels us to 
examine other factors for this observed variation. 
 
A range of methodologies have been used by DLB prevalence studies, but this heterogeneity has 
made comparison of these studies difficult. In demonstrating a range of DLB prevalence rates 
among participating services, using the same methodology, our findings provide support to the 
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suggestion that variation in DLB prevalence is primarily related to elements other than 
environmental factors. 
 
6.2.3 The role of clinical factors in DLB prevalence 
One such factor contributing to the range in DLB prevalence rates may be differences in rates of 
DLB detection. The observational nature of our study brings into focus the importance of service 
and clinician factors in DLB diagnosis. Other studies investigating DLB prevalence have adopted a 
selective, research-focused, highly detailed approach to case identification that often included 
comprehensive neurological examination, routine functional neuroimaging and the use of 
specialist rating tools on every patient within their respective cohort. Our methodology, 
deliberately designed to answer the clinically relevant question of current frequency of DLB 
diagnosis, recognised that several facets potentially contribute to case recognition outside the 
specialist setting, and that routine clinical practice may preclude such detailed approaches to 
diagnosis in every patient. 
 
Thus, our real world and clinically representative sample included all patients attending 
participating services over an 18-month period; patients contributing to the data in the first phase 
of the study were not subject to any other inclusion or exclusion criteria. This allowed the process 
of diagnosis in clinical services to be viewed in a naturalistic NHS setting. Rather than a systematic 
process using validated scales, designed with the purpose of identifying DLB, clinicians working in 
contributing services had a broader, more pragmatic brief, subject to comorbidities, family 
dynamics and time pressures. 
 
Other aspects of DLB diagnosis could adversely influence detection in clinical practice. The first is 
the suboptimal sensitivity of DLB criteria itself (Aarsland et al., 2008); even if we were to assume 
that each clinician were to have judiciously applied consensus criteria to each case, at each 
appointment, a large proportion of cases will be not be detected. Thomas et al. (2017a) recently 
reported a sensitivity of clinical diagnosis of 87% against neuropathological diagnosis, highlighting 
that even expert clinical assessment is not sufficient to recognise all DLB cases in a population.  
 
What is more likely is that a proportion of clinicians either fail to detect the core and suggestive 
features that comprise the criteria or fail to combine this information appropriately in formulating 
a diagnosis. This is complicated by the apparent masking of core DLB symptoms in cases with 
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concomitant AD pathology; a higher prevalence of visual hallucinations (33%) is reported in cases 
with low levels of AD pathology, than those with a higher burden of disease (65%) (Merdes et al., 
2003) and DLB detection rates are inversely correlated with Braak AD staging. Sensitivity for 
antemortem DLB is has been reported to be as low as 15% in cases demonstrating higher stages 
(Braak V-VI) of AD pathology (Weisman et al., 2007). 
 
The most likely source of variation between services is related to the structures of the 
organisations involved and the diagnosticians that comprise them. As an observational study, our 
data must be viewed through the prism of the organisations from which the data was retrieved; 
every point of the patient’s journey, from initial presentation to his or her GP presents a factor 
that might impact upon overall prevalence and incidence within our sampled services.  
 
An example of this is the fact that our study included only POA services. Should a patient present 
to their GP with DLB symptoms, and the GP decide that referral is indeed necessary, he or she may 
wish to refer to a service other than POA; autonomic dysfunction or falls may prompt referral to a 
geriatrician, or the presence of parkinsonism might increase likelihood to refer to neurology, even 
in the presence of cognitive dysfunction. In both of these types of services, non-DLB dementia is 
likely to be much less common, and therefore likely to raise our prevalence and incidence were 
they to be included in our sample population. Although such patients are often later transferred to 
POA (Table 5.15), it is possible that younger, higher functioning patients requiring fewer social 
care or non-pharmacological interventions may be retained in, or discharged directly from, 
neurology or geriatric medicine services. 
 
It is also entirely possible that there exist patients with clinical dementia within the general 
population that never come to the attention of any secondary care service. One meta-analysis has 
reported that 43% of dementia cases in UK populations go undetected (Lang et al., 2017). The 
same study found that underdetection was associated with male patients and younger patients, 
two groups among which our study has observed higher prevalence rates of DLB.  
 
It therefore appears likely that clinical factors, and in particular DLB case detection, could play an 
important role in clinical prevalence. The range of DLB case frequency among different services 
participating in the study (3.5% to 5.9%), and among those participating in our sister study in East 
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Anglia (2.8-5.1%) (Kane et al., 2018), could therefore represent varying rates of clinical detection, 
as it is less likely that geographical differences in genetic or environmental factors could be 
present in neighbouring services. There may be a higher sensitivity for DLB amongst clinicians in 
participating North East England services, perhaps related to the prominent role of Newcastle 
University in the DLB research community and might explain the significant difference in observed 
prevalence between our cohort (5.6%) and those seen in the East Anglia cohort (3.3%). The 
prospect of accessing specialist support groups and experimental treatments through research 
participation may further incentivize clinicians to recognize the signs and symptoms of DLB. 
 
In summary, there is evidence to suggest that the DLB prevalence rates we observed, and the 
range observed between different services, could be influenced more by clinical detection rather 
than variation in true disease prevalence. This is particularly the case when the findings of our 
sister study, also conducted in a UK clinical cohort, are considered alongside our data. 
  
6.2.4 The relationship between DLB prevalence and DLB incidence 
The relationship between our observed prevalence and incidence figures is important as few 
studies explore both of these parameters, citing either new cases presenting to services or 
prevalent cases in small, defined populations. The striking similarity between our figures for 
prevalence and incidence suggests that patients leave our services, either through discharge or 
death, at roughly the same rate as they enter. This may reflect pressures on services to discharge 
patients shortly after diagnosis and establishment of acetylcholinesterase inhibitor therapy but is 
somewhat surprising given the carer stress (Lee et al., 2013) and higher rate of hospitalisation and 
neuropsychiatric symptoms (Hanyu et al., 2009) that may necessitate longer follow-up in patients 
with DLB. This may be offset by the higher mortality associated with DLB compared with other 
dementias (Williams et al., 2006; Price et al., 2017).   
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6.2.5 DLB prevalence and gender 
Our observation of a male preponderance of DLB is noteworthy in light of the findings reported by 
meta-analysis (Vann Jones and O’Brien, 2014), which did not find a difference in gender 
prevalence. The predominance of females was noted in five of eight included clinical studies, 
although this may be more closely linked to a failure to report gender composition in some studies 
than a composition of the samples themselves. A male preponderance observed amongst PD 
patients (Mayeux et al., 1995) and neuropathological DLB samples (Klatka, Louis and Schiffer, 
1996) has led to unsubstantiated suspicions that similar patterns of disease exist in clinical DLB 
populations. Subsequent population samples have both supported and refuted this hypothesis 
(Savica et al., 2013; Yue et al., 2016), but our data represents the strongest support for a male 
preponderance of DLB in a clinical sample to date. 
 
6.2.6 DLB prevalence and age 
We found no significant difference in age between our DLB and non-DLB cohorts. A positive 
relationship between DLB prevalence and mean age of sample has been observed in population-
based studies, and but no such relationship has been identified in clinical populations (Vann Jones 
and O’Brien, 2014).  
 
We did identify a separate age effect in observing that DLB comprised a higher proportion of 
dementia cases in younger age groups than in older ones. This observation that DLB prevalence 
decreased with age could be related to the fact we researched patients in clinical services; in such 
services, increasing age may be accompanied by a shift of clinical focus away from investigation 
and subtype diagnosis to a more pragmatic, needs-based service that aims to establish adequate 
social care. In some instances, older cases could circumvent POA services, and thus our study 
population, entirely; a patient with functional impairment due to physical illness, subsequently 
admitted to a nursing home to address this impairment, may not have cognitive symptoms 
identified as readily as a younger, less impaired counterpart, and would perhaps be less likely to 
be referred to a memory clinic. The higher mortality rate associated with DLB than AD (Price et al., 
2017), and thus higher representation of older patients with non-DLB dementias, is also likely to 
contribute to this finding. 
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The absence of an association between DLB and age in our overall sample, but a separate 
significant inverse relationship between increasing age groups and the DLB prevalence, might be 
explained by the relatively small number of patients that comprise groups at each end of the age 
scale. Three age groups representing patients with dementia 70 years old and under, 91 to 95, and 
95 years and over comprised 7.8%, 8.7% and 1.9% (cumulatively 18.4%) of our sample, and DLB 
prevalence ranged between 3.9% and 8.0% within these groups. In four groups spanning the ages 
of 71 to 90, representing 81.6% of the overall sample, there was relatively little variation in DLB 
prevalence (4.8% to 6.2% of dementia cases). Whilst this suggest that DLB may not be associated 
with younger age groups, it could still be important for clinicians to retain a higher index of 
suspicion for DLB in the relatively small proportion of patients who present to services under the 
age of 70 years old than in other populations.  
 
6.3 Time taken to DLB diagnosis 
We found that the median time from referral to final diagnosis was 265 days for DLB cases and 
125 days for non-DLB subjects. In many instances the delay involved reassessment; over one in 
three (39%) DLB cases were initially given an alternative dementia subtype diagnosis prior to 
subsequent diagnostic revision. In contrast, only one of 51 patients (2%) with non-DLB dementias 
had their dementia subtype diagnosis revised during their contact with secondary care. 
 
Despite a recognition that differentiating DLB from AD may be challenging in clinical practice 
(Huang and Halliday, 2013), data on delayed diagnosis and revised diagnosis is sparse. A survey of 
carers of patients with DLB or PDD reported that 49% of diagnoses occurred over a year after 
initial presentation, with 31% taking over two years; only 9% received a diagnosis at first 
presentation (Galvin et al., 2010). The same study reported that patients were given an initial 
diagnosis other than Lewy body dementia in 78% of cases. These figures may however reflect 
some of the differences characteristic of the USA healthcare system, and as survey findings may 
be affected by recall bias. Initial diagnosis appears to have occurred at the first point of contact 
with any service; whilst this not an uncommon practice in the UK, the median of 88 days between 
initial assessment and first non-DLB dementia diagnosis would suggest that it is not the 
convention in our participating services. 
 
It is far from unusual for UK patients to undergo two or three clinical appointments, often with 
allied health professionals, prior to an initial diagnostic appointment.  Clinicians working in 
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services contributing to our study not only had the benefit of prior assessment and 
neuropsychological testing, but in 33% of cases, abnormal FP-CIT results. This less immediate 
approach to diagnosis may explain the much lower rate of initial misdiagnosis in our cohort, but 
likely contributes to a longer period of time before a diagnosis is made; patients who had FP-CIT 
experienced a median of 103 days between initial assessment and initial dementia diagnosis, and 
154 days between initial assessment and final diagnosis.  
 
Our findings regarding time to diagnosis in the context of FP-CIT provide an insight into how the 
biomarker influences diagnostic practice. DLB cases who had FP-CIT imaging encountered a 
significantly longer period of time from referral to initial dementia diagnosis (median 210 days) 
than DLB cases who weren’t scanned (100 days), perhaps suggesting that in such instances 
clinicians postpone subtype diagnosis until FP-CIT scans have been reported. However, patients 
who had FP-CIT scans did not encounter a significantly longer time from referral to final diagnosis 
(245 days) when compared with patients who did not have scans (358 days). This may be partly 
due to an observed non-significant trend for non-FP-CIT DLB patients to encounter a longer period 
of time for revision of diagnosis to occur than in FP-CIT DLB cases.  
 
While this might be seen to suggest that FP-CIT does not shorten the period to DLB diagnosis, and 
prolongs the time to initial dementia diagnosis, it is important to consider that DLB patients 
referred for FP-CIT are likely to represent a different population from DLB patients that are not 
referred for scans. Clinicians are less likely to require the support of FP-CIT findings with more 
established disease, or a higher number of symptoms, that those with milder or fewer symptoms. 
One study suggested that clinicians referring patients with possible DLB for FP-CIT had a mean 
diagnostic certainty of 50% (Walker et al., 2015a); this is likely to be higher in cases of probable 
DLB, with biomarkers adding little to clinical assessment. It may also be the case that some 
clinicians, anticipating the wait for initial dementia diagnosis associated with FP-CIT may be 
dissuaded from accessing the biomarker in some patients. Decreasing the waiting times associated 
with FP-CIT may therefore not only decrease the longer time to initial dementia diagnosis, but the 
proportion of clinicians accessing the investigation. 
 
Although rates of diagnostic revision were equal in FP-CIT and non-FP-CIT DLB groups, the utility of 
FP-CIT as a biomarker for DLB is well established (McKeith et al., 2007). It has demonstrated 
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superior sensitivity to expert clinical assessment when compared with autopsy findings (Thomas et 
al., 2017a), and therefore could have the ability to detect DLB cases neither picked up by clinical 
assessment nor our diagnostic validation process. It also be noted that clinicians may use FP-CIT 
investigation not only in advising diagnosis, but perhaps in some cases in confirming diagnosis 
made on the basis of clinical symptoms alone; four (4/24; 17%) of the DLB patients who had FP-CIT 
in our sample had their scan after their DLB diagnosis had been made. 
 
The period of time observed from referral to first assessment in DLB patients who had FP-CIT 
scans (median 47 days) compared to those who did not (median 22 days) may suggest that DLB 
cases with clearer clinical features are both less likely to require use of biomarkers and more likely 
to be seen more quickly in clinical services. Visual hallucinations, where identified, are often 
recognised as a “red flag” symptom in both GP and POA services, expediting initial assessment, 
and the symptom was the most prevalent core DLB feature identified in our cohort. Thus, clearer 
clinical symptoms could both have expedited assessment, and diminished the need for diagnostic 
investigations. 
 
6.4 Contact with clinical services 
We found that patients with DLB attended a significantly higher number of appointments during 
their contact with services (median 17 appointments) than those with other dementia subtypes 
(median 10 appointments).  Although studies in both USA (Murman et al., 2003; Zhu et al., 2008) 
and Sweden (Boström and Jönsson, 2007) have reported higher resource use by DLB patients, only 
the Swedish group identified a significant difference in outpatient appointment contact, or the 
cost of this input. Our findings therefore provide an important insight into resource use by DLB 
patients in UK clinical practice. 
 
DLB cases were seen by medical practitioners with a significantly higher frequency (median 7 
appointments) than their non-DLB counterparts (5 appointments), perhaps reflecting the greater 
clinical complexity of DLB presentations. The higher rates of neuropsychiatric symptoms and 
inpatient admission in patients with DLB (Hanyu et al., 2009; Mueller et al., 2018) are likely to 
have required both management and repeated assessment. This may also explain why DLB 
patients attended a higher number of appointments with specialist nurses (median 11 
appointments) than those with non-DLB dementia subtypes (3 appointments). 
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A higher proportion of DLB patients than non-DLB patients attended appointments with 
geriatricians during their contact with services (Table 5.17). Symptoms like parkinsonism, falls, and 
autonomic dysfunction, all associated with DLB, are likely to have prompted referral to geriatric 
services, either from POA practitioners or from other professionals. This relationship did not reach 
statistical significance when prediagnostic appointments alone were included in analysis, lending 
further support to the development of additional DLB symptoms over time. 
 
We had decided against correcting this data for multiple comparisons on the basis of its 
exploratory and post hoc nature (Armstrong, 2014), but it could be argued that in comparing DLB 
and non-DLB appointments with up to ten allied healthcare professionals, that we should have 
corrected this accordingly. Were we to have used a Bonferroni-adjusted significance level of 
p=0.005, all of our non-corrected statistically significant findings related to appointments attended 
during the course of secondary care would have reached statistical significance; DLB patients 
attended a higher frequency of appointments with both medical practitioners and specialist 
nurses than their non-DLB controls. However, our observation that cases with DLB attended a 
higher number of prediagnostic appointments with social workers and lower number with 
specialist nurses than non-DLB patients would not have reached this corrected significance level. 
Caution should be exercised before dismissing these prediagnostic symptoms entirely, however, 
not least due to the conservative nature of the Bonferroni correction (Armstrong, 2014). Access to 
a larger sample size, perhaps by combining our data with that of our East Anglian sister study, 
could offer a further insight into the relationship between DLB and prediagnostic clinical contact. 
 
A significantly higher proportion of patients with DLB than those with non-DLB dementia had 
contact with social workers both prior to diagnosis, and over the entire course of their contact 
with clinical services. A possible reason for this finding could be explained by the frequent role of 
social workers in the process preceding compulsory admission to hospital. Symptoms like 
delusions and hallucinations, as well as increased rates of carer stress (Bjoerke-Bertheussen et al., 
2012), are all frequent precipitants of inpatient admission in DLB, and the disease is associated 
with higher rates of hospitalisation (Hanyu et al., 2009). It is possible that detention under mental 
health legislation, or consideration of detention, could have contributed to our observed 
figures.  Another role of the social worker in NHS clinical services is identification of suitable 
residential and care home placement when it is no longer possible for patients to remain in their 
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own home, and the time from initial assessment to nursing home admission is significantly shorter 
in DLB patients when compared to AD patients (Rongve et al., 2014). The fact that a significantly 
higher proportion of DLB patients had contact with an occupational therapist prior to diagnosis 
could support a higher degree of functional impairment than that seen in matched non-DLB 
dementia patients. 
 
In both prediagnostic appointments, and in overall appointments, non-significant trends for DLB 
patients to be seen both in higher proportions, and with greater frequency than non-DLB patients, 
is observed amongst most professional groups. It is possible therefore that the number of patients 
recruited simply did not provide us with the power to adequately detect significant differences 
between the two groups, particularly given our finding that 39% of patients with DLB will undergo 
revision of diagnosis, which itself require additional clinical appointments, treatments and follow-
up. Combination of our data with that of our East Anglian counterparts may help clarify this.  
 
Our findings with respect to the higher proportion of DLB patients than non-DLB patients 
attending geriatric medicine services, and the higher frequency with which the former attend 
specialist nurses and medical professionals, strongly suggest that DLB is associated with higher 
healthcare costs than other dementia subtypes in a UK population. Indeed, unpublished data from 
our group, using the same cohort of participants, will report that the mean costs of secondary care 
for DLB subjects were £6,557 compared with £3,425 for matched non-DLB controls. It may be that 
opportunities to enhance the management of DLB in NHS services could be pursued in an effort to 
decrease the extent of contact required, but it may also support the allocation of greater 
resources to services routinely managing high rates of patients with the disease.  
 
6.5 DLB symptom prevalence 
We found that the proportion of DLB patients with a recorded history of core, supportive and 
suggestive features increased over the course of contact with services. Visual hallucinations was 
the most prevalent of the core symptoms, followed by parkinsonism. The increased proportion of 
patients demonstrating core and suggestive features over time suggest that services are 
continuing to detect DLB symptoms not only after initial diagnosis, but after revision of diagnosis 
has occurred.  
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6.5.1 Visual hallucinations 
At each of the three time points observed, visual hallucinations were the most commonly 
recognised of all core, suggestive and supportive symptoms, present in 77% of DLB cases. This 
figure is towards the lower end of the 69-100% range observed in both population-based and 
clinical cohort studies (Aarsland et al., 2008; Jefferis et al., 2013; Savica et al., 2013; Yue et al., 
2016). Visual hallucinations are an important symptom to detect. Tiraboschi et al. (2006), despite 
reporting a lower rate of the symptom at presentation (22%) than that seen at our point of initial 
dementia diagnosis (47%), found that visual hallucinations were a highly specific feature for 
differentiating DLB and AD in a neuropathologically-validated cohort.  
 
It is important to recognise that our data relating to each of the observed clinical features is based 
on the simple presence or absence statements in clinical records. Visual hallucinations, however 
brief or poorly formed, were recorded as present for DLB patients, if documented in the clinical 
notes. This methodology therefore failed to capture the qualitative and phenomenological 
information necessary to differentiate complex and repeated visual hallucinations characteristic of 
DLB from the simple hallucinations associated with eye disease and those associated with other 
aetiologies, such as delirium. However, it could be expected that practitioners working in the POA 
setting, though less comfortable in assessing parkinsonian and RBD symptoms, would be more 
accustomed to a more phenomenological approach to detection and interpretation symptoms like 
visual hallucinations than their colleagues in other specialties. 
 
6.5.2 Fluctuations in alertness and consciousness 
Fluctuations in alertness and consciousness were detected in 57% in our DLB sample, and only 
33% at the point of initial dementia diagnosis. Fluctuations have been suggested as occurring in 
over 80% of DLB patients (Byrne et al., 1989), but even well-characterised research samples have 
reported the symptoms in proportions as low as 25% (Palmqvist et al., 2008; Savica et al., 2013; 
Walker et al., 2016; Yue et al., 2016). Detection of fluctuations in research samples is complicated 
by poor inter-rater reliability (Mega et al., 1996; Luis et al., 1999), and accurate observation is 
likely to be even more variable in clinical populations like ours. Although identification and 
characterisiation of fluctuations have been made easier by the Clinician Assessment of Fluctuation 
and the One Day Fluctuation Assessment scales (Walker et al., 2000), in most cases these tools 
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have failed to have been adopted into clinical practice to the same degree as cognitive or 
neuropsychiatric scales. 
 
The lower rate of fluctuations identified in our sample may not be solely attributable to clinical 
sensitivity for the symptom and may reflect the therapeutic effect of cholinesterase inhibitor 
prescription (Onofrj et al., 2003). It is therefore possible that the widespread use of cholinesterase 
inhibitors in a clinical population not only diminished the observed prevalence of such symptoms, 
but in some cases prevented re-referral and after initial assessment and discharge from services. 
 
6.5.3 Spontaneous parkinsonism 
Parkinsonism was noted in 63% of our DLB cohort and was the core feature least frequently 
recognised at the point of initial dementia diagnosis (31%). The overall proportion of patients was 
considerably less than the 64 - 79% cited in some other studies (Harvey, Skelton-Robinson and 
Rossor, 2003; Savica et al., 2013; Walker et al., 2016); a comparable proportion of patients with 
tremor alone has been reported in a clinical DLB cohort (Onofrj et al., 2013).  
 
A lower prevalence of parkinsonism in comparison with other cohorts is not entirely unexpected; 
DLB patients participating in clinical trials are likely to be better characterised, and more 
systematically examined, with the use of scales such as the UPDRS, than those in observational 
studies such as ours (Savica et al., 2013; Yue et al., 2016). Our study design, incorporating only 
POA services, is likely reflecting a less sensitive approach to history and examination of 
parkinsonian symptoms, or in many cases, no neurological examination at all. This may, in part, be 
related to the perceived value of detecting parkinsonian symptoms; a recent survey of clinicians in 
tertiary DLB services suggested that only 61.8% of diagnosticians considered extrapyramidal signs 
to be relevant for DLB diagnosis, less than the proportions who considered visual hallucinations 
(94.1%) or fluctuating cognition (76.5%) relevant (Bonanni et al., 2016)  
 
Our detected prevalence of parkinsonian symptoms at diagnosis is somewhat comparable to the 
25-50% cited in some areas of the literature (Walker et al., 2016) but the higher rate of emergence 
of extrapyramidal symptoms reported by longitudinal studies (Ballard et al., 2000; Walker et al., 
2015a) suggest that detection of such symptoms after initial diagnosis may be suboptimal in 
clinical services. This may suggest that a more systematised, longitudinal approach to examination 
of parkinsonism could feasibly be implemented in some services, leading to a higher case 
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detection and clinical DLB prevalence. Further support to this point is lent by the observation that 
of studies contributing to Vann-Jones and O’Brien’s DLB prevalence meta-analysis (2014), those 
that included neurological examination in their methodology detected higher DLB prevalence 
rates than those that did not (Walker et al., 2015b). One proposed mechanism for improvement of 
detection of parkinsonian symptoms is the routine use of an assessment toolkit for DLB (Thomas 
et al., 2017b).  
 
6.5.4 REM sleep behaviour disorder 
RBD itself has been shown to have a high sensitivity for Lewy body pathology; 76% of DLB patients 
demonstrated PSG-validated RBD (Ferman et al., 2011). The presence of RBD in patients with two 
other core DLB features increased the sensitivity of consensus to 88% (Ferman et al., 2011). 
Although included as a suggestive feature of the third consensus criteria (McKeith et al., 2005), 
RBD’s sensitivity and early emergence relative to other symptoms has led to its classification as a 
core feature in the fourth consensus criteria (McKeith et al., 2017).  
 
Much smaller proportions (15-20%) of RBD in DLB are reported in epidemiological studies (Grace, 
Walker and McKeith, 2000b; Rongve, Boeve and Aarsland, 2010; Yue et al., 2016), often in the 
context of high rates of sleep disturbance in dementia, with DLB patients more likely to suffer 
from disturbances than those with AD (Grace et al., 2002; Farina et al., 2009). Many of these 
studies employed validated questionnaires such as the Mayo Sleep Inventory, a component of 
which was reported as having 98% sensitivity for RBD (Boeve et al., 2011). 
 
Thus, caution should be applied in interpreting the 53% prevalence of RBD in our DLB cohort, none 
of whom had PSG studies. It is also unlikely that the Mayo Sleep Inventory was administered to 
any more than a handful of patients. In addition to the overall prevalence, the failure to determine 
any difference in RBD prevalence between our male and female cohorts lends further uncertainty 
to our findings, as the disorder has been shown to have a strong male preponderance. 
 
The diagnostic utility of clinical history taking for RBD in our included services could therefore be 
legitimately questioned. Conflation of RBD with less specific sleep disorders could easily occur, 
especially in the form of confirmation bias; sleep symptoms may be more likely to be 
characterised as RBD in the presence of core symptoms or positive FP-CIT scanning. Further 
 94 
research comparing clinical sensitivity and specificity of participating services against either 
validated questionnaire and/or PSG is necessary to accurately interpret our findings.  
 
6.5.5 Neuroleptic sensitivity  
Neuroleptic sensitivity was detected in three DLB cases (6%). This small sample size is very likely to 
be attributed to decreasing rates of antipsychotic prescription in patients with dementia in the 
UK over the last decade; antipsychotic medications were prescribed to 11.4% of patients with 
dementia in 2015, compared with 22.1% in 2005 (Donegan et al., 2017). 
 
Although increasingly rare due to the declining rate of prescription, neuroleptic sensitivity has 
been shown to be a specific sign for Lewy body disease, occurring in 30-40% of patients prescribed 
antipsychotics (Aarsland et al., 2005). Varying practices therefore make comparison of observed 
neuroleptic sensitivity with that of other groups challenging, and statistics for prevalence of the 
symptom are not always provided. Figures of 6.7%- 10.3% have been reported in Chinese (Yue et 
al., 2016) and Finnish community samples (Rahkonen et al., 2003), but smaller, clinical samples 
often report no cases at all amongst smaller study clinical groups (Aarsland et al., 2008).  
 
6.5.6 Low dopamine transporter uptake in basal ganglia 
An important factor in DLB diagnosis, and thus clinical prevalence, is likely to be the use of FP-CIT 
imaging as a biomarker.  Although the utility of FP-CIT has long been established (McKeith et al., 
2007; O’Brien et al., 2014b), Walker et al. (2016) demonstrated its usefulness in the clinical 
setting, frequently contributing to a change in diagnostic category and improving diagnostic 
confidence. The former is apparent in our DLB group, with three patients who had FP-CIT imaging 
demonstrating evidence of abnormal striatal uptake after initial dementia diagnosis, who 
subsequently had a revision of diagnosis to DLB.   
 
The high proportion of patients in our sample who had abnormal FP-CIT imaging prior to initial 
dementia diagnosis (n=17, 33%) may go some way to explaining the high rate of DLB detection at 
initial diagnosis when compared with that of their American counterparts. Galvin et al. (2010) 
reported that patients were given an initial diagnosis other than DLB in 78% of cases, in a study 
conducted one year before the USA Food and Drug Administration approved the use of FP-CIT 
imaging in DLB diagnosis. It is also possible that the infrequent use of FP-CIT in the services 
surveyed by our sister study in East Anglia may contribute to their significantly lower rate of DLB 
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prevalence in the same area; only one (4%) of 23 patients that underwent detailed case note 
review had FP-CIT imaging, compared with 52% in our DLB group (p <0.01).  
 
In summary, we found that prevalence of core, suggestive and supportive features increased over 
the course of DLB patients’ contact with services, including the use of the biomarker FP-CIT. Each 
of the clinical symptoms contributing to diagnosis were, however, observed at lower rates than 
those described by many research samples adopting a more systematic approach to symptom 
identification.  
 
6.6 Study strengths and weaknesses  
This study represents one of the largest cohorts to date examining DLB epidemiology, and the 
largest in a UK population. Through an observational study design, it lends clinical context to the 
existing data relating to neuropathological and clinical studies that report varying rates of DLB 
diagnosis. Similarly, our observations on symptom prevalence allow us to compare clinical data 
with the findings of more systematic studies that utilise validated questionnaires and expert 
assessment. Data derived from case note review is both detailed and longitudinal, allowing us to 
observe symptom prevalence and disease status at various points of the patient’s journey before, 
during and after the diagnostic phase, and illustrating the disease course of DLB. 
 
Our data relating to time to diagnosis and degree of clinical contact is largely unprecedented and 
gives us a unique insight into the patient and carer’s experience in interacting with services. It 
makes a clear case to policy makers and service coordinators to allocate proportionate resources 
for the care of patients with DLB. We anticipate that a detailed economic analysis of clinical 
contact, conducted using in the same patients as our study, will report that the cost of care for 
patients with DLB is significantly higher than that of patients with non-DLB dementias. 
 
Our study provides baseline data on DLB prevalence against which the effect of clinical 
interventions and tools, such as that proposed by Thomas et al. (2017b) can be measured. It also 
provides a yardstick against which the representativeness of smaller study cohorts could be 
measured. 
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Our study, nonetheless, is subject to limitations. The accuracy of the data collected used in this 
study is greatly determined by that of the notes reviewed, and the consultations which they detail. 
Bias could influence every point of the information gathering process from symptom to data 
collection. Patients and carers must have recognised a symptom in order to report it to clinician, 
provided that they recall having done so, for the clinician may or may not have asked about the 
symptom in question. The clinician must consider this symptom noteworthy to document it in the 
clinical notes or have deemed it sufficiently significant to communicate to the patient’s GP, and 
therefore logged it during the data collection process.  
 
The significance of each symptom itself could be argued to be related to the distress conferred by 
the symptom to the patient and carer. Although we found visual hallucinations and fluctuating 
attention to be the most prevalent and least prevalent of core DLB features respectively, this may 
in reality represent a reporting bias based how problematic these features are to patients and 
carers. Thus, patients developing fluctuations and RBD after a diagnosis of AD may not present 
again to health services, and diagnosis would therefore not be revisited; a patient developing 
visual hallucinations and neuroleptic sensitivity, however, could be much more likely to undergo 
revision of diagnosis. 
The data to which the research team had access was restricted to the clinical records held by each 
participating organisation. This is relevant as two of the participating services formed part of a 
mental health trust, and therefore did not include complete data regarding patients’ interactions 
with local acute trusts. Information from clinic letters and discharge summaries from acute care, 
filed in mental health notes as per standard practice, did provide us with some information. 
However, these communications usually represent the most condensed, immediately necessary 
clinical information, and it is likely that some data relevant to the study may not have been 
included in such documentation. 
 
Every patient diagnosed with DLB during the Phase 1 screening period was approached for 
consent to participate in Phase 2. Nevertheless, a number of factors prohibited us from recruiting 
all identified DLB patients; the exclusion of patients since deceased, and those for whom approach 
was deemed inappropriate, could have contributed to a recruitment bias against patients with 
more severe disease. We also failed to adequately cross-reference databases from Phases 1 and 2. 
This meant that age and sex data (gathered during Phase 1) for patients who did not participate in 
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Phase 2 were not available for comparison with those of who did participate, and this precluded 
further exploration of potential recruitment bias. 
 
Although our sample size was sufficient to detect differences between DLB and non-DLB cohorts, 
our subgroups were too small to determine differences between male and female patients, and 
differences between patients diagnosed with DLB at initial presentation or after diagnostic 
revision. The observed preponderance of DLB amongst men observed in Phase 1, and the high rate 
of DLB recognition at the point of presentation contributed to smaller sample sizes of the groups 
in question. In particular, the increased rate of observed visual hallucinations amongst female DLB 
patients, observed at all three time points, may have yielded more significant results with a larger 
sample size. Combining our data with that of our sister study in East Anglia may remedy this issue.  
 
6.7 Conclusions 
We observed that DLB represented 5.6% of dementia cases in clinical services, with DLB more 
common among men and younger patients. We observed a range in DLB prevalence (3.5-5.9%) 
among different clinical services, in keeping with data collected by our sister study and suggesting 
that variation in the DLB frequency could be related to clinical factors such as case identification. 
The time from referral to dementia subtype diagnosis was longer for DLB patients than non-DLB 
patients, and DLB patients required a larger number of clinical contacts than non-DLB patients 
during the course of their care. Core symptoms increased in prevalence over time, but core and 
suggestive symptoms were seen at lower than figures cited in literature to date.  
 
Although the factors underpinning our findings are multifactorial, a more systematic approach to 
both symptom identification, and application of diagnostic criteria, may increase case detection 
and thus increase prevalence. Of core and suggestive features demonstrated by DLB patients in 
our cohort, impaired striatal uptake on FP-CIT imaging was second only to visual hallucinations 
 in prevalence. Furthermore, several scans were conducted after initial diagnosis, likely 
contributing to diagnostic revision. Our findings therefore support the use of biomarkers in DLB 
diagnosis, both in the initial phase of assessment and in the reappraisal of cases in whom the 
disease is not apparent or detected. Identification of alternative or complementary biomarkers 
may further enhance diagnosis in the clinical setting. 
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One such biomarker may be the measurement of cardiac denervation, using MIBG cardiac 
scintigraphy, to detect DLB. Though not typically employed in routine clinical use in UK 
populations, pooled analysis of MIBG has cited a superior sensitivity (98%) and specificity for DLB 
(94%) to both FP-CIT and expert clinical assessment (Treglia and Cason, 2012). It has also recently 
been included as an indicative biomarker in the fourth consensus criteria (McKeith et al., 2017). 
The suggestion that autonomic denervation, and thus abnormal MIBG uptake, occurs early in the 
course of DLB pathology (Orimo et al., 2005), suggests that MIBG could detect DLB at earlier time 
point than FP-CIT. It should be noted, however, that none of the data contributing to the MIBG 
evidence base has been conducted among a clinically representative UK population, and caution is 
urged in translating MIBG utility from study populations to our clinical cohort.  
 
 
 
 
 
 
 
 
 
  
 
 
99 
Chapter 7 
MIBG cardiac scintigraphy as a biomarker for DLB – aims, hypotheses and methods 
 
7.1 Aims 
The primary aim of this pilot study was to determine; 
- the feasibility and utility of MIBG as a diagnostic biomarker in distinguishing DLB from AD; 
- whether optimal HMR cut-offs derived from other, nearly all Japanese, populations were 
applicable to the UK population.  
It aimed to do so in a cohort of patients representative of a UK population; this included patients 
with medical comorbidities and drug histories that included agents potentially capable of 
interacting with MIBG uptake. In addition, we included a pilot study into the utility of MIBG as a 
biomarker in probable and possible DLB patients with a normal FP-CIT scan. 
 
7.2 Objectives and hypotheses 
Our objective was to determine the diagnostic utility of MIBG in distinguishing DLB from AD. We 
hypothesised that; 
- mean myocardial MIBG uptake, measured by the late HMR, would be significantly lower in 
the DLB group than the AD group; 
- MIBG would demonstrate good sensitivity (>80%) and specificity (>90%) in differentiating 
DLB from AD; 
- there would be some probable DLB patients with a normal FP-CIT scan who show evidence 
of impaired myocardial MIBG uptake, suggesting variation in DLB pathophysiology. 
 
For each of these hypotheses, late HMR was used as the primary outcome. This is recommended 
in diagnostic studies, as late HMR reflects the active neuronal uptake of MIBG without passive 
components and maximises the ratio of specific to non-specific binding (Rascol and Schelosky, 
2009). Our use of late HMR is in keeping with the majority of published research in the field 
(Treglia and Cason, 2012).   
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7.3 Methods 
7.3.1  Ethical and regulatory approval 
Ethical approval for this study was granted by Newcastle and North Tyneside NHS Research Ethics 
Committee (REC). Approval was also sought and granted by the sponsor (Newcastle upon Tyne 
Hospitals NHS Foundation Trust), research and development departments at participating trusts 
(Northumberland, Tyne and Wear NHS Foundation Trust, Northumbria Healthcare NHS 
Foundation Trust, Gateshead Health NHS Foundation Trust) and by the Administration of 
Radioactive Substances Advisory Committee (ARSAC). 
 
7.3.2 Sample size 
Sample size was calculated based on the main hypothesis that the mean HMR will be lower in the 
DLB group compared to AD group.  We conducted an a priori independent samples t-test power 
calculation using the Minitab programme (v17).  Mean HMR values and standard deviations (SD) 
for DLB and AD populations in a large multicentre MIBG study were; HMR (DLB) = 1.8 (SD ± 0.7); 
HMR (AD) = 2.8 (SD ± 0.70) (Yoshita et al., 2015).  However, in our population the SD may be 
larger, and a smaller difference would be of clinical importance.   
 
Table 7.1 Sample sizes required at 80% power and 95% confidence to detect various 
differences in mean HMR between DLB and AD groups for different assumed pooled 
HMR standard deviations  
 
Estimated difference Estimated SD Sample size (per group) 
1 0.7 9 
1 1 17 
0.7 1 34 
 
The required sample size (Table 7.1) is sensitive to HMR variability, which is not well known in a 
group of well-characterised subjects in the UK population.  We therefore aimed to recruit between 
10-30 subjects per group within the time constraints of this pilot study. 
  
7.3.3 Subjects 
Patients were of both sexes and over the age of 60 at the point of recruitment. Each participant 
had been diagnosed by local clinicians as having probable DLB, possible DLB or probable AD. Each 
diagnosis was later independently reviewed by members of the research team, according to third 
consensus criteria for DLB (McKeith et al., 2005) or NIA-AA criteria for AD (McKhann et al., 2011). 
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All participants had a reliable informant, who was in contact with the participant at least twice per 
week. Patients were identified through referral from the North East DeNDRoN (Dementias and 
Neurodegenerative Diseases Research Network) Case Register, or note screening of local 
Psychiatry of Old Age, geriatric medicine and neurology clinic caseloads. Regional neuroimaging 
databases were also screened for potential participants.  
 
Exclusion criteria for the study were minimised, with the aim of recruiting a clinically 
representative population from the NHS. Nevertheless, some factors established as reducing MIBG 
uptake were incorporated into exclusion criteria.  
 
Although a large number of frequently prescribed medications have been identified as capable of 
potentially decreasing MIBG uptake (Giammarile et al., 2008), only the restriction of labetalol and 
tricyclic antidepressants has been recommended on the basis of strength of published studies 
(Jacobson and Travin, 2015). For this reason, patients prescribed labetalol or tricyclic 
antidepressants were excluded.  
 
Subjects with a history of ischaemic heart disease and past history of myocardial infarction (MI) 
were included in the study. Although transmural denervation is observed immediately after MI, 
sympathetic neuronal regeneration can take place over several months after the event (Carrió et 
al., 2010).  To conservatively account for the effects of acute denervation, patients with a recent 
history (within 12 months) of MI were therefore excluded from recruitment. 
 
Patients with cardiac pacemaker in situ, or those with symptoms of cardiac failure corresponding 
to Class II ("Slight limitation of physical activity. Ordinary physical activity results in fatigue, 
palpitation, dyspnoea or angina pectoris"), III or IV of the New York Heart Association Classification 
(Marvin, 1964), were also excluded from participation.  For the purposes of patient safety, 
potential recruits with a history of contraindications to either FP-CIT or potassium iodate were 
also excluded. 
Where potential participants had not already provided permission to be approached directly, 
patients were contacted by their treating clinician and subsequently by JK to answer any questions 
or issues. Written informed consent was provided by the participant. In cases where potential 
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participants did not demonstrate capacity to provide consent, a nominated consultee 
provided written consent on their behalf.   
 
As part of the study we also aimed to recruit an additional cohort of patients. Each patient met 
clinical criteria for probable or possible DLB, and had recently had an FP-CIT, reported by standard 
clinical report as normal, conducted as part of routine secondary care. These patients were 
identified through screening of local neuroimaging databases. No such cohort has been previously 
investigated in this manner, and so this was exploratory. Both the Braak hypothesis of DLB 
pathogenesis (Braak et al., 2003) and previous studies demonstrating disagreement between 
MIBG and FP-CIT (Tiraboschi et al., 2016) suggest that some of these patients will demonstrate 
cardiac denervation, and thus low HMR. 
 
This cohort was subject to the same exclusion and inclusion criteria as the participants described 
in the main study and underwent investigations using identical methodology. Nevertheless, as 
these patients comprised a population less representative of clinical practice (by definition due to 
their false negative FP-CIT) their results are analysed and discussed separately.  
 
7.3.4 Assessment and diagnosis 
All patients underwent detailed diagnostic assessment by JK. This comprised a review of clinical 
records, including structural imaging findings, routine dementia screening and bloods, psychiatric 
and medical history review and physical examination, as well as results of a battery of tests and 
scales relating to neuropsychological ability, functioning and disease-specific symptoms. These 
scales are outlined below.  
 
The revised Addenbrooke’s Cognitive Examination (ACE-R) is a 100-point scale administered to the 
patient, measuring cognitive functioning across five domains – attention and orientation, memory, 
verbal fluency, language and visuospatial function (Mioshi et al., 2006). Embedded within the ACE-
R are the 30 questions that comprise the Mini-Mental State Examination (MMSE), a shorter 
cognitive assessment tool in routine use in clinical practice (Folstein, Folstein and McHugh, 1975). 
The widely-used motor subscale of the Unified Parkinson’s Disease Rating Scale (UPDRS) (Goetz et 
al., 2008) was used to identify and characterise participants’ parkinsonian symptoms. The scale 
rates the severity of each of 33 symptoms, including bradykinesia, tremor, rigidity and postural 
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instability, on a scale of zero (symptom not present) to four (severe). It has been validated 
(Ramaker et al., 2002) and is in widespread use in dementia studies. 
 
Functioning was measured using the Bristol Activities of Daily Living Scale (BADLS) (Bucks et al., 
1996) and Lawton Instrumental Activities of Daily Living Scale (IADLS) (Lawton and Brody, 1969), 
both administered to each patient’s primary carer. Both scales are widely validated and used 
routinely in dementia studies. The BADLS rates a patient’s abilities to perform 20 tasks on a scale 
from zero (able to perform task independently or not applicable) to three (not able to perform 
task), with a maximum score of 60 representing a high level of functional impairment. IADLS 
scores patients from zero (unable to perform task) to one (able to perform) on eight tasks, with a 
maximum score of eight denoting independent functioning in all included activities. 
 
The Neuropsychiatric Inventory (NPI) is a scale administered to the carer to determine the 
presence, severity and frequency of a range twelve neuropsychiatric symptoms: delusions, 
hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, aberrant 
motor behaviour, night time behaviours and appetite disturbance (Cummings et al., 1994). The 
scale also measures the level of distress to the carer from each symptom. The NPI subscale 
records the frequency and severity of all hallucinations but could be used in this study as a 
measure of visual hallucinations, as no subject described hallucinations in any other modalities. 
 
The revised Dementia Cognitive Fluctuations Scale (DCFS-R), measures six symptoms recognised as 
capable of reliably differentiating DLB from AD; variation in function, daytime sleepiness, daytime 
lethargy and overall level of consciousness, disturbed arousal and disorganised speech (Ferman et 
al., 2004; Lee et al., 2014). 
 
Depressive symptoms were measured using the Cornell Scale for Depression in Dementia (CSDD) 
(Alexopoulos et al., 1988), a 19-item clinician-administered scale that uses information retrieved 
from both the patient and carer.  
 
Clinical Dementia Rating (CDR) rates level of impairment, as determined by clinicians’ global 
assessment, in six domains – memory, orientation, judgement and problem solving, community 
affairs, home and hobbies, and personal care. An overall score from zero to three is calculated by 
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an algorithm (https://www.alz.washington.edu/cdrnacc.html) (Morris, 1993); a score of 0.5 is 
consistent with MCI or dementia, and 1 to 3 with dementia.  
 
Each diagnosis was reviewed by two experienced diagnosticians (JK and Alan Thomas, AT; 
Professor of Old Age Psychiatry). Where disagreement arose between the two raters, a third 
independent rater, John O’Brien (JOB, Professor of Old Age Psychiatry) provided a deciding 
opinion. If needed, cases were discussed by all three diagnosticians and a consensus reached. All 
cases underwent a repeat clinical assessment, including repeat neuropsychological testing, one 
year following initial assessment.  
 
7.3.5 MIBG image acquisition 
All MIBG scans were conducted within 12 months of FP-CIT scans and within 2 months of 
recruitment. All MIBG scans were conducted at Newcastle Royal Victoria infirmary, using Siemens 
Symbia T Series or Siemens Symbia Intevo systems. 
 
Gemma Roberts (GR; senior medical physicist) calibrated both cameras prior to the study, using a 
planar cardiac MIBG phantoms. GR adopted the same design employed by Nakajima et al. (2012) 
for standardisation of HMR at Japanese centres prior to a multicentre trial (Yoshita et al., 2015). 
This standardisation study converted HMR values measured at each of the centres in this 
multicentre study to a “standardised value” to correct for differences in camera and collimator.  
The correction factor was based on measurement at each centre with a standard phantom and 
comparison of the values obtained (Nakajima et al., 2012). We participated in a European study, 
using the same phantom as in the Japanese study to determine a correction factor for our systems 
with assistance from the team involved in the original work (Verschure et al., 2017) 
 
Although one of the purposes of the study was to determine an optimal HMR cut-off value for a 
UK population, a HMR cut-off was calculated for the purposes of initial sensitivity and specificity 
analysis. Rather than converting all of our HMR values to “standardised” ones, we calculated what 
the threshold cited by Yoshida et al. (2015) (2.1 for both early and late images) would have been 
on our system. Our cameras used medium energy general purpose (MEGP) collimators, which tend 
to give higher HMRs as they are more effective at removing spurious counts due to septal 
penetration (Chen, Cao and Dilsizian, 2011; Inoue et al., 2014). We therefore needed to apply a 
slightly higher cut-off to be equivalent to the Yoshida et al’s (2015) study, which were 
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standardised to typical low or medium energy collimators, and therefore tend to have slightly 
lower HMR ratios than our systems. The 2.1 HMR cut-off used in the multicentre study was 
equivalent to 2.24 and 2.25 for Series T and Intevo systems respectively when conversion factors 
were taken into consideration, and a 2.2 cut-off was therefore adopted for this study. Individual 
HMR values were calculated to one decimal point throughout analysis, in keeping with published 
data and reflecting the level of accuracy realistically achievable in the clinical setting. Mean HMR 
values were calculated to two decimal points. 
 
Patients were asked to administer all medications as prescribed on the morning of the study. On 
the day of the scan, a detailed history of medication prescription and administration was 
retrieved. Upon arrival subjects were administered 170mg of potassium iodate. This agent 
protects the thyroid gland from any free radioactive iodine that may be associated with both 
MIBG and FP-CIT radiopharmaceuticals. One hour after potassium iodate administration, a single 
bolus of 111 MBq (3 mCi) of 123I-MIBG and a single saline flush was delivered intravenously. 
 
Early planar images in anterior view were obtained 20 mins following MIBG injection. Images 
were obtained using a dual headed gamma camera fitted with MEGP collimators. Patients were 
positioned with arms down in supine position. Images were acquired over 10 minutes and stored 
in a 128 x 128 matrix.  
 
Late planar images and were obtained 240 minutes following injection. Where possible, patients 
were positioned with arms above their head for the purposes of SPECT imaging, although SPECT 
images were not analysed as part of this study. Images were acquired over 10 minutes and stored 
in a 128 x 128 matrix.  
 
Subjects were provided with 170mg potassium iodate and instructed to administer 12 hours 
following MIBG injection. 
 
7.3.6 MIBG analysis 
Regions of interest (ROIs) were identified for “heart” and “mediastinum”. A myocardial region of 
interest (“heart" ROI), was circumscribed using freehand tool (Figure 7.1). A rectangular ROI of 
area 48 pixels was then placed on the midline of the upper chest, as a reference region of low and 
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consistent non-specific uptake. This size was chosen to be small enough to not be subject to 
interference from the lungs and large enough to give a reasonable sample of background counts. 
 
ROIs were identified for both early and late images and HMR calculated in each case. This 
methodology is consistent with several previous studies exploring MIBG utility in DLB (Hanyu et 
al., 2006; Yoshita et al., 2006; Wada-Isoe et al., 2007; Estorch et al., 2008). 
 
Figure 7.1 MIBG Regions of Interest 
   
Late anterior planar images of MIBG uptake in two study participants. Both depict 
48-pixel mediastinal ROIs (M) and heart ROIs (H). Picture a demonstrates normal 
cardiac MIBG uptake (HMR 3.27); b demonstrates decreased uptake (HMR 1.46) 
suggestive of an abnormal scan result.  
 
 
 
Two raters, blinded to patient identity, measured the HMR on the early and late planar images 
independently (JK, GR). The mean of these two HMRs was calculated to two decimal points for use 
in further analysis and discussion. 
 
Statistical analysis was performed using SPSS 24.0 for Windows. Continuous variables (including 
HMR) and categorical variables were analysed using Student’s t test for independent samples and 
χ2 test respectively. The Mann-Whitney test was used to compare the means of non-parametric 
data. We calculated sensitivity (true positives, the percentage where the HMR was ≤2.2 in patients 
with a clinical diagnosis of DLB), specificity (true negatives, the percentage where the HMR was 
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>2.2 in patients with a clinical diagnosis of AD), and accuracy (the percentage of times the HMR 
result matched the clinical diagnosis). Receiver operating characteristic (ROC) analysis was 
performed using the pROC package for the R statistical programme (version 3.3.1) (Robin et al., 
2011). 
 
7.3.7 FP-CIT Image acquisition 
FP-CIT imaging was conducted in accordance with established protocols (Thomas et al., 2017a) at 
the Newcastle Royal Victoria Infirmary, Gateshead Queen Elizabeth Hospital or Sunderland Royal 
Hospital.  
 
The study used data from FP-CIT scans conducted both as part of patients’ routine clinical care, 
and those conducted within the study protocol. In cases where a participant had undergone FP-CIT 
imaging as part of their NHS care less than 12 months prior to MIBG imaging, this data was 
accessed and analysed, with permission, by the study team. Patients whom had previously 
undergone FP-CIT imaging more than 12 months prior to MIBG underwent a further scan at 
Newcastle Royal Victoria Infirmary. 
 
Patients were again asked to administer medication as prescribed and a record made of all 
medications on the morning of FP-CIT examination. One hour after administration of 170mg of 
potassium iodate, subjects received a single bolus injection of 111–185 MBq of 123I-FP-CIT. Within 
3–6 hours of FP-CIT injection, the patient underwent a brain SPECT scan to assess the functional 
integrity of the nigrostriatal dopaminergic neuron terminals in the striatum. 
 
Image acquisition was conducted in accordance with standard FP-CIT practice, with a 
calibrated gamma camera fitted with a low-energy high-resolution (LEHR) collimator. Cameras 
were positioned prior to data acquisition, with as a radius of rotation as small as possible set 
without the cameras touching or distressing the patient. One hundred and twenty views in a 
circular orbit were acquired (3° steps over 360° rotation). The radius of rotation was set as small as 
possible. Acquired images were stored in a 128 x 128 matrix. 
Transverse images were reconstructed using a ramp-filtered back projection with a Butterworth 
filter (cut-off 0.3 cycles/cm; order 10). They were not corrected for gamma ray attenuation. They 
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were converted to a DICOM format for subsequent visual and DaTQUANT analysis. For visual 
analysis 16 contiguous 1.95 mm slices were displayed using the “GE” colour scale (Figure 7.2). 
 
Figure 7.2 FP-CIT Transverse images 
 
Examples of the reconstructed transverse FP-CIT images reviewed by each rater. The 
images demonstrate significantly impaired reduction in bilateral putaminal FP-CIT 
uptake, with activity confined to the caudate nuclei, and therefore represents an 
abnormal study. 
 
 
 
7.3.8 FP-CIT analysis 
Transverse images of each FP-CIT scan were assessed by five independent raters blinded to patient 
identity and clinical information: one consultant medical radiologist, two consultant medical 
physicists experienced in nuclear medicine reporting, and two certified old age psychiatrists. Each 
completed a training exercise prior to assessing study images, comprising familiarisation with the 
visual rating scale and examinations of ten independent FP-CIT images ranging from normal to 
markedly abnormal. 
 
Each transverse image was given a visual rating by each independent rater in accordance with 
established practice (Benamer et al., 2000); 0 (normal uptake in all regions), 1 (asymmetric activity 
with one putamen showing reduced uptake), 2 (absent activity in the putamen of both 
hemispheres), or 3 (absent activity in the putamen of both hemispheres and greatly reduced in 
one or both caudate nuclei). Where three or more raters agreed upon a rating, this rating was 
used in further analysis. Where fewer than three raters agreed on a rating, the images were 
discussed at a meeting and a consensus reached.  
 
JK used DaTQUANT software (provided by GE Healthcare) to calculate the specific binding ratio 
(SBR) of striatal uptake. The method provided an additional means of identifying abnormal scans 
that may have been rated as normal by visual rating (i.e. consensus score of 0).  
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The study design deliberately favoured visual rating over DaTQUANT result, in keeping with clinical 
practice and validation studies (Thomas et al., 2017a). DaTQUANT was considered as an additional 
measure of sensitivity, rather than a means of superseding visual rating. Therefore, where any 
scans were identified as abnormal by DaTQUANT, but normal by visual rating, the panel were 
asked to reappraise and discuss the images in question. Where scans were identified as normal by 
DaTQUANT, but abnormal by visual rating, the visual rating was upheld. 
 
The DaTQUANT quantification process followed established methodology (Tossici-Bolt et al., 
2006). Volumes of interest (VOIs) were semi-automatically placed over right and left putamina and 
caudate nuclei in the transaxial slice from which most intense tracer uptake was observed. JK 
repositioned striatal VOIs where required. Another VOI was placed over the occipital lobe to 
represent cortical background. SBR was calculated by dividing the mean counts per pixel in the 
VOIs corresponding to caudate nucleus, anterior and posterior putamen and the striatum as a 
whole, by the mean count per pixel in the occipital lobe VOIs. No attenuation correction measures 
were employed. Values for SBR were considered abnormal if they were more than two standard 
deviations below the normal population mean provided by the Parkinson Progression Marker 
Initiative (PPMI) database (Marek et al., 2011).  
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Chapter 8 
MIBG cardiac scintigraphy as a biomarker for DLB - results 
 
8.1 Recruitment 
We recruited 17 participants with DLB (16 meeting criteria for probable DLB, 1 for possible DLB) 
and 16 participants with probable AD.  
 
Table 8.1 Demographic and clinical characteristics of DLB and AD participants 
 
 DLB (n=17)  
Mean score (± SD) 
AD (n=16) 
Mean score (± SD) 
p  
 
Age in years at MIBG scan (± SD) 
 
77.0 (± 7.9) 
 
76.4 (± 6.6) 
 
0.81 
Gender male/female (% Male) 15/2 (88%) 12/4 (75%) 0.33 
    
Revised Addenbrooke’s Cognitive Examination (ACE-R) 66.6 (± 15.1) 65.1 (± 15.7) 0.79 
ACE-R subscale Attention and Orientation 13.9 (± 3.6) 13.7 (± 3.7) 0.89 
ACE-R subscale Memory 13.4 (± 5.1) 11.4 (± 4.7) 0.24 
ACE-R subscale Fluency 6.4 (± 3.3) 6.3 (± 3.4) 0.88 
ACE-R subscale Language 22.3 (± 5.1) 21.8 (± 4.7) 0.78 
ACE-R subscale Visuospatial 10.6 (± 4.1) 12.0 (± 3.3) 0.29 
Mini-Mental State Examination (MMSE)  22.1 (± 4.9)  22.2 (± 4.2)  0.97  
    
Bristol Activities of Daily Living Scale (BADLS)  22.3 (± 13.2) 13.9 (± 7.7) 0.04 
Instrumental Activities of Daily Living Scale (IADLS) 2.6 (± 1.9) 3.7 (± 1.9) 0.13 
    
MDS Unified Parkinson’s Disease Rating Scale (UPDRS) 
Motor subscale 
32.8 (± 23.4) 3.6 (± 3.6) < 0.01  
Neuropsychiatric Inventory (NPI) Hallucinations subscale 
(Frequency x Severity)  
2.1 (± 2.5) 0.0 (± 0.0) < 0.01 
Dementia Cognitive Fluctuations Scale (DCFS-R) 10.9 (± 3.7) 6.5 (± 1.9) < 0.01 
    
Neuropsychiatric Inventory (NPI) Total 23.9 (± 19.5) 11.1 (± 6.9) 0.03 
Neuropsychiatric Inventory (NPI) Carer total 17.6 (± 14.4) 10.7 (± 7.9) 0.12  
Cornell Scale for Depression in Dementia (CSDD) 6.5 (± 4.3) 3.8 (± 3.0) 0.06 
    
Clinical Dementia Rating (CDR) 1.2 (± 0.5) 0.9 (± 0.2) 0.08 
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The demographic, clinical and neuropsychological characteristics for the DLB cohort are 
summarised in Table 8.1. Clinical and neuropsychological scores were unavailable for one patient 
whose condition deteriorated shortly after MIBG scan and precluded further data collection.  
 
The NPI subscale records the frequency and severity of all hallucinations but was used in analysis 
and discussion as a measure of visual hallucinations, as no subject described hallucinations in any 
other modalities. 
 
As would be expected, patients with DLB had significantly higher scores in each of three scales 
measuring core DLB symptoms; UPDRS, NPI Hallucinations subscale and DCFS. A higher total NPI 
score, indicating greater symptom frequency and/or severity, and a higher BADLS score, indicating 
greater functional impairment, were also observed in the DLB group when compared to the AD 
group. 
 
8.2 Late HMR 
Our primary MIBG outcome measure, the mean late HMR for DLB cases (1.69, SD ± 0.70) was 
significantly lower than that of AD cases (2.35, SD ± 0.41; U=57.0, p<0.01) (Figure 8.1). 
 
Using the HMR of 2.2 to differentiate between “abnormal” and “normal” HMR values, of 17 cases 
meeting clinical criteria for probable or possible DLB, 12 had abnormal HMR values, while 5 had 
normal HMR values. This corresponded to a sensitivity of 71% (95% CI 44-90%) (Table 8.2). 
 
Twelve of 16 patients with a clinical diagnosis of AD had a normal MIBG result, corresponding to a 
specificity of 75% (95% CI 48 - 93%). MIBG result correctly corresponded to clinical diagnosis in 24 
of 33 participants, demonstrating an overall accuracy of 73%. 
 
As described in the methods chapter, raters divided MIBG uptake in a myocardial ROI, drawn using 
a freehand tool, by a reference mediastinal ROI. The mean value of HMRs independently 
calculated by two practitioners (JK and GR) contributed to this data. 
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Figure 8.1 Late HMR in DLB and AD patients 
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Table 8.2 MIBG result and clinical diagnosis 
  
Clinical DLB Clinical AD Total 
MIBG abnormal (HMR < 2.2) 12 4 16 
MIBG normal (HMR ≥ 2.2) 5 12 17 
Total 17 16 33 
 
The two raters’ normal/ abnormal MIBG result agreed on 97% (32/33) of cases (Cohen’s kappa = 
0.94). In five cases (5/33; 15%) the difference between the two raters’ HMRs exceeded 10% of the 
mean HMR (Table 8.3). In one of these cases (MID027), HMR values reported by each rater would 
have corresponded to a disagreement over the scans normal/abnormal MIBG status. 
 
Table 8.3 Disagreement between HMR raters 
  
Clinical 
Diagnosis 
Late HMR (JK) Late HMR 
(GR) 
Mean HMR Difference between 
HMRs/Mean HMR (%) 
MID003 Probable AD 2.84 2.46 2.67 14.2% 
MID014 Probable DLB 1.21* 1.66* 1.43* 31.5% 
MID023 Probable DLB 1.05* 1.34* 1.20* 24.2% 
MID027 Probable AD 2.41 2.10* 2.25 13.8% 
MID038 Possible DLB 2.60 2.91 2.76 11.2% 
   
*Abnormal MIBG (HMR <2.2) 
 
8.3 FP-CIT 
Of 17 patients with DLB, 14 (82%) had an abnormal FP-CIT result. Two patients (2/16; 13%) with a 
diagnosis of probable AD also had an abnormal FP-CIT result (Table 8.4); both of these cases had a 
HMR within normal ranges.  
 
Table 8.4 FP-CIT result and clinical diagnosis 
  
Clinical DLB Clinical AD Total 
FP-CIT Abnormal 14 2 16 
FP-CIT Normal 3 14 17 
Total 17 16 33 
 
FP-CIT therefore had a sensitivity of 82% (95% CI 57- 96%) and specificity of 88% (95% CI 62-99%). 
FP-CIT result correctly corresponded to clinical diagnosis in 28 of 33 participants, demonstrating 
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an overall accuracy of 85%. None of the cases determined by consensus panel review to have a 
normal FP-CIT on visual rating had abnormal uptake results on DaTQUANT analysis. 
 
8.4 Agreement between MIBG and FP-CIT 
MIBG and FP-CIT concurred in 23 of 33 (70%) of DLB and AD cases (Cohen’s kappa = 0.39). FP-CIT 
findings were abnormal in 11 cases in which MIBG was abnormal (11/16; 69%) and were normal in 
12 cases where MIBG findings were normal (12/17; 71%) (Table 8.5).  
 
Table 8.5 Consensus between FP-CIT and MIBG findings 
  
FP-CIT Abnormal FP-CIT Normal Total 
MIBG Abnormal 11 5 16 
MIBG Normal 5 12 17 
Total 16 17 33 
 
Five (5/33; 15%) participants with abnormal FP-CIT had a MIBG HMR within normal ranges. Two of 
these cases (Late HMRs 2.5, 3.0) had a clinical diagnosis of probable AD; the remaining three cases 
had clinical diagnoses of probable DLB (Late HMRs 2.3, 2.4, 3.2). 
 
Agreement between FP-CIT and MIBG is explored further in receiver operating characteristic (ROC) 
analysis below. 
 
8.5 Receiver operating characteristic (ROC) analysis 
The area under the ROC curve was calculated at 0.79 (95% CI 0.62 – 0.97).  The optimum HMR cut-
off, as determined by the point of the ROC curve furthest from the diagonal line, is 1.7. This value 
would be 100% specific and 71% sensitive in differentiating DLB from AD, corresponding to an 
accuracy of 85% (Figure 8.2).  
 
Table 8.6 and Figure 8.2 demonstrate sensitivity (for detecting DLB), specificity (for AD) and overall 
diagnostic accuracy at a range of different HMR cut-offs. MIBG sensitivity in this cohort would 
remain at 71% were any HMR cut-off between 1.7 and 2.3 to be employed; however, a 1.7 cut-off 
would offer greater specificity (100%) than the 2.2 figure set at the beginning of the study (75%). 
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Agreement between MIBG and FP-CIT would also have been highest (82%) at a HMR cut-off of 1.7 
or 1.5 (Table 8.6). Although MIBG would report agreement on the same proportion of abnormal 
results at cut-offs of both 1.7 and 2.2 (11/16; 69%), the two modalities would agree on a higher 
proportion of normal results at the 1.7 cut-off (16/17; 94%) than at the 2.2 boundary (12/17; 
71%). 
 
Figure 8.2 ROC curve of MIBG sensitivity and specificity in DLB vs AD 
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Table 8.6 MIBG sensitivity, specificity, accuracy and agreement with FP-CIT at a range of HMR 
cut-off values 
 
 Figures corresponding with the HMR cut-off associated with the highest accuracy 
(1.7) are displayed in bold. 
 
  Agreement with FP-CIT 
HMR cut- off Sensitivity (%) Specificity (%) Accuracy 
(%) 
Abnormal  
FP-CIT (%) 
Normal  
FP-CIT (%) 
Overall  
(%) 
1.1 0.0 100.0 48.5 0.0 100.0 51.5 
1.2 11.8 100.0 54.5 12.5 100.0 57.6 
1.3 41.2 100.0 69.7 43.8 100.0 72.7 
1.4 52.9 100.0 75.8 56.3 100.0 78.7 
1.5 58.8 100.0 78.8 62.5 100.0 81.8 
1.6 64.7 100.0 81.8 62.5 94.1 78.7 
1.7 70.6 100.0 84.8 68.8 94.1 81.8 
1.8 70.6 87.5 78.8 68.8 82.4 75.7 
1.9 70.6 81.3 75.8 68.8 76.5 72.7 
2.0 70.6 81.3 75.8 68.8 76.5 72.7 
2.1 70.6 81.3 75.8 68.8 76.5 72.7 
2.2 70.6 75.0 72.7 68.8 70.6 69.7 
2.3 70.6 68.8 69.7 68.8 64.7 66.6 
2.4 76.5 43.8 60.6 75.0 41.2 57.6 
2.5 82.4 37.5 60.6 81.3 35.3 57.6 
2.6 82.4 31.3 57.6 87.5 35.3 60.6 
2.7 82.4 25.0 54.5 87.5 29.4 57.6 
2.8 82.4 18.8 51.5 87.5 23.5 54.5 
2.9 94.1 12.5 54.5 87.5 5.8 45.5 
3.0 94.1 6.3 .51.5 87.5 0.0 42.4 
3.1 94.1 0.0 48.5 93.8 0.0 45.5 
3.2 94.1 0.0 48.5 93.8 0.0 45.5 
3.3 100.0 0.0 51.5 100.0 0.0 48.4 
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8.6 Early HMR and Late HMR 
We observed a significant correlation between early HMR and late HMR (r=0.90, p<0.01; R2=0.85) 
(Figure 8.3). However, two cases, one with a clinical diagnosis of probable DLB, the other a 
diagnosis of probable AD, demonstrated HMRs within the abnormal range on early imaging, only 
for their late HMR values to rise into the normal range. These are depicted within the pink area of 
Figure 8.3. One probable DLB case would have demonstrated the same pattern if the HMR 1.7 
threshold suggested by ROC analysis had been employed. None of the cases with normal early 
HMR values had abnormal late HMR values using either a priori or post hoc cut-offs. 
 
Figure 8.3 Correlation between early HMR and late HMR with line of best fit 
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8.7 Myocardial infarction and late HMR 
Five of the 33 patients (15%) recruited to Phase 1 of the study had a history of MI; three with a 
diagnosis of Probable AD (3/16; 19%), two with a diagnosis of probable DLB (2/17; 12%) (Table 
8.7). In one of the three AD cases with a history of MI, MIBG yielded a false positive result. 
 
No significant differences were observed between late HMR in patients with a history of MI and 
those without. No significant difference in age was observed between patients with history of MI 
and those without (U=49.0, Z=-1.06, r=-0.18, p=0.29) (Table 8.8). 
 
Table 8.7 Subjects with a history of MI 
 
 Clinical diagnosis FP-CIT result MIBG Late HMR 
MID007 Probable AD Abnormal 2.5 
MID029 Probable AD Normal 2.9 
MID040 Probable AD Normal 2.1* 
MID042 Probable DLB Abnormal 1.2 
MID047 Probable DLB Normal 2.8** 
  
* False positive result 
** False negative result 
 
 
Table 8.8 Late HMR in patients with and without a history of MI 
 
 History of MI No history of MI  
 Mean Late 
HMR 
(± SD) 
Mean 
Rank 
Mean age 
(± SD) 
Mean Late 
HMR 
(± SD) 
Mean 
Rank 
Mean age 
(± SD) 
p  
(Mean 
Late HMR) 
DLB 1.98 (± 0.67) 10.5 79.0 (± 9.9) 1.64 (± 1.12) 8.8 76.7 (± 8.0) 0.66 
AD 2.52 (± 0.42) 10.0 73.3 (± 9.1) 2.31 (± 0.41) 8.2 77.1 (± 6.2) 0.54 
Overall 2.30 (± 0.70) 21.2 75.6 (± 8.7) 1.95 (± 0.65) 16.3 76.9 (± 7.1) 0.29 
 
Among these five cases with a history of MI, MIBG demonstrated a sensitivity, specificity and 
accuracy of 50% (95% CI 1-99%), 100% (95% CI 29-100%) and 80% (95% CI 28-99%), irrespective of 
whether the a priori (2.2) or post hoc (1.7) cut-off was used. No alternative cut-off would provide 
superior accuracy that these values. 
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8.8 Potentially interacting medications and late HMR 
Eighteen of 33 subjects (55%) were prescribed agents identified as capable of influencing MIBG 
uptake (Giammarile et al., 2008). These comprised six patients with a clinical diagnosis of probable 
AD (6/16; 38%) and twelve with a diagnosis of probable DLB (12/17; 71%).  
 
No significant differences in late HMR were observed between patients prescribed interacting 
agents (1.82 ± 0.67) and those not prescribed such medications (2.24 ± 0.59), although this did 
approach statistical significance (U=92.0, Z=-1.56, r= -0.27, p=0.12). However the fact HMRs were 
lower in this group is unsurprising as there were proportionately more DLB patients than in the 
group not prescribed medications (Table 8.9). There was no significant difference in age between 
the two groups (U=92.5, p=0.12). 
 
Table 8.9 Late HMR in patients prescribed interacting medications 
 
  Prescribed interacting medication Not prescribed interacting medication   
  Mean Late 
HMR 
(± SD) 
Mean 
rank 
Mean age  
(± SD) 
Mean Late 
HMR 
(± SD) 
Mean 
Rank 
Mean age  
(± SD) 
p  
(Mean 
Late HMR) 
DLB 1.54 (± 0.58) 8.1 75.4 (± 8.5) 2.01 (± 0.91) 11.2 80.8 (± 4.9) 0.25 
AD 2.35 (± 0.52) 9.0 74.7 (± 6.7) 2.35 (± 0.36) 8.2 77.4 (± 6.7) 0.75 
Overall 1.82 (± 0.67) 14.6 75.2 (± 7.8) 2.24 (± 0.59) 19.9 78.5 (± 6.2) 0.12 
 
However, it is noteworthy that seven of 18 subjects prescribed potentially interfering medications 
(39%) were prescribed levodopa compounds; in five of 18 subjects (28%), dopaminergic 
medication was the only interacting agent prescribed. Every patient prescribed levodopa had a 
clinical diagnosis of probable DLB and was therefore likely to have a greater degree of cardiac 
denervation, and a lower HMR, irrespective of medication prescription. 
 
When dopamine was not considered as an interacting medication (Table 8.10), no significant 
difference was identified between late HMR of those prescribed interacting medications (1.96 ± 
0.69) and those not prescribed these agents (2.04 ± 0.65; U=128.0, Z=-0.18, r=-0.03, p=0.86). 
There was no significant difference in age between the two groups (U=92.0, p=0.14). 
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Table 8.10 Late HMR in patients prescribed interacting medications (excluding dopamine) 
 
  Prescribed interacting medication Not prescribed interacting medication   
  Mean Late 
HMR 
(± SD)  
Mean 
Rank 
Mean age  
(± SD) 
Mean Late 
HMR 
(± SD)  
Mean 
Rank 
Mean age  
(± SD) 
p  
(Mean 
Late HMR) 
DLB 1.67 (± 0.68) 8.4 75.6 (± 5.3) 1.70 (± 0.75) 9.6 78.2 (± 9.8) 0.63 
AD 2.35 (± 0.52) 8.2 74.7 (± 6.7) 2.35 (± 0.36) 9.0 77.4(± 6.7) 0.75 
Overall 1.96 (± 0.69) 16.6 75.2 (± 5.7) 2.04 (± 0.65) 17.3 77.8 (± 8.1) 0.86 
 
Four subjects with AD were prescribed amlodipine, a calcium channel blocker; a false positive 
HMR was observed in two of these four subjects (50%). Three DLB patients were prescribed two or 
more agents. Three false negative results were observed among this group (3/12; 25%), 
comprising patients prescribed diltiazem and venlafaxine (Table 8.11). 
 
Table 8.11 Subjects prescribed medications potentially interacting with MIBG uptake 
 
 Clinical diagnosis FP-CIT result MIBG Late HMR Agents prescribed 
MID025 Probable AD Normal 2.8 Mirtazapine+ 
MID035 Probable AD Normal 2.4 Diltiazem++ 
MID039 Probable AD Normal 1.7* Amlodipine+ 
MID040 Probable AD Normal 2.9 Amlodipine+ 
MID044 Probable AD Normal 1.8* Amlodipine+ 
MID047 Probable AD Abnormal 2.5 Amlodipine+ 
MID002 Probable DLB Abnormal 1.1 Quetiapine+ 
MID004 Probable DLB Abnormal 1.6 Dopamine+ 
MID007 Probable DLB Abnormal 1.2 Dopamine+ 
MID015 Probable DLB Abnormal 2.3** Amlodipine+, dopamine+ 
MID016 Probable DLB Abnormal 1.3 Dopamine+ 
MID018 Probable DLB Abnormal 1.2 Amlodipine+ 
MID019 Probable DLB Abnormal 1.1 Dopamine+, mirtazapine+, quetiapine+ 
MID020 Probable DLB Abnormal 1.2 Dopamine+ 
MID023 Probable DLB Abnormal 1.2 Dopamine+ 
MID028 Probable DLB Abnormal 1.3 Amlodipine+, salbutamol+, salmeterol+ 
MID029 Probable DLB Normal 2.8** Diltiazem++ 
MID031 Probable DLB Abnormal 2.4** Venlafaxine+ 
 
*  False positive result  +  Theoretical interaction 
**  False negative result  ++ Probable interaction 
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The sensitivity, specificity and accuracy of MIBG for patients prescribed potentially interfering 
medications (including dopamine) were 75% (95% CI 43-95%), 67% (95% CI 22-96%) and 72% (95% 
CI 47-90%) using the a priori (2.2) cut off and 75% (95% CI 43-95%), 83% (95% CI 35-100%) and 
78% (95% CI 52-94%) using the post hoc (1.7) cut-off. When patients prescribed dopamine were 
excluded, the sensitivity, specificity and accuracy of MIBG were 43% (95% CI 10-82%), 67% (95% CI 
22-96%) and 54% (95% CI 25-81%) using the a priori cut-off and 43% (95% CI 10-82%), 83% (95% CI 
36-100%) and 62% (95% CI 32-86%) using the post hoc cut off. 
 
The optimum cut-off in patients prescribed interfering medication was 1.6, corresponding to a 
sensitivity, specificity and accuracy of 43% (95% CI 10-82%), 100% (95% CI 54-100%) and 69% (95% 
CI 39-91%). The same value was the optimum cut-off when patients prescribed dopamine were 
excluded; MIBG would demonstrate a sensitivity, specificity and accuracy of 43% (95% CI 10-82%), 
100% (95% CI 54-100%) and 69% (95% CI 39-91%) were it to be used. 
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8.9 Late HMR and core DLB symptoms 
Late HMR showed a significant negative correlation with the hallucinations subscale of NPI in DLB 
patients (r=-0.56, p=0.03) (Table 8.12), indicating the more abnormal the cardiac imaging, the 
more severe and frequent were hallucinations.  Late HMR did not correlate significantly with any 
other cognitive, functional or core symptom scale. 
 
Table 8.12 Correlation between late HMR and cognitive, functional and core DLB symptom 
measures 
 
 DLB 
(n=17) 
Pearson r  p 
Revised Addenbrooke’s Cognitive Examination (ACE-R) 0.28 0.27 
Mini-Mental State Examination (MMSE)  
 
0.30 0.29 
   
Bristol Activities of Daily Living Scale  -0.33 0.19 
Instrumental Activities of Daily Living Scale  0.36 0.23 
   
Unified Parkinson’s Disease Rating Scale (UPDRS) Motor subscale -0.38 0.14 
Neuropsychiatric Inventory (NPI) Hallucinations subscale -0.56 0.03 
Dementia Cognitive Fluctuations Scale (DCFS) -0.43 0.11 
 
FP-CIT’s possible suboptimal sensitivity in patients without parkinsonism (O’Brien et al., 2014b) 
necessitates exploration of the relationship between late HMR and UPDRS motor subscale score; 
MIBG would be of greatest clinical benefit in patients for whom FP-CIT would be likely to produce 
a false negative result. 
 
Four (4/17; 24%) of DLB cases, all meeting criteria for probable DLB, scored less than 15 on the 
UPDRS motor subscale, with three (3/17; 18%) scoring eight or less (Figure 8.4). Two cases (A and 
B), had both an abnormal FP-CIT and abnormal MIBG result; one case (C) had an abnormal FP-CIT 
and normal (HMR=2.4) MIBG result; and one case (D) had a normal FP-CIT, and normal (HMR =2.8) 
MIBG. Thus, the only DLB cases without parkinsonism in which MIBG produced an abnormal result 
were those who also had abnormal FP-CIT findings. The status of each of these four cases were the 
same irrespective of the use of the predetermined HMR cut-off of 2.2 or the 1.7 cut-off 
determined by sensitivity analysis.  
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Figure 8.4 Correlation between late HMR and UPDRS motor subscale score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.10 DLB patients with normal FP-CIT 
In addition to the 33 patients recruited to the study, we identified six participants meeting 
diagnostic criteria for probable or possible DLB but who recently had a normal FP-CIT scan. These 
patients had significantly lower levels of functional impairment as measured by the Bristol 
Activities of Daily Living Scale (t(19)= 2.5,p=0.02), and lower levels of parkinsonism (t(20)=2.3 , 
p=0.03) than participants recruited to the main study cohort (Table 8.13). 
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Table 8.13 Demographic and clinical characteristics of DLB patients in the main study cohort 
and FP-CIT negative cohort 
 
 DLB Main cohort 
(n=17)  
Mean score (± SD) 
DLB Normal FP-CIT 
cohort (n=6) 
Mean score (± SD) 
p  
Age in years at MIBG (± SD) 77.0 (± 7.9) 78.0 (± 4.4) 0.77 
Gender male/female (% Male) 15/2 (88%) 5/1 (83%) 0.76 
    
Revised Addenbrooke’s Cognitive Examination (ACE-
R) 
66.6 (± 15.1) 69.2 (± 7.6) 0.58 
ACE-R subscale Attention and Orientation 13.9 (± 3.6) 14.7 (± 2.5) 0.69 
ACE-R subscale Memory 13.4 (± 5.1) 13.2 (± 4.4) 0.63 
ACE-R subscale Fluency 6.4 (± 3.3) 6.7 (± 1.5) 0.91 
ACE-R subscale Language 22.3 (± 5.1) 22.8 (± 2.6) 0.87 
ACE-R subscale Visuospatial 10.6 (± 4.1) 11.8 (± 2.3) 0.80 
Mini-Mental State Examination (MMSE)  22.1 (± 4.9)  23.3 (± 3.1) 0.49 
    
Bristol Activities of Daily Living Scale  22.3 (± 13.2) 12.3 (± 5.0) 0.02 
Instrumental Activities of Daily Living Scale  2.6 (± 1.9) 4.3 (± 1.0) 0.05 
    
Unified Parkinson’s Disease Rating Scale (Motor 
subscale) 
32.8 (± 23.4) 7.8 (± 7.7) 0.03 
Neuropsychiatric Inventory (Hallucinations subscale) 2.1 (± 2.5) 1.0 (± 2.5) 0.35 
Dementia Cognitive Fluctuations Scale  10.9 (± 3.7) 9.0 (± 3.5) 0.30 
Mayo Sleep Questionnaire 6.8 (± 2.3) 9.3 (± 0.6) 0.09 
    
Neuropsychiatric Inventory (Total) 23.9 (± 19.5) 17.7 (± 13.6) 0.48 
Neuropsychiatric Inventory (Carer total) 17.6 (± 14.4) 15.0 (± 9.9) 0.69 
Cornell Scale for Depression in Dementia  6.5 (± 4.3) 5.7 (± 2.7) 0.68 
    
Clinical Dementia Rating (CDR) 1.2 (± 0.5) 0.7 (± 0.3) 0.06 
 
All FP-CIT data collected from these recent scans underwent reprocessing and review by a blinded 
panel using a methodology identical to that employed elsewhere in the study (Chapter 7.3.8). In 
two of six cases (33%), the FP-CIT result determined by our blinded study panel contradicted the 
normal result previously reported by local nuclear medicine practitioners (Table 8.14).  
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Two of six recruited cases showed late HMR results <2.2, both with a diagnosis of probable DLB. 
One of these cases (MID005) had a history of MI and calcium channel blocker prescription and 
comprised one of the cases in whom FP-CIT results was revised to abnormal. The second case with 
an abnormal late HMR (MID009) was subject to neither significant cardiac history nor prescription 
of interfering medications. 
 
Table 8.14 DLB patients with normal FP-CIT 
 
Study ID Sex Age Clinical diagnosis Review panel 
FP-CIT result 
Late 
HMR 
History 
of MI 
Interfering 
medications 
MID005 M 76 Probable DLB Abnormal 1.7 Yes Diltiazem++ 
MID009 M 78 Probable DLB Normal 1.4 Yes None 
MID022 M 71 Probable DLB Normal 3.3 No None 
MID032 M 81 Probable DLB Normal 3.3 No None 
MID013 F 78 Possible DLB Normal 2.7 No None 
MID017 M 84 Possible DLB Abnormal 2.7 No None 
 
 
8.11 Summary 
Our study recruited 33 patients; 17 DLB and 16 AD. The mean HMR for patients with clinical DLB 
was significantly lower than that of cases with AD. Using the a priori cut-off set for the study (2.2), 
based on the Japanese literature (Yoshita et al., 2015), MIBG demonstrated a sensitivity of 71% 
and specificity of 75% for separating DLB from AD, compared with 82% sensitivity and 88% 
specificity for FP-CIT. MIBG and FP-CIT results concurred in 70% of cases recruited to the study. 
ROC analysis identified an optimum HMR cut-off of 1.7, which would be 71% sensitive and 100% 
specific in differentiating DLB from AD. 
 
Eighteen of 33 subjects (55%) participating in the study were prescribed agents identified as 
potentially influencing MIBG uptake, and five subjects (15%) recruited to the study had a history of 
MI. No significant differences were identified between patients exposed to these factors and 
those who were not, but calcium channel blockers were prescribed in participants with both false 
positive and false negative results.  
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With the exception of the negative correlation between late HMR and the hallucinations subscale 
of the NPI, no significant relationships were identified between late HMR and cognitive, clinical or 
functioning scales in DLB patients. MIBG only reported abnormal values for DLB patients without 
parkinsonism where FP-CIT had also reported abnormal findings. 
 
Six additional patients were recruited to the study, who each met criteria for probable or possible 
DLB but who had recently had a normal FP-CIT scan in clinical services. In two of these cases, 
independent FP-CIT review reported an abnormal study contrary to that reported by local nuclear 
medicine practitioners. Two cases with a diagnosis of probable DLB had abnormal MIBG findings, 
one of whom had neither a history of MI, interfering medication, nor revision of FP-CIT result by 
independent panel. 
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Chapter 9 
MIBG cardiac scintigraphy as a biomarker for DLB - discussion 
 
9.1 Introduction 
Our discussion will, in keeping with the theme of this thesis, discuss the results of this study from a 
clinical perspective. We will first discuss the sensitivity and specificity of MIBG in this cohort using 
the a priori cut-off derived from phantom calibration (Nakajima et al., 2012) and a previous 
multicentre study (Yoshita et al., 2015). This will be followed by exploration of another of the aims 
of the study; determination of an appropriate HMR cut-off for a UK population. In doing so we will 
examine the results of ROC analysis and the factors contributing to the differences observed 
between our a priori and post hoc optimum cut-offs. The relationship between interacting 
medications, MI and late HMR, will then be considered before discussion of MIBG utility in DLB 
patients without parkinsonian features and in those who had previously had normal FP-CIT scans. 
Finally, we will discuss how our findings contribute to our understanding of DLB pathogenesis. 
 
9.2 Sensitivity 
Our study design adopted a necessarily exploratory approach to HMR cut-off in a population in 
whom MIBG had not previously been researched. However, for our initial analysis we adopted the 
mean HMR values from the largest MIBG DLB sample published to date (Yoshita et al., 2015) and a 
phantom calibration process used to standardise multiple machines contributing to the same 
study (Nakajima et al., 2012). This process identified an early and late HMR threshold of 2.2 to 
distinguish between normal (≥2.2) and abnormal (<2.2) studies. Although we had anticipated that 
our data would identify an alternative post hoc HMR cut-off for our cohort, it is important to first 
discuss the utility of MIBG using the a priori values adopted. 
 
We found that MIBG demonstrated a sensitivity of 71% in our study cohort. This is considerably 
lower than the 93% reported by meta-analysis (Treglia and Cason, 2012), comprising mostly 
Japanese studies, but is also lower than that reported by Italian (93%) and Spanish (94%) groups 
(Estorch et al., 2008; Tiraboschi et al., 2016). This sensitivity is, however, very similar to the 69% 
reported by a multicentre Japanese trial (Yoshita et al., 2015), which assessed the largest single 
cohort in the field to date. 
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When MIBG results were compared directly with FP-CIT results the two investigations concurred in 
70% of cases. Every combination of clinical diagnosis, MIBG result and FP-CIT result, with the 
exception of AD cases testing positive for both MIBG and FP-CIT (n=10), were represented in this 
sample (Figure 9.1). 
 
Figure 9.1 Relationships between clinical diagnosis, MIBG result and FP-CIT result in the main 
cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Five of 17 patients meeting diagnostic criteria for possible or probable DLB (29%) had a late HMR 
within the normal range. Three of these five cases (60%) had an abnormal FP-CIT scan (Table 9.1). 
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Possible reasons for the false negative status of these patients, and the effect of these on overall 
sensitivity, will be explored in turn; the inclusion of participants with possible DLB, the accuracy of 
clinical diagnosis, the effect of medications and MI, and the HMR cut-off used by the study. 
 
Table 9.1 DLB patients with normal late HMR values 
 
 Clinical diagnosis FP-CIT result Late HMR History of MI Interacting medications 
MID010 Probable DLB Abnormal 3.2 no none 
MID015 Probable DLB Abnormal 2.3 no Amlodipine, dopamine 
MID029 Probable DLB Normal 2.8 yes Diltiazem 
MID031 Probable DLB Abnormal 2.4 no Venlafaxine 
MID038 Possible DLB Normal 2.8 no none 
 
We adopted clinical diagnosis, as determined by a panel of three independent practitioners, as our 
gold standard measurement. This was on the basis of both the validity of this process as an 
alternative to post-mortem assessment (McKeith et al., 2000b), and the desire for our study to 
maintain a clear clinical relevance. However, the 85% specificity associated with this use of third 
consensus criteria (McKeith et al., 2000b) compels us to consider the possibility that a proportion 
of patients recruited to our DLB group may have alternative diagnoses not associated with cardiac 
denervation. This suspicion should be greatest in two cases with both normal FP-CIT and normal 
MIBG (Table 9.1; MID029, MID038). The reported sensitivity of FP-CIT of 80% in a 
neuropathological cohort (Thomas et al., 2017a) requires consideration that either or both of 
these cases could represent other dementia subtypes misdiagnosed by the clinician panel. 
 
Conversely, the abnormal FP-CIT results for the remaining three DLB cases with normal MIBG 
(MID010, MID015, MID031), make misdiagnosis in this group unlikely, particularly given the 
combined sensitivities of FP-CIT and independent clinician rating. However, pathologies such as 
FTD, vascular parkinsonism, MSA and PSP could all produce false positive FP-CIT results (Zijlmans 
et al., 2007; Vlaar et al., 2008; Morgan et al., 2012) and can exhibit clinical features suggestive of 
DLB, without compromising cardiac innervation (Kashihara and Yamamoto, 2006; Novellino et al., 
2010; Navarro-Otano et al., 2014). Attention was paid in each case to exclude these conditions 
during the assessment process, by examination of structural imaging and detailed neurological 
examination of each patient (JK), but the possibility of such cases influencing our results cannot be 
excluded. 
 132
It is also entirely possible that these five cases, and in particular, the three cases with abnormal 
FP-CIT, could have Lewy body pathology without autonomic cardiac involvement; Orimo et al.  
(2016) reported normal MIBG results in two of thirteen (15%) neuropathologically confirmed DLB 
cases, while Beach et al. (2010) detected α-synuclein in the epicardium and ventricles of one of 
four (25%) DLB subjects. Thus our 71% sensitivity could be an accurate measure of the proportion 
of DLB patients with cardiac sympathetic α-synuclein pathology. 
 
Although unlikely, the possibility that our HMR threshold of 2.2 was too low to detect denervation 
in these five false negative cases should be explored. A higher cut-off of 2.9, for example, would 
have increased sensitivity to 94%. There are a number of arguments which strongly suggest that a 
higher HMR threshold would not be justifiable for our study population. The first is that our HMR 
cut-off of 2.2 already exceeds all cut-off points in published literature; with the exception of 
Yoshita et al‘s 2.1 post hoc cut-off, HMR thresholds, where reported, have ranged between 1.4 
and 1.8 (Yoshita et al., 2006, 2015; Wada-Isoe et al., 2007; Estorch et al., 2008; Novellino et al., 
2010; Tiraboschi et al., 2016).  
 
Secondly, any increase in HMR threshold would have affected the specificity of MIBG in identifying 
AD cases. In the specialist setting in particular, the high specificity of a test is arguably more 
important than a high sensitivity and compromising the former to enhance the latter would 
diminish its clinical value. The late HMR of three of five false negative DLB cases far exceeded the 
2.2 cut-off, the highest of which (MID010) was the single highest HMR value recorded in the entire 
cohort. Increasing the cut-off to 2.8, although increasing sensitivity, would have lowered 
specificity to only 13%.  
 
Finally, the optimum HMR cut-off determined by ROC analysis suggested a lower HMR threshold 
(1.7), rather than a higher one. Thus, it is unlikely that our reported sensitivity can be attributed to 
a low HMR cut-off. HMR cut-off is discussed further in the following section. 
 
Medications or past medical history of MI were both unlikely to have produced false negatives in 
this study. Although some calcium channel-blocking medications have been implicated in elevating 
late HMR (Jacobson and Travin, 2015), any agents prescribed to patients enrolled in our study 
were more likely to decrease than increase MIBG uptake. These are discussed further in 9.6. 
Similarly, a history of MI would be more likely to adversely influence specificity than sensitivity. 
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A sensitivity of 71% is not a strongly persuasive argument for the routine clinical use of MIBG, but 
the variation in DLB detection rates, as discussed in previous chapters, makes any tool capable of 
minimising false negative cases in the DLB diagnostic process useful.  
 
9.3 Specificity 
Our reported specificity for distinguishing AD from DLB was 75%. This was lower than the that 
reported by Japanese and European groups, who reported specificity ranging from 89% to 100% 
(Estorch et al., 2008; Treglia and Cason, 2012; Yoshita et al., 2015; Tiraboschi et al., 2016). 
 
Four of twelve cases (33%) meeting diagnostic criteria for probable AD demonstrated abnormal 
late HMR values (Table 9.2). We will adopt the same approach in discussing factors contributing to 
false positive cases, and thus specificity, as we did for false negative cases and sensitivity. 
 
Table 9.2 Probable AD cases with abnormal late HMR 
 
Study ID Clinical diagnosis FP-CIT result Late HMR History of MI Interacting medications 
MID001 Probable AD Normal 1.7 no none 
MID039 Probable AD Normal 1.7 no none 
MID042 Probable AD Normal 2.1 yes none 
MID044 Probable AD Normal 1.8 no none 
 
None of the cases with probable AD recruited to the study were prescribed medications identified 
as capable of inhibiting MIBG uptake. Only one case (MID042) had a history of MI, although it is 
noteworthy that this case’s late HMR was the highest of the four false positive cases.  
 
The same limitations of both the independent clinician panel and FP-CIT imaging discussed 
previously apply to the false positive cases. The combined high sensitivity of third consensus 
criteria (83%) and FP-CIT (80%) (McKeith et al., 2000b, 2007) suggest that there are unlikely to be 
DLB cases among those listed in Table 9.2.  Furthermore, the high specificity of NIA-AA criteria 
(95%) (Harris et al., 2015) make inclusion of other subtypes such as FTD, doubtful, and such 
subtypes would be unlikely to demonstrate impaired MIBG uptake. 
 
Consideration of the late HMR cut-off is again important when considering the role of specificity. 
All four of the late HMRs of false positive cases listed above fell between 1.7 and 2.1. Were we to 
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use a threshold of 1.7, a figure similar to that employed in several previous studies (Yoshita et al., 
2006; Wada-Isoe et al., 2007; Tiraboschi et al., 2016) and the optimum cut-off suggested by ROC 
analysis in this cohort, this would increase the specificity of MIBG in this group to 100%. Doing so 
would have no effect on the sensitivity, which would remain at 71%. 
 
Taken together, the sensitivity (71%) and specificity (75%) associated with our a priori HMR cut-off 
suggest that MIBG could represent a useful diagnostic test but is not strongly persuasive in favour 
of routine clinical use. This would appear to concur with the findings of multicentre studies 
investigating the utility of FP-CIT (sensitivity 78%, specificity 90%) and MIBG (sensitivity 69%, 
specificity 89%) (McKeith et al., 2007; Yoshita et al., 2015) 
 
However, the 71% sensitivity and 100% specificity offered by the 1.7 cut-off is encouraging, 
particularly given the comparatively inferior specificity for AD of FP-CIT (McKeith et al., 2007), and 
merits further discussion of HMR cut-off. We did also observe abnormal MIBG findings in one of 
the three DLB subjects in our main cohort with normal FP-CIT. While this represents a small 
sample, it could suggest that MIBG may have a second-line diagnostic role in FP-CIT negative 
patients.  
 
MIBG may yet prove useful in subgroups of DLB patients beyond the scope of this study. These 
may include prodromal DLB subjects, challenging diagnostic cases, or those with specific structural 
imaging biomarkers. Larger studies, adopting a similar inclusive approach towards recruitment as 
ours, could help further understanding of the role that MIBG should play in routine clinical 
practice. 
 
9.4 Practical considerations in MIBG use 
Although our findings regarding utility may support FP-CIT in preference to MIBG, other factors 
may encourage the use of the latter in clinical DLB diagnosis. Firstly, MIBG could be a more 
tolerable investigation than FP-CIT among cognitively impaired or frail patients, necessitating less 
time for data acquisition and less overall time spent by the patient and carer in the hospital. 
Planar MIBG images are acquired over ten minutes, with the patient in a seated or semi-
recumbent position, compared to FP-CIT, which requires the patient to lie supine and still for a 20-
minute period. Early planar MIBG images are collected 20 minutes following radioligand injection, 
while FP-CIT data acquisition takes place three to six hours after injection. We did not, as part of 
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this study examine the clinical utility of early HMR but did observe a significant correlation 
between early and late MIBG uptake, and in only two of 33 cases (6%) did the normal/ abnormal 
status differ between early and late scans. Yoshita et al. (2015) noted the comparable utility of 
data from the two acquisition periods, and the practical and economic potential of shorter 
investigations encourage further research into the use of early HMR. 
 
Secondly, MIBG confers a lower dose of radiation than FP-CIT when used in the quantities 
employed in our study (MIBG 1.5mSv, FP-CIT 4.35mSv) and importantly, MIBG (£220 per scan) is 
cheaper than FP-CIT (£630 per scan). FP-CIT is currently better established in UK services and is 
supported by a more mature evidence base in comparison to that of MIBG (Sonni et al., 2017), but 
these practical considerations, particularly around tolerability, could support the use of MIBG in 
selected patients, such as those unable to tolerate longer scans. 
 
9.5 Late HMR cut-off 
We have discussed how the observed sensitivity and specificity of MIBG are greatly affected by the 
level of the threshold between a normal and abnormal scan; the late HMR cut-off. Determination 
of an accurate cut-off HMR for use in a UK population was a key aim of the study.  
 
Below we will discuss the factors that could contribute to the differences between our a priori cut-
off, derived from a previous multicentre study (Yoshita et al., 2015), and our post hoc cut-off. 
These causes can be considered as related to acquisition parameters or patient-based factors.  
 
As discussed in the methods section, our a priori threshold of 2.2 was determined by the phantom 
calibration method used to standardise practice across ten sites contributing to a Japanese 
multicentre MIBG study (Nakajima et al., 2012; Yoshita et al., 2015). This helped to account for 
some differences between our methodology and that of other studies; notably our use of medium 
energy general purpose collimators (MEGPs), rather than the low energy high resolution (LEHR) 
collimators used in other studies. MEGPs maximise contrast between areas of specific uptake and 
non-specific uptake, important in determining the boundaries of cardiac ROIs. The thicker septa of 
MEGPs minimise penetration from the high energy photons contributing to background signal, 
thus producing higher HMRs (Chen, Cao and Dilsizian, 2011; Inoue et al., 2014). Despite the 
calibration process, however, we found that the optimum post hoc cut-off was lower than the a 
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priori cut-off derived and converted from previous studies. It is therefore unlikely that collimator 
choice contributed to the difference between our two cut-offs. 
 
This calibration process, while helping to address some differences in parameters between 
Japanese centres and our practice did not consider a number of patient-specific factors affecting 
MIBG uptake and quantification. These factors could have contributed to the variation in accuracy, 
and optimum cut-off observed between this study and others. 
 
Although the method for HMR quantification through comparison of ROIs is a constant throughout 
MIBG research, accurate analysis using this method is not without its issues. Among these is the 
effect of non-cardiac MIBG uptake. Scattered radiation from liver and lungs can adversely 
influence the accurate definition of manually drawn cardiac ROIs. Unintended inclusion of such 
uptake in the cardiac ROI can therefore raise the HMR and produce a false negative result (Figure 
9.2) (Verberne et al., 2009; Verschure et al., 2015).  
 
As this is dependent on the size and position of the left lobe of the liver (Verberne et al., 2009), 
this can vary greatly between patients. MIBG SPECT has been shown to demonstrate a superior 
sensitivity to planar MIBG by reducing the number of the false negative scans caused by non-
cardiac uptake in a cohort of PD patients (Oh et al., 2015). However, while non-cardiac MIBG 
uptake could influence measurement of HMR on an individual patient basis, it is unlikely this 
would systematically affect either one of our AD or DLB groups more than the other, and thus 
unlikely to account for the large difference between a priori and post hoc cut-offs. 
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Figure 9.2 High MIBG uptake in liver and lungs of a study participant 
 
The uptake in the liver and lungs makes visual discernment of the cardiac border 
challenging. The cardiac ROI may therefore inadvertently include uptake in other 
tissues, thus raising the HMR. 
 
 
 
In addition to these image acquisition factors, a number of factors related to our patient cohort 
could have contributed towards the difference between our a priori and post hoc cut-offs. The 1.7 
cut-off suggested by ROC analysis, although more comparable to the cut-offs cited by previous 
MIBG studies than the 2.2 a priori margin used (Table 9.3), effectively represents a lower 
threshold of MIBG uptake in our study cohort when the fact that MEGPs were used is considered. 
 
One such patient factor is obesity which, due to attenuation and scatter, has been shown to 
significantly decrease recorded cardiac MIBG counts and increase non-specific background counts 
(Pellegrino et al., 2015). This is worth particular consideration given that 26.9% of the UK adult 
population is obese, compared to 4.4% of the Japanese population (Organisation for Economic Co-
operation and Development, 2017). Thirty four percent of adults in North-East England, from 
where our participants were recruited, meet criteria for obesity (NHS Digital, 2017).  Although we 
did not measure body mass index (BMI) in our participants, the relative preponderance of obesity 
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in the general population might have been reflected in our study population and it is possible that 
this could have contributed towards this lower HMR. 
 
Table 9.3 Collimator type, HMR cut-off, sensitivity and specificity of previous MIBG studies to 
date 
 
 
LEHR Low energy high resolution 
MEGP Medium energy general purpose 
NR Not reported 
* Estimated 
 
 
 
Study 
 
Collimator 
 
Late HMR  
cut-off 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Watanabe et al. (2001) NR 1.6* 100% (72-100) 100% (69-100) 
Yoshita et al. (2001) LEHR 1.6* 100% (91-100) 100% (92-100) 
Oide et al. (2003) LEHR 1.9* 100% (69-100) 100% (69-100) 
Hanyu et al. (2006) LEHR 1.8* 100% (82-100) 92% (79-98) 
Yoshita et al. (2006) LEHR 1.7 100% (91-100) 100% (92-100) 
Estorch et al. (2008) LEHR 1.4 94% (74-100) 96% (80-100) 
Wada-Isoe et al. (2008) LEHR 1.8 100% (83-100) 91% (75-98) 
Noguchi-Shinohara  
et al. (2009) LEHR NR 100% (77-100) 100% (77-100) 
Novellino et al. (2010) NR 1.4* 100% (66-100) 100% (54-100) 
Treglia et al. (2012) NR 1.6 90% (67-98) 91% (57-100) 
Yoshita et al. (2015) LEHR, MEGP 2.1 69% (57-81) 89% (80-98) 
Tiraboschi (2016) NR 1.6 93% (78-99) 100% (88-100) 
Thesis a priori MEGP 2.2 71% (44-90) 75% (48-93) 
 post hoc MEGP 1.7 65% (38-86%) 100% (79-100) 
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Although we found no association between history of MI and HMR (HMR was higher in DLB 
patients with MI), ischaemic heart disease, even in the absence of previous MI, could have 
contributed towards subtle changes in cardiac denervation as sympathetic innervation is more 
susceptible to ischaemia than cardiac myocytes (Dae et al., 1995). This is particularly important 
when we consider that males, among whom MI is three times more common (Bhatnagar et al., 
2015), comprised a higher proportion of DLB cases (15/17; 88%) in our study than the 38-70% 
seen in preceding MIBG studies (Noguchi-Shinohara et al., 2009; Treglia and Cason, 2012; Yoshita 
et al., 2015; Tiraboschi et al., 2016). Although this is in keeping with the male preponderance of 
DLB observed in in the same geographical region, the proportion is considerably greater than the 
55.6% cited in our epidemiological study (Chapter 5).  
 
In summary, a range of factors may have contributed to the difference between the optimum 
HMR cut-off in our study and those used in other MIBG studies. We used different collimators to 
those used many other MIBG studies, but our post hoc cut-off was lower than the a priori cut-off, 
rather than higher as would be expected if attributable to collimator choice. This would suggest 
that differences between our general population and those in other countries, such as obesity and 
ischaemic heart disease, may account for differences between our optimum cut-off and those 
reported elsewhere.  
 
9.6 Relationship between early and late HMR 
As previously discussed, we employed late HMR as the primary outcome measure for cardiac 
denervation, a practice in keeping with previous studies. Nevertheless, the potential role of early 
HMR is an important topic given our focus on the clinical utility of MIBG.  
 
Early images in this study were taken 20 minutes after radioisotope injection and late images were 
taken 180 to 240 minutes after injection. FP-CIT images were gathered between 240 and 360 
minutes after each participant’s arrival. Any investigation able to provide comparable accuracy to 
FP-CIT in a shorter period of time would be preferable to both patient and service provider, 
potentially allowing a higher turnover of patients, while also minimising distress to a vulnerable 
population. 
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Usage of early HMR, using the same cut-off, would have only marginally decreased MIBG 
sensitivity (69%; 95% CI 41- 89%) and increased specificity (77 %; 95% CI 50% - 93%). While this 
would not have affected overall accuracy of MIBG (73%; 95 CI 55-87%), two cases (one probable 
DLB, one probable AD) demonstrated abnormal early HMRs but normal late HMRs.  
 
What is notable from the comparison of early and late HMR data is that none of the participants 
with normal early HMR went on to have abnormal late HMRs when either the a priori or post hoc 
cut-off was used. Furthermore, specificity was 100% in patients with abnormal early HMR when 
the post hoc cut-off was used. This suggests that an early HMR <1.7 might be sufficiently 
suggestive of cardiac denervation in DLB and remove the necessity for collection of late images. 
While further research could further inform this practice, the potential health economic and 
patient wellbeing benefits of a considerably shorter hospital visit could make MIBG a more 
attractive investigation to clinicians. 
 
9.7 MIBG in patients with interacting medications and myocardial infarction 
The high proportion (55%) of participants in the study that were prescribed medications identified 
as capable of interacting with MIBG uptake (Giammarile et al., 2008) is noteworthy in itself. In 
order for MIBG to become a useful diagnostic tool in clinical practice, it cannot be considered 
unfeasible in over half of the patient population. Even when dopaminergic medications were 
excluded, 13 of 33 patients (39%) were prescribed potentially interacting medications. Stopping or 
holding these medications for the purposes of an investigation would be potentially harmful for 
patients scheduled for MIBG, particularly given that many of the proposed interactions are 
theoretical or supported by little or no experimental evidence (Jacobson and Travin, 2015).  
 
The same principles apply to the 15% of participants (5/33) with a history of MI. The UK 
prevalence of MI is reported as 12.1% in men and 5.5% in women over 75 years old (Bhatnagar et 
al., 2015). When we consider that cardiovascular risk and MI prevalence is higher in patients with 
dementia (Norton et al., 2014) and higher in North East England than the UK average (Bhatnagar 
et al., 2015), excluding patients with ischaemic heart disease from MIBG would exclude an 
unfeasibly large cross-section of the clinical population for whom the test could be useful. 
It is beyond the scope of this study to dismiss the significance of MI or interacting medications, 
particularly given our small sample size and the small effect sizes observed between groups. 
Nevertheless, our results are encouraging and support further investigation in this area, 
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particularly as even a small effect size could have great clinical significance given our observation 
that HMR cut-offs could greatly influence MIBG utility. A false positive result was suspected in one 
of our three participants with probable AD and a history of MI, and this case fell only marginally 
below the 2.2 HMR cut-off (Table 8.8). Were our post hoc cut-off to be used, none of these three 
AD cases would have produced an abnormal MIBG result. 
 
Similarly, an abnormal MIBG result was observed in two of the seven (29%) patients with probable 
AD that were prescribed an interacting medication; both would have been considered as within 
normal range were our revised cut-off of 1.7 to be employed (Table 8.12). In both cases, the agent 
in question was amlodipine, for which approximately 2.4 million prescriptions are made in England 
every month (Curtis and Goldacre, 2018). However, two other participants with probable AD were 
prescribed amlodipine and had normal MIBG scans; another patient, prescribed diltiazem, also a 
calcium channel blocker, demonstrated late HMR within normal parameters.  
 
Four patients with probable DLB (4/17; 24%) were also prescribed calcium channel blockers, two 
of whom underwent false negative MIBG scans; one was prescribed amlodipine, one prescribed 
diltiazem.  Thus, of nine patients participating in the study with either false positive or false 
negative MIBG, four (4/9; 44%) were prescribed a calcium blocker, compared to five of 24 
participants with true positive or true negative results (5/24;21%). Despite the theoretical 
expectation that calcium channel blockade would suppress sympathetic activity, clinical studies of 
amlodipine have reported an increase (Inui et al., 2014) or no significant effect on HMR, albeit in 
patients with cardiac disease demonstrating an increase in sympathetic activity in response to 
treatment (Sakata et al., 1998). 
 
A multitude of factors related to calcium channel blocker therapy, and drug prescription in 
general, could influence HMR. These include, but are not limited to, drug dose, frequency, 
compliance, and interpatient pharmacokinetic variability. Our data does however, at the very 
least, cast doubt on any suggestion that such factors should contraindicate, or comprise exclusion 
criteria from studies of MIBG in DLB populations. Nevertheless, any clinical conclusions from MIBG 
results in patients prescribed calcium channel blockers should continue to be drawn with caution. 
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We found that the post hoc cut-off of 1.6 providing the optimum diagnostic accuracy in patients 
prescribed medications thought to interfere with cardiac MIBG uptake was marginally lower than 
the 1.7 optimum cut-off identified for cohort as a whole. The small sample size of this subgroup 
should lead this finding to be interpreted with caution, particularly as a single AD case (MID039, 
Table 8.11) would be interpreted as false positive were the 1.7 cut-off to be used. However, the 
finding might suggest that an adjusted HMR cut-off may be a possible alternative to both 
compromising clinical utility and withdrawing potentially interfering medications. 
 
9.8 MIBG in patients without parkinsonian symptoms 
As previously discussed (Chapter 3.3.4), clinical and neuropathological studies have identified the 
presence of patients with DLB who fail to demonstrate parkinsonian symptoms throughout the 
course of their illness, and those who, despite the presence of neocortical Lewy body pathology, 
show little or no striatal pathology post-mortem (Harvey, Skelton-Robinson and Rossor, 2003; 
Ferman et al., 2006; Savica et al., 2013; Zaccai et al., 2015; Walker et al., 2016). There is 
insufficient evidence to clearly demonstrate that FP-CIT has limited sensitivity in cohorts without 
parkinsonism, but lower levels of dopamine transporter loss in subjects without extrapyramidal 
symptoms (Piggott et al., 1999) do raise the possibility that alternative biomarkers, such as MIBG, 
could be useful in such patients.  
 
We therefore further scrutinised MIBG results for a subgroup of patients without parkinsonism, 
using a UPDRS cut-off score of 15, employed in other studies, to distinguish patients with clinically 
significant parkinsonism from those without (McKeith et al., 2007). A cut-off of 15 was chosen as 
the UPDRS motor subscale comprises 14 components, and that a score in each of those 
components could have been attributable to cognitive or physical comorbidities in normal ageing 
(McKeith et al., 2007). This is supported by the fact that none of the AD group recruited scored 
over 10 on the scale. 
 
Four patients (4/17; 24%) with DLB had UPRDS scores under 15, none of whom were treated with 
dopaminergic medication that could potentially have decreased their score. This could be 
considered an under-representation of such patients when considered alongside the results from 
our epidemiological study, which showed that 27% of patients did not have parkinsonism 
identified at any point of their contact with services (Chapter 5.3.5). However, milder parkinsonian 
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symptoms, less likely to identified in routine clinical practice, would have been identified through 
the systematic use of UPDRS in our study methodology. 
 
Of these four patients without parkinsonism, two demonstrated HMR values lower than both a 
priori and post hoc cut-offs, but in both of these cases had abnormal FP-CIT results. Of the 
remaining two cases, both had late HMRs over 2.2 and UPDRS under 6; one had an abnormal FP-
CIT, the other normal. The second of these cases in particular is important; the sole recruit with a 
history of probable DLB, diagnosed on the basis of fluctuations and visual hallucinations, but 
neither an abnormal FP-CIT nor abnormal MIBG. On one hand, this could represent a lack of 
specificity, as previously discussed, of the third consensus criteria and our process of rating 
through independent diagnosticians; on the other, it could represent a case of DLB, with cortical 
α-synuclein pathology but no significant cardiac denervation or striatal involvement. If the latter is 
to be presumed, and the small sample size taken into consideration, the sensitivity of MIBG in 
differentiating DLB in patients without parkinsonism from AD is 50% (95% CI 7% - 93%). This 
clearly does not support the use of MIBG in such patients without further research into this group, 
particularly as FP-CIT provides higher sensitivity in this group of patients without parkinsonism 
(75%; 95% CI 19% - 99%). 
 
9.9 MIBG in patients with normal FP-CIT 
We recruited six patients meeting criteria for probable or possible DLB, who had recently had a 
normal FP-CIT scan (Chapter 8.10). It was important to consider this group separately from our 
main cohort, not only because of the different mechanism of recruitment (potential participants 
were identified after screening of regional neuroimaging databases), but because of the clear 
differences in demographic and clinical characteristics between the two subsets. 
 
FP-CIT scans are generally requested and conducted in the diagnostic phase of contact with 
services. This is reflected in patient demographics, where participants recruited from FP-CIT 
databases trended towards lower scoring in scales measuring cognitive ability, core symptoms, 
neuropsychiatric symptoms, carer distress and global condition when compared to the main study 
cohort, despite a higher mean age observed in the former.  Participants identified in this 
diagnostic phase of contact with services could also be less likely to be prescribed medications, 
such as levodopa, identified as capable of interacting with MIBG. 
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These participants not only differ from our main study population in demographic and clinical 
scale measurements, but in having been referred for FP-CIT, they also represent a phenotypically 
different population, with a higher degree of diagnostic uncertainty, than patients in the main 
cohort. Clinicians detecting more than one clear core feature need not refer to FP-CIT, as such 
cases meet criteria for probable DLB with or without an indicative biomarker (McKeith et al., 2005, 
2017). This is reflected, if not perhaps underestimated, by the higher proportion of possible DLB 
cases in our sample identified through FP-CIT screening (2/6; 33%), than in our main cohort (1/17; 
6%). 
 
The small sample size in our FP-CIT negative DLB group makes direct comparison with the main 
cohort difficult, but the significantly lower scores in scales UPDRS in the former is understandable 
as striatal uptake has been shown to correlate with UPDRS score in DLB and PD populations 
(Benamer et al., 2000; Del Sole et al., 2015). 
 
What is immediately striking about the results of the group recruited from neuroimaging 
databases are the FP-CIT results reported; two of six DLB cases (one probable DLB, one possible 
DLB) underwent FP-CIT scans clinically reported as normal but reported as abnormal by our panel 
of five practitioners. It should be noted that this reflects two interpretations of the same scan 
data, rather than two scans conducted separately in the clinical and research settings. 
 
High levels of inter-reader agreement have been observed in FP-CIT raters (Seibyl et al., 2014) and 
panels of practitioners blinded to clinical data, like the one employed in this study, have 
demonstrated superior specificity and inferior sensitivity to their non-blinded counterparts 
(O’Brien et al., 2014b). However, the two normal clinical interpretations, later revised to 
abnormal, are likely to reflect false negatives; a lower sensitivity by a single non-blinded rater than 
the methodologically more robust five-person panel adopted by our study. 
 
These two cases, together with the rest of our results, may suggest therefore that MIBG has a role 
in two types of cases with normal FP-CIT results; those with an insufficient or absent striatal LB 
pathology; or those reported as normal by a single reader. It may be prudent, therefore, to 
suggest that FP-CIT negative patients undergo a secondary review of study images, or semi-
quantitative analysis, prior to recommendation or authorisation of subsequent MIBG study.  This is 
particularly pertinent when one considers that the majority of FP-CIT research has been conducted 
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near DLB research centres, using 3-5-person rater panels; the accuracy of the modality is likely to 
decrease among single raters in other settings.  
 
Abnormal MIBG results were reported in two of the six participants (33%) identified through our 
FP-CIT screening process, both in cases meeting criteria for probable DLB. The first such 
participant had both a history of MI and of prescription of interacting medication (diltiazem), who 
despite falling under our a priori threshold would be reported as a normal scan were our post hoc 
to be employed. Furthermore, this participant comprised one of two cases described above; FP-
CIT initially reported as normal but revised to abnormal upon blinded panel rating. This therefore 
represents a case where both FP-CIT and MIBG individually represent a high degree of uncertainty, 
but when combined lend considerable support to DLB diagnosis.  
 
The second of the cases with abnormal MIBG, recruited using neuroimaging databases, had 
neither a history of MI nor of interacting medications, and had a negative FP-CIT; late HMR for this 
patient was lower than both a priori and post hoc cut-offs. A case sharing each of these 
characteristics was also recruited to our main study using our conventional clinical screening 
mechanism. We therefore identified two DLB cases with abnormal MIBG results, suggesting the 
presence of marked cardiac sympathetic pathology (late HMRs of 1.4 and 1.5) in the absence of 
striatal pathology sufficient to produce an abnormal FP-CIT.  
 
9.10 MIBG and DLB neuropathology 
The combinations of clinical, FP-CIT and MIBG findings among patients participating in our main 
cohort (Figure 9.1) appear to contradict the Braak hypothesis of LB pathogenesis (Braak et al., 
2003). According to this hypothesis, the spread of α-synuclein disease through the nervous system 
should be sequential and predictable. Peripheral nervous system pathology, measured in this 
study using MIBG as a marker of cardiac sympathetic denervation, should precede striatal 
involvement, measured using FP-CIT, which should in turn precede cortical disease.  However, 
three DLB patients recruited to the main cohort exhibited findings contrary to the ascending 
pattern proposed by the Braak hypothesis, demonstrating normal MIBG scans, indicative of an 
absence of cardiac sympathetic pathology, but abnormal FP-CIT findings, suggesting the presence 
of striatal LB pathology (Table 9.1). 
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This data joins a growing body of evidence disputing the Braak theory of pathogenesis. Yokota et 
al. (2007) identified advanced limbic and cortical LB pathology in two cases without parkinsonism, 
both with a degree of epicardial involvement and intact but relative preservation of the brainstem. 
Zaccai et al. (2015) reported that only 39.3% of a sample of 208 community-recruited participants 
demonstrated patterns of pathology concurrent with the Braak hypothesis, with 21.4% adhering 
to an amygdala-predominant pattern and 39.3% demonstrating an atypical distribution of disease.  
 
These neuropathological findings are supported by the large number of observational studies 
reporting that less than 85% of patients with DLB demonstrate parkinsonian symptoms during the 
course of their illness (Harvey, Skelton-Robinson and Rossor, 2003; Ferman et al., 2006; Savica et 
al., 2013; Walker et al., 2016). These patients are therefore less likely to have striatal α-synuclein 
pathology, or at least sufficient pathology to be detected by FP-CIT. Although a proportion of such 
subjects may be detectable if more sensitive measures of striatal function were available, Thomas 
et al. (2017a) recently reported that 10% of DLB cases exhibited substantial LB disease in cortical 
and limbic areas without substantial levels of striatal disease. 
 
Despite several studies investigating the use of MIBG in differentiating DLB from non-DLB 
dementia, relatively few neuropathological studies have explored the prevalence of cardiac 
sympathetic involvement in LB disease. Orimo et al. (2005) observed loss of tyroxine hydroxylase 
immunoreactive nerve fibres, a marker for sympathetic denervation, in all 11 patients with DLB or 
mixed DLB/AD disease. This was followed by work from the same group that identified α-synuclein 
aggregates in 18 of 20 patients with incidental Lewy body disease and 6 of 10 with PD (Orimo et 
al., 2008), a finding proposed to suggest distal sympathetic degeneration preceded clinical PD and 
progression to more proximal structures.  
 
More recently, Takahashi et al. (2015) published the results of the only study to date comparing 
MIBG uptake directly with neuropathological data, finding a significant correlation between HMR 
and degree of cardiac axonal degeneration. Notably, the study did identify two of 13 cases 
meeting neuropathological criteria for DLB that had no decrease in MIBG uptake but did 
demonstrate at least a degree of sympathetic denervation. This is important to consider in the 
context of our MIBG false negative DLB cases; despite normal HMR values they may have cardiac 
α-synuclein pathology. This shows consistency with the finding that DLB subjects with cortical and 
striatal α-synuclein pathology, but without significant nigrostriatal loss, may not demonstrate 
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sufficient deficits in FP-CIT uptake to produce an abnormal scan result (Colloby et al., 2012). This 
may suggest that a marker that measured α-synuclein directly, rather than dysfunction associated 
with α-synuclein, could provide a higher diagnostic accuracy than that provided by both FP-CIT 
and MIBG. 
 
Generalising the scarce neuropathological data to our findings is challenging. All of the 
aforementioned studies have taken place among Japanese populations and data among other 
groups have produced more modest rates of aggregation in cardiac tissues; Beach et al. (2010) 
detected cardiac α-synuclein pathology in only one of four DLB cases undergoing multi-organ post-
mortem examination. As previously discussed, all neuropathological studies can be subject to 
recruitment bias (Fillenbaum et al., 1996; Tsuang et al., 2006; Zaccai, Ince and Brayne, 2006) and 
consideration of must also be drawn to the younger mean age of these study cohorts. The 
superior sensitivity (95.7%) of MIBG in Takahashi et al’s study to that reported in the majority of 
clinical studies could also suggest that this sample was less clinically representative than that seen 
in our study (Takahashi et al., 2015). 
 
Our data, in demonstrating evidence of cardiac denervation in a range of patients with different 
combinations of clinical phenotypes and FP-CIT imaging statuses, represent in vivo imaging 
findings that support the body of evidence disputing the Braak hypothesis. However, more 
research is needed to understand the relationship in particular between MIBG myocardial uptake 
and histopathological lesions before the prevalence and temporality of cardiac denervation in DLB 
can be further understood. 
 
9.11 Strengths and weaknesses 
We report clinically relevant and generalisable findings from what we believe to be the first study 
examining MIBG utility in a UK cohort. In including patients with a history of MI, and those 
prescribed medications identified as capable of interfering with MIBG uptake, ours constitutes a 
more clinically representative sample than those seen in previous studies. In keeping with our 
aims, the study identified a feasible cut-off point for future studies, demonstrating excellent 
specificity and satisfactory sensitivity. 
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The prevalence of both MI and potentially interacting medications underline the importance of 
understanding the relationship between these factors and MIBG uptake, and in particular our data 
has added to a relatively sparse group of human studies examining the significance of calcium 
channel blockers in late HMR. 
 
The process by which clinical diagnoses were assigned was robust and replicable, as was the 
methodology for reporting of the FP-CIT data. Our findings relating to abnormal early HMR data 
raises important economic questions for services and if supported by further evidence could 
comprise an important factor for clinicians considering use of MIBG. 
 
Varying combinations of clinical diagnosis, FP-CIT and MIBG and our findings in an FP-CIT negative 
cohort provide a clinical insight into DLB pathogenesis and support a growing body of evidence 
disputing the Braak hypothesis. 
 
Our study was not without limitations. The small sample size limited the power of analyses and 
while providing a degree of reassurance to clinicians regarding these factors it fell considerably 
short being able of offer firm conclusions. This was the case in particular regarding MI and 
interfering medications and the small effect sizes observed groups in these analyses. Our sample 
size was a product of the challenges of identifying and recruiting DLB patients and the time 
constraints to which the study was bound. These also likely contributed to a selection bias; every 
patient with DLB diagnosed within the region within the study recruitment phase was likely to 
have been considered as a candidate for participation. This was not the case for AD patients, who 
having been drawn from a much larger pool, were more likely to have volunteered for 
participation through local registers or referred from other studies. 
 
9.12 Summary 
Our findings support the potential of MIBG as a diagnostic biomarker in differentiating DLB from 
AD in a clinical population. An optimum sensitivity for DLB of 71% and specificity for AD of 100% 
suggest moderate clinical utility but underline the importance of an appropriate cut-off, 
necessitating calibration and consideration of technical and patient-based factors. Our failure to 
identify significant relationships between HMR and both MI and interacting medications is 
encouraging regarding the feasibility of MIBG, but unquestionably requires further research 
before dismissing the role of these factors. In particular, the role of calcium channel blockers, 
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prescribed frequently in older adults and capable of producing false negative and false positive 
MIBG results, merits further exploration. 
 
Our observation that DLB patients can exhibit normal MIBG results and abnormal FP-CIT findings 
would appear to add to a body of evidence challenging the Braak hypothesis of LB disease 
propagation. However, a greater understanding of the relationship between HMR and LB 
pathology must be achieved before MIBG findings can be extrapolated to contribute to models of 
pathogenesis with greater certainty.  
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Chapter 10 
Conclusions and directions for future research 
 
This thesis has explored the detection of DLB in routine clinical care and the impact that the 
diagnosis has on patients’ contact with secondary care services. It investigated the role of the 
diagnostic biomarkers FP-CIT and cardiac MIBG in enhancing clinical DLB diagnosis. Future 
research should consider both improving detection of clinical features and the use of biomarkers 
in optimising DLB case recognition in routine secondary care. 
 
10.1 Summary of main findings 
The first half of this thesis concerned the clinical epidemiology of DLB. It also explored the contact 
that DLB cases and matched dementia controls had with secondary care services. Our cross-
sectional survey of 5 569 patients seen in POA services found that DLB represented 5.6% of 
dementia cases and was more common among males and younger age groups. We observed a 
range of DLB prevalence rates between neighbouring services, which may be more closely related 
to differences in disease detection rather than in the true prevalence of pathology; it seems 
unlikely that regions and services so geographically close could be subject to pronounced variation 
in environmental factors. This range in detection may explain the variation in DLB prevalence rates 
seen in previous studies (Vann Jones and O’Brien, 2014). 
 
Over a third of DLB cases were assigned a different dementia subtype diagnosis during their initial 
contact with secondary care, and patients with DLB encountered a significantly longer time from 
presentation to final diagnosis (median 265 days) than that seen in other dementia subtypes 
(median 125 days). During the course of their care, patients with DLB also had more extensive 
contact with clinical services (median 17 contacts) than those with non-DLB subtypes (10 contacts) 
and had a higher frequency of appointments with specialist nurses (median 11 appointments 
(DLB) vs 3 appointments (non-DLB)) and medical practitioners (median 7 appointments (DLB) vs 5 
appointments (non-DLB)). 
 
We observed that clinicians routinely used biomarkers throughout the diagnostic process; nearly 
half of all DLB patients were referred for FP-CIT scans. Of core and suggestive DLB symptoms, only 
visual hallucinations were recorded more frequently than impaired striatal uptake on FP-CIT 
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scanning, suggesting that FP-CIT plays an important role in the diagnostic process. Patients with 
DLB who had FP-CIT scans experienced a significantly longer time from referral to initial dementia 
diagnosis (median 211 days) than those that did not (100 days). This may suggest that waiting 
times for FP-CIT, and the wait for a subsequent POA appointment at which to discuss the results of 
the scan, may be a factor in delaying initial DLB diagnosis. There was also a non-significant trend 
for patients in this FP-CIT group to experience a shorter period of time from referral to final 
diagnosis (median 245 days) when compared to the non-FP-CIT group (358 days). This may suggest 
that the waiting time associated with FP-CIT may be offset in part by a longer time for revision of 
diagnosis in patients who did not undergo FP-CIT, and quicker access to biomarkers such as FP-CIT 
may shorten the time to final diagnosis in DLB patients. 
 
The second half of the thesis therefore explored how DLB case detection might be enhanced 
through the introduction of a second DLB biomarker; MIBG cardiac scintigraphy. We investigated 
the utility of MIBG for differentiating DLB from AD in a clinically representative population. Using a 
HMR cut-off derived from the results of a Japanese multicenter study (Yoshita et al., 2015), we 
found that MIBG had a moderate sensitivity (71%) and specificity (75%) for differentiating DLB 
from AD. However, we found that when an optimum threshold, as determined by ROC analysis, 
was used to differentiate abnormal scans from normal ones, the specificity for AD of MIBG was 
enhanced (100%), without compromising sensitivity for DLB (71%). MIBG diagnostic accuracy is 
therefore highly dependent on the choice of cut-off used, and factors affecting different 
populations may influence this cut-off.  We found that a high proportion of our participants 
possessed clinical characteristics that would have excluded them from previous studies on the 
basis that these might adversely affect clinical utility; a history of MI (15%), and the prescription of 
medications thought to interfere with MIBG uptake (55%). We identified no significant 
relationships between these characteristics and HMR, which encourage further research into 
MIBG using clinically representative populations.  
 
10.2 Directions for future research 
Although we believe variation in DLB prevalence rates between different services to be related to 
detection of disease rather than true variation in the pathological changes associated with DLB 
(Kane et al., 2018), there remains an important role for further research into the clinical 
epidemiology of the condition. This includes research that uses designs that identify DLB on the 
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basis of clinical symptoms, even with the expectation that such cohorts will fail to include a 
proportion of cases with neuropathological DLB.  
 
Further research is also needed into DLB prevalence rates in different clinical services. We 
included a range of services that we believed to be representative of those that comprise NHS 
POA services throughout the UK. Although only one of the services included had close links with 
Newcastle University, proximity alone to a research centre may produce a greater awareness of 
DLB that may result in higher rates of diagnosis (Bonanni et al., 2013). Epidemiological studies that 
include a more heterogenous group of services and regions may further aid understanding of the 
clinical factors underpinning DLB diagnosis. 
 
Such research could be facilitated by the development of electronic care records, which enable 
retrospective access to large, clinically representative populations of anonymised cases suitable 
for epidemiological research (Fernandes et al., 2013). Such studies are vulnerable to the effects of 
incomplete or unclear data (Goodman et al., 2017), but are feasible, and would allow observation 
of changes in prevalence over time, assuming consistency of diagnostic practice. 
 
The support lent by our data to the hypothesis that detection, rather than true disease 
prevalence, is responsible for differences in case frequency emphasises the need for research 
studies into enhancing clinical DLB case detection, such those investigating diagnostic scales and 
toolkits (Galvin, 2015; Thomas et al., 2017). Systematic use of such toolkits in non-DLB populations 
could identify their potential to detect DLB cases otherwise missed in routine clinical care. 
 
Our finding that patients with DLB received more extensive contact with secondary care than 
those with non-DLB dementias has important implications for resource allocation and should be 
followed by studies exploring the economic impact of DLB compared with that of other dementia 
subtypes, and in particular, whether processes allowing earlier or more accurate diagnosis, would 
be more cost-effective.  This is important when one considers the cost of biomarkers in DLB 
diagnosis, and our finding that time from referral to initial diagnosis may have been prolonged in 
DLB patients by waiting for FP-CIT scans. Diagnostic revision may also come with an opportunity 
cost to clinical issues like pharmacological management; early and accurate DLB diagnosis could 
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allow for a more assertive, proactive approach to treatment, and more studies on the clinical 
outcomes of DLB detection should be pursued. 
 
Our data regarding MIBG utility are encouraging but suggest that further work is required before 
the biomarker can feasibly be integrated into routine clinical practice. MIBG studies to date have 
been limited by either non-representative populations or, as in our case, smaller sample sizes. An 
important next step in determining MIBG utility is therefore a multicentre study in a clinically 
representative population, particularly as larger sample sizes will be important in identifying and 
validating suitable HMR cut-offs, and in adequately clarifying the issues discussed below.  
 
Our study did not identify overall group differences in HMR between patients administered and 
not administered potentially interacting medications, but a future, larger multicentre study could 
allow subgroup analysis of different drug classes to further investigate this. Other study designs, 
such as case series reporting serial MIBG on individual patients, could also be helpful in clarifying 
the effects of such medications and are not unprecedented (Sisson et al., 1987; Apeldoorn, 
Voerman and Hoefnagel, 1995). A multicentre study would also allow subgroup analysis of 
patients with comorbidities, but other study designs may also be helpful in this regard. Using 
SPECT-CT to understand how regional decreases in cardiac MIBG relate to overall HMR (Odagiri et 
al., 2016), and correlation of HMR with cardiac neuropathological findings (Orimo et al., 2016) 
would further support use of the biomarker in patients with ischaemic heart disease. Comparison 
of MIBG data with neuropathological findings, the gold standard for DLB diagnosis (McKeith et al., 
2017), will be a crucial step in validating MIBG as a biomarker. 
 
Even if validated by neuropathological findings, other considerations must be made before MIBG 
can be considered alongside FP-CIT as a first line investigation for DLB. This is reflected in revised 
UK clinical guidelines for the investigation of dementia, which recommend MIBG only when FP-CIT 
is unavailable (NICE, 2018). Among important areas for future research are technical 
considerations, such as the identification of appropriate HMR thresholds, which as demonstrated 
by our study, have important implications for MIBG utility. This would best be achieved by the 
development of calibration protocols for MIBG (Nakajima et al., 2012; Verschure et al., 2017) and 
the creation of international MIBG databases (Nakajima et al., 2016). It is worth noting that FP-CIT 
images are acquired using SPECT methods, and considerable research has been devoted to 
optimisation of the processing and quantifying of these images.  The current methods of 
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acquisition, processing and analysis of MIBG images is relatively crude by comparison, and further 
technical research in this area is warranted. A greater knowledge of how normal ageing affects 
MIBG uptake, and how much variation in HMR could be expected in both healthy populations and 
dementia cohorts, will be important in determination of suitable HMR cut-offs for use in routine 
clinical practice. Further work should also be conducted on interrater agreement in MIBG 
(Veltman et al., 2012; Yoshita et al., 2015). 
 
Eventual integration of MIBG into clinical practice should be done so with consideration of 
optimising the combined utility of FP-CIT and MIBG. Larger sample sizes may help in identifying 
phenotypes associated with higher diagnostic utility, and therefore direct clinicians towards the 
appropriate investigation in patients with particular clinical symptoms. Such algorithmic 
approaches have been previously proposed for the use of FDG PET in DLB investigation (Firbank et 
al., 2016). One such group that may benefit from this approach is patients meeting criteria for 
prodromal DLB (McKeith et al., 2016). 
 
Further research is also required into the pathogenesis and temporal development of pathology in 
DLB. We identified three DLB participants with insufficient cardiac α-synuclein pathology to 
produce an abnormal MIBG result, but with striatal degeneration capable of producing abnormal 
FP-CIT findings. This pattern challenges the Braak hypothesis of DLB pathogenesis (Braak et al., 
2003) that has also been contradicted by community neuropathological samples (Zaccai et al., 
2015).  
 
A greater understanding of DLB pathogenesis might be supported by further research into how 
and when α-synuclein pathology affects the peripheral nervous system in DLB as this may lead to 
other diagnostic markers. The colon, submandibular gland, and skin have all been investigated as 
practicable biopsy sites capable of demonstrating evidence of α-synuclein pathology, but studies 
have mostly been confined to single-centre designs (Lee et al., 2017). The suggestion made by the 
Braak hypothesis that such peripheral pathology occurs earlier than that in the CNS (Braak et al., 
2003) encourages work into the use of biopsy markers in patients with prodromal DLB. Such 
biopsy data would be most valuable when collected at multiple time points, and compared with 
other biomarkers, such as MIBG and FP-CIT, and clinical signs and symptoms. This could also be 
supported by more widespread investigation of peripheral neuropathology, and comparison with 
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CNS pathology in post mortem samples. 
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